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ABSTRACT 
 
Introduction: Smoking is a major risk factor for development of serious disease and smoking 
cessation greatly reduces this risk. The association between smoking, smoking cessation and 
mental health however, is less clear-cut, therefore this thesis aimed to further investigate this 
association. 
 
Methods: The first part of the thesis reports a systematic review and meta-analysis of 
longitudinal studies to determine the difference in change in mental health between quitters 
and continuing smokers. The second part of the thesis reports three prospective analyses of 
individual level-patient data from five trials for smoking reduction treatment. The first 
analysis examined the association between cessation and change in mental health using 
propensity score matching (PSM). The second analysis examined the association between 
cessation and risk of psychiatric disorder using PSM. The final analysis examined the 
association between change in mental health after quitting and odds of relapse. 
 
Results and interpretations: Cessation was associated with improvements in mental health 
compared with continuing smoking; there was no association between cessation and risk of 
psychiatric disorder, and no association between change in mental health after cessation and 
future relapse. Results support the misattribution hypothesis, and have implications for future 
research, smoking cessation treatment and public health policy. 
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THESIS OUTLINE 
 
This thesis examined the association between smoking, smoking cessation and mental health 
in light of current theories and evidence from various disciplines. The first chapter denotes the 
public health importance of the thesis and introduces the field by critically reviewing relevant 
literature. The subsequent chapters represent four independent studies on the theme of 
smoking cessation and mental health. The data presented in Chapter Two were derived from a 
systematic review of published studies. Chapters Four to Six were prospective analyses of 
individual level patient data from five randomised controlled trials of nicotine therapy for 
smoking reduction, which were provided by McNeil AB pharmaceutical company, as 
described in detail in Chapter Three.  
 
All chapters were written according to the relevant reporting guidelines. Chapter Two 
followed PRISMA (Moher et al. 2009) and MOOSE reporting guidelines (Stroup et al. 2000), 
and Chapters Four to Six were written according to STROBE guidelines for reporting of 
observational studies (Von Elm et al. 2007). Reporting of propensity score matching (PSM) 
procedures in Chapters Four and Five followed criteria outlined by a review of PSM methods 
(Thoemmes and Kim 2011). 
 
Chapter Two reports a systematic review and meta-analysis of longitudinal studies which 
measured change in mental health outcomes from baseline to follow-up (>6 weeks) in 
smokers who quit and smokers who continued smoking. Numerous sensitivity analyses were 
conducted to address within and between study heterogeneity. In this study there was a 
significant association between stopping smoking and improvements in anxiety, depression, 
psychological quality of life, positive affect and stress at follow-up, compared with continuing 
to smoke. This finding was consistent in people from different clinical and general 
populations and the effect estimates were equal or greater than those of anti-depressant 
treatment for mood disorders. However, these findings were potentially susceptible to group 
membership bias and unmeasured confounding.  
 
Chapter Three describes data from six randomized placebo-controlled trials provided by 
McNeil AB Pharmaceutical Company and these data were used for analysis in Chapters Four 
to Six. This chapter describes the application process, data extraction, cleaning and synthesis, 
and also provides descriptive information about participants, trials and treatment 
characteristics. 
 
In Chapter Four, the risk of group membership bias to the association between cessation and 
mental health was addressed using propensity score matching (PSM). PSM is a method used 
to balance covariates predictive of propensity to achieve abstinence between exposure groups. 
If a balance between the groups is reached the matched sample can be analysed to produce 
causal estimates. Mental health was measured using the SF-36 and repeated point-prevalence 
smoking status was biologically-validated over a six month period. Linear regression 
modelling was used to compare change in mental health from baseline to 12 month follow-up 
between quitters and continuing smokers, and effect estimates derived from matched and 
unmatched samples were compared. Estimates from both samples were similar and suggested 
that cessation was associated with clinically meaningful improvements in mental health. 
 
The analysis of mean mental health scores in Chapters Two and Four may have concealed the 
rare occurrence of psychiatric disorder. Therefore, Chapter Five estimated the risk of 
psychiatric diagnosis after quitting compared with continuing to smoke. Similar to Chapter 
Four, estimates were compared between the whole sample and from participants matched 
using PSM in aim of overcoming group membership bias and confounding. Psychiatric 
diagnosis was ascertained by coding trials’ adverse event data according to MedDRA 16.1 
terminology. In a small sample of quitters, there was no evidence of psychiatric events six 
months after achieving abstinence, whereas about 2% of those who continued smoking 
reported evidence of a psychiatric disorder during the same six month period. The difference 
was similar between matched and unmatched samples, although results were not significant. 
The results in this chapter were inconclusive and a larger study using similar methodology 
should be conducted. 
 
One of the potential explanations for the findings in Chapters Two, Four and Five is that some 
people stop smoking, experience improved mental health and therefore remain abstinent; 
whereas some people quit smoking, experience worse mental health and therefore relapse 
back to smoking. Chapter Six examined this hypothesis using logistic regression modelling to 
determine if post-cessation change in mental health was associated with future relapse. This 
chapter found no significant association and the findings were discussed in relation to 
smokers reported reasons for relapse. 
 
Chapter Seven discusses how the thesis adds to current knowledge and contextualises the 
knowledge-to-date according to Bradford Hill’s criteria for inferring casual associations. 
Secondly, clinical and public health implications are discussed and suggestions for future 
research are made. The chapter concludes with summary statement for the overall 
contribution of the thesis. 
  
DEFINITIONS 
 
Mental health — The World Health Organization (2005) defines mental health as: 
 
“A state of well-being in which every individual realizes his or her own potential, can cope 
with the normal stresses of life, can work productively and fruitfully, and is able to make a 
contribution to her or his community… health is a state of complete physical, mental and 
social well-being and not merely the absence of disease or infirmity." 
 
1 
 
CHAPTER ONE 
1. LITERATURE REVIEW: SMOKING, SMOKING CESSATION AND 
MENTAL HEALTH 
 
1.1. Introduction to Chapter One 
 
Chapter One introduces the importance of the thesis is by illustrating the global tobacco 
epidemic, physical health hazards of smoking and the public health importance of smoking 
cessation. The second part of the chapter highlights evidence showing that most smokers want 
to quit however continue smoking because they feel that smoking offers mental health 
benefits, moreover that this belief is widespread amongst health professionals and presents a 
barrier to smoking cessation treatment in both general and clinical populations. The chapter 
then examines the epidemiological association between smoking, quitting and mental health 
in light of three hypotheses which aim to explain the causal nature of the association, and 
critically evaluates evidence from different fields in relation to these hypotheses. The final 
section evaluates current areas of uncertainty and presents the aims of the thesis. 
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1.2. Prevalence of tobacco smoking worldwide and in the United Kingdom 
 
The Tobacco Atlas (Eriksen et al., 2012) estimated that approximately 20% of the world’s 
adult population smoked in 2012. In the UK rates are similar, the Office of National Statistics 
(ONS) estimated that approximately 10 million or 20% of the UK general population were 
current smokers in 2011, with a slight gender gap in prevalence (Figure 1.1) (Office for 
National Statistics, 2013). The Smoking Tool Kit Study offers the most up-to-date data for 
smoking rates in England, and shows that prevalence has dropped below 20% for the first 
time to 19.2% (West and Brown, 2014). Smoking prevalence has decreased dramatically since 
1974 (Figure 1.1) (Office for National Statistics, 2013) due to the success of public health 
policies and development of cessation interventions (Department of Health, 2008). Of the 
remaining UK smoking population, it has been estimated that over two thirds would like to 
quit (Lader, 2009), and this estimate is similar across western nations, for example, in the US 
(Centres for Disease Control and Prevention, 2011). In 2009, 75% of smokers had reported a 
recent quit attempt (Lader, 2009; Zhou et al., 2009). However, most quit attempts are 
unsuccessful, in the UK about 92% of smokers who attempt to quit relapse within two years 
(Lader, 2009). 
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Figure 1.1 Changes in UK smoking prevalence by sex, between 1974 and 2011 (data 
from ONS) 
 
1.3. Smoking, smoking cessation and physical health 
 
Tobacco use continues to be the leading global cause of preventable death and has been 
described as a global epidemic (The World Health Organization, 2011). The association 
between tobacco smoking and hazards to physical health are well documented. In 2004 the 
Surgeon General of the United States’ Centre for Disease Control and Prevention conducted a 
comprehensive literature review of the ‘effects’ of smoking in which evidence was collated 
from ecological, cross-sectional, cohort, case-control studies and intervention trials, and was 
peer reviewed by over 100 field experts. The report concluded there was sufficient evidence 
to infer a causal relationship between smoking and 10 different types of cancer, heart and 
respiratory diseases, and notably these diseases are amongst the top 10 most common causes 
of death in the UK (Cancer Research UK, 2013) (Office for National Statistics, 2011). In 
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2001 it was estimated that there were 2.3 million deaths worldwide from smoking related 
disease and that approximately every one in two long-term smokers will be killed by their 
addiction (Jha, 2009).  
 
Two major longitudinal prospective cohort studies have aimed to determine the association 
between smoking and risk of morbidity and mortality. Pirie et al. (2013) conducted an 
analysis of data from 1.3 million women, over a 12 year period. The authors calculated 12 
year relative risks for smokers versus never-smokers for all-cause mortality and death from 
specific disease with adjustment for demographic, geographic, and lifestyle factors. The 
results showed that current smokers had a greater relative risk (RR) compared with never-
smokers for 30 different diseases including lung disease, RR=35.3 (95% CI: 29.2 to 42.5), 
lung cancer, 21.4 (19.7 to 23.2) and aortic aneurysm, 6.3 (5.2 to 7.7). In a study of data from 
34,439 male doctors, Doll and colleagues (2004) aimed to determine the health hazards of 
smoking over 50 years. The researchers calculated the annual all-cause mortality rates per 
1000 men in life-long smokers and non-smokers. The study found that life-long smokers aged 
35 to 44 had a mortality rate 1.6 times greater than non-smokers, this mortality rate increased 
with age and peaked at 2.7 times greater for smokers aged 65 to 74 compared with non-
smokers.  
 
Several key studies have aimed to establish the physical health benefits of stopping smoking. 
The US Surgeon General (1990) compiled a report of available evidence from case-control 
studies, cross-sectional studies, and clinical trials which examined the association between 
smoking cessation and health outcomes. The report concluded that stopping smoking 
decreases the risk of many types of cancer, heart attack and stroke, and has significant health 
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benefits for pregnant women and their unborn child. The report concluded that smoking 
cessation has major and immediate health benefits at all ages, and these benefits occur for 
people with and without smoking-related disease.   
 
Since the Surgeon General (1990) report, two major prospective longitudinal cohort studies 
have aimed to measure the health benefits of stopping smoking. Pirie et al. (2013) in a study 
referred to previously calculated the relative risk (RR) of all-cause mortality in later life, for 
ex-smokers compared with never-smokers. Results indicated that stopping before the age of 
40 avoids more than 90% of excess mortality, and stopping smoking before the age of 30 
avoids more than 97% of excess mortality. In the UK male doctors’ study referred to above, 
Doll and colleagues (2004) calculated the annual all-cause mortality rates per 1000 men in 
life-long cigarette smokers and non-smokers over a 50 year period. Results showed that 
smokers who stopped before the age of 35 had similar survival rates as non-smokers, smokers 
who stopped at 40 gained about nine years of life expectancy, smokers who stopped at 50 
gained about six years, and smokers who stopped at 60 were estimated to gain at least three 
years. The report concluded that the earlier one stops smoking the greater the reduction in the 
risk of mortality from smoking.  
 
1.4. Reasons for continuing to smoke 
 
As noted previously in section 1.2, most smokers want to stop smoking but are unsuccessful 
in doing so. Both qualitative and quantitative studies have investigated reasons why smokers 
continue to smoke. These studies have found that smokers consistently report that smoking 
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offers mental health benefits and that these benefits are an important reason for continuing. 
Studies involving interviews with smokers have identified that smokers report smoking 
relieves their emotional problems, feelings of depression and anxiety, stabilises mood, and 
can be used for relaxation and pleasure, as well as for relieving stress (Kerr et al., 2006; Lawn 
et al., 2002; Thompson et al., 2003). Smokers affirm that the emotional support gained from 
smoking is reinforcing and defers cessation, and these reports are consistent amongst smokers 
of all ages, in both heavy and light smokers, and in smokers with and without mental health 
disorders (Kerr et al., 2006; Lawn et al., 2002; Thompson et al., 2003).  
 
The findings from qualitative research are supported by population surveys. Fidler et al. 
(2009) analysed survey data from over 2000 UK smokers and found about half of smokers 
reported smoking for enjoyment and stress-relief. Similarly, another study of over 2500 UK 
smokers (McEwen et al., 2008) found smokers ranked smoking “to cope with stress” above 
all other motives to smoke (i.e. for enjoyment). In a study conducted by Lerman and 
colleagues (1996) smokers with and without emotional difficulties reported smoking “to cope 
with unwanted emotion.” A study of 2069 smokers (Ferguson et al., 2005) found that 
“smoking to cope” was significantly associated with lower cessation rates one year later, 
compared with other reasons for smoking, for example, smoking for pleasure, and similar 
studies have replicated these findings (McEwen et al., 2008). Finally, smokers report reduced 
confidence in their ability to refrain from smoking during times of stress (Ng and Jeffery, 
2003), and “smoking to cope” has been found the only significant predictor of relapse across 
all socio-demographic groups (Pisinger et al., 2011).  
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1.5. Health professionals’ beliefs about smoking 
 
Health professionals’ beliefs about patients’ potential response to treatment influence whether 
or not they recommend the treatment in question (Lewis and Wilkinson, 2003; Vogt et al., 
2005; Vogt et al., 2006). Health professionals have a major role in promoting and 
implementing smoking cessation treatments and their attitudes about the benefits of smoking 
and risks of cessation can influence the implementation of smoking cessation treatment in 
practice (Landman et al., 2007; Prochaska, 2011; Richards et al., 1996; Sargent et al., 2001). 
 
Qualitative and quantitative studies have explored clinicians’ attitudes towards promoting 
cessation in different health care settings. An international survey found that general 
practitioners perceived patients’ stress levels as a major barrier to helping them stop smoking 
(Pipe et al., 2009), this is counter-intuitive given that a patient is more likely to experience 
life-changing illness from smoking rather than stress. Sarna and colleagues (2001) found that 
in secondary care settings oncology nurses believed that “cessation intervention may be 
harmful and increase stress” in patients with smoking-related cancer, this attitude is 
detrimental to patients’ health as cessation has been found to improve the prognosis of 
smoking related cancer (Parsons et al., 2010). 
 
In mental health settings, smoke-free hospital policies have been introduced to improve the 
health of psychiatric patients (Department of Health, 2008; 2010). However, views that 
smoking offers mental health benefits for psychiatric patients are widely-held (Mendelsohn 
and Montebello, 2013; Ratschen et al., 2009a). Qualitative studies have identified that many 
mental health clinicians believe smoking enhances the patient-clinician alliance, that cessation 
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may worsen their patients’ condition and leave them socially isolated, and some clinicians 
feel that they are taking away one of their patients only pleasures in life (Campion et al., 
2008; Johnson et al., 2010; McNally et al., 2006; Parker et al., 2012; Ratschen et al., 2009a; 
2009b). These beliefs likely present barriers to smoking cessation treatment in patients with 
mental health problems (Parker et al., 2012) and likely contribute to the existence of health 
inequalities in smoking prevalence (discussed ahead in 1.8). 
 
1.6. Neurobiology of tobacco’s psychoactive effects  
 
Tobacco smoke contains an estimated 4000 plus chemical components and some of which are 
psychoactive (Borgerding and Klus, 2005; Rose, 2006; Rose et al., 2010; Thielen et al., 2008; 
United States Environmental Protection Agency, 1992). Smokers report that smoking has 
psychoactive effects (e.g. stress-relieving or mood enhancing) and this belief is also upheld by 
health professionals. This section will examine the neurobiological evidence to determine the 
validity of any psychoactive effects from smoking tobacco. 
 
Tobacco has two main neurological mechanisms which initiate and maintain addiction. 
Firstly, it produces rewarding or pleasant effects which reinforce smoking behaviour, for 
example euphoria and relaxation (Benowitz, 2010). Secondly, after chronic exposure to 
tobacco, abstinence leads to a withdrawal syndrome, in which the smoker seeks to avoid by 
continuing to smoke (Benowitz, 1999; 2010). Withdrawal symptoms from tobacco include 
anxiety, irritability, depressed mood, anger, impatience and restlessness (Hughes, 2007b), and 
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these begin to occur shortly after having smoked a cigarette (Jarvik et al., 2000). These 
mechanisms will be discussed in relation to tobacco’s main psychoactive ingredients. 
 
1.6.1. Effects of nicotine  
 
Nicotine is the most researched component of tobacco smoke and is generally agreed to be the 
most addictive (Office on Smoking and Health and Office of the Surgeon General, 1998). 
When nicotine travels to the brain it binds to nicotinic acetylcholine receptors (nAChR) at the 
synaptic cleft (the gap between the neurons) and this opens the channel between the neurons, 
allowing entry of sodium or calcium in turn causing the release of neurotransmitters (jas-
Bailador and Wonnacott, 2004). Tobacco use is associated with an up-regulation of binding to 
nAChR transmitters, and after chronic exposure to tobacco this up-regulation eventually 
results in a change to the neurotransmitter pathway (termed a neuroadaptation), leaving the 
person tolerant to the rewarding effects of nicotine (Benowitz, 2010; Wang and Sun, 2005). 
Thus, during periods of abstinence from tobacco withdrawal symptoms occur as the pathway 
is unable to function normally without a nicotine supply (Wang and Sun, 2005). 
 
Results from studies in animals have shown a dose-response effect whereby increased 
nicotine exposure is correlated with higher concentration of nAChR density (Rowell and Li, 
1997). Negative affect experienced during nicotine withdrawal appears to be mediated by 
nAChRs and is regulated by a number of neurotransmitter systems (Balfour, 2009; Fowler et 
al., 2003; Kenny and Markou, 2001; Rose, 2007). During withdrawal from tobacco, nicotinic 
receptors promote inhibition or release of numerous neurotransmitters which act on mood 
regulation. For example, corticotrophin is a neurotransmitter which is involved in stress 
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response. The corticotrophin-releasing factor receptor system is activated during withdrawal 
leading to an increase in levels of extra-hypothalamic corticotrophin, which in turn, is thought 
to heighten stress-levels during withdrawal (Benowitz, 1999; George et al., 2007). Serotonin 
(5-HT) is involved in mood regulation, and its release is thought to be reduced during tobacco 
withdrawal leading to feelings of depression and anxiety (Benwell and Balfour, 1979; Ridley 
and Balfour, 1997), and this is supported by evidence that anti-depressants targeting the re-
uptake of serotonin during withdrawal reverse withdrawal-effects (Harrison et al., 2001). 
Gamma-aminobutyric acid (GABA) and glutamate systems are affected by nicotine use and 
are also involved in mood disturbances (Sanacora et al., 2012). The effect of tobacco on these 
systems is less well understood but it is thought that Glutamate and GABA release is 
selectively increased in certain brain sites and decreased in others, leading to an increase in 
anxious reactions during withdrawal (Kenny and Markou, 2001). In summary, the 
combination of withdrawal effects in multiple neurotransmitter explains the marked 
disruption in mood during times of withdrawal which last up to 30 days after cessation 
(Hughes, 2007b). Furthermore, there is a dose-response relationship between tobacco 
consumption and increases in neuroadaptations, which may elucidate severity of withdrawal 
symptoms in those who are more dependent (discussed ahead in section 1.7).  
 
Compared with other addictive drugs, nicotine has weak reinforcing effects and these do not 
seem powerful enough to explain the intense addiction reported by smokers (Balfour, 2009). 
Moreover, some chemical components of tobacco smoke interact with nicotine to create 
effects whereas other chemical components act independently to nicotine (Borgerding and 
Klus, 2005; Rose, 2006; Rose et al, 2010; Thielen et al., 2008; United States Environmental 
Protection Agency, 1992).   
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1.6.1. Effects of tobacco on dopamine pathways 
 
Dopamine is an important factor in the initiation and maintenance of tobacco addiction and is 
mediated by nicotinic pathways (Mansvelder and McGehee, 2002) and the MAO system 
(Mansvelder and McGehee, 2002). Dopamine is associated with feelings of pleasure and 
reward, and is involved in initiation and maintenance of many addictive drugs (Volkow et al., 
2004). MAO inhibition through non-nicotinic pathways is thought to increase levels of 
dopamine inside the synapse (Dani and De Biasi, 2001; Nestler, 2005). Nicotine causes the 
release of dopamine in the mesolimbic area, the corpus striatum and the frontal cortex, in turn 
producing positive feelings. The dopaminergic neurons in the ventral tegmental area of the 
midbrain and the release of dopamine in the nucleus accumbens are particularly important as 
this pathway is involved in feelings of reward and pleasure (Dani and De Biasi, 2001; Nestler, 
2005). Activation of these pathways and associated positive feelings have a role in initiation 
of nicotine addiction, however chronic exposure to tobacco leads to neuroadaptations in these 
pathways and the smoker will need to maintain nicotine levels to enable dopamine 
transmission (Benowitz, 2010). There is evidence that smoking-induced dopamine release is 
dose-dependent (Brody et al., 2010) and nicotine withdrawal is associated with significant 
increases in reward threshold, deficiencies in dopamine release and reduced reward (Benowitz 
1999; Epping-Jordan et al., 1998). Thus evidence suggests that activation of dopamine 
pathways are likely to initiate addiction, possibly suggesting initial self-medication 
behaviours; however after chronic exposure to tobacco regular consumption is required to 
maintain optimal levels.  
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1.6.2. Effects of tobacco on the monoamine oxidaise system 
 
Tobacco has been found to influence the monoamine oxidaise (MAO) system which is 
responsible for the metabolism of neurotransmitters associated with mood. Tobacco use is 
believed to inhibit monoamine subtypes (MAO-A and MAO-B), in turn reducing the 
breakdown of mood neurotransmitters such as, serotonin, norepinephrine, dopamine and 
phenethylamine. Inhibition of MAO-A and MAO-B reduces the breakdown of these 
neurotransmitters, therefore increasing their presence within the synapse and improving 
mood. For these reasons, tobacco has been compared to anti-depressants known as 
monoamine oxidaise inhibitors (MAOI)s (Berlin et al., 1995; Fowler et al., 2003; Norman et 
al., 1987). Smokers have been found to have low levels of MAO platelet activity and this is 
thought to be a result of chronic exposure to nicotine rather than a biological characteristic of 
smokers (Norman et al., 1987). Rose et al. (2001) found that the intensity of withdrawal 
symptoms was inversely related to platelet MAO levels activity, in that smokers with the 
lowest platelet MAO experienced the most intense withdrawal symptoms.  
 
It has been suggested that those with poor mental health have a certain neurobiological 
disposition which makes them susceptible to tobacco addiction (Berg et al., 2013). People 
with high levels of MAO activity are at risk for mood disorders as MAO-A and MAO-B 
breakdown mood-related neurotransmitters and therefore decreasing their presence within the 
synapse and lowering mood (Meyer et al., 2006). Individuals with depression are more also 
likely to be dependent upon tobacco (section 1.7) and this may be due to the inhibitory effects 
of tobacco on MAO activity.  
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In sum, the effects of tobacco on the MAO system likely act independently from the nAChR 
system and provide anti-depressant effects on mood while simultaneously exacerbating 
tobacco withdrawal symptoms. It is possible that smokers with mood disorders are more 
susceptible to tobacco dependency because of these anti-depressant effects. 
 
1.6.3. Reversibility of neuroadaptations 
 
It is possible that neuroadaptations resulting from chronic tobacco use and associated mood 
effects return to normal functioning after cessation. Equally, it is also possible that chronic 
tobacco use is associated with permanent damage in neurotransmitter systems which in turn 
may cause ‘offset effect(s)’ in mood functioning following abstinence from tobacco. An offset 
effect is termed as a permanent worsening in mental health and is thought to occur as a result 
of sustained cessation (Hughes, 2007a; 2007c). There are a small number of studies which 
have examined the influence of cessation on neurotransmitter systems.  
 
Mamede et al. (2007) investigated functioning in nicotinic receptor pathways after sustained 
cessation using SPECT imaging (single-photon emission computed tomography). The 
researchers compared functioning of non-smokers with smokers who had stopped at four 
hours, 10 and 21 days after continuous abstinence. Results indicated that the nicotinic receptor 
functioning of abstainers down-regulated to the level of non-smokers at three weeks after 
smoking cessation. This indicates that the up-regulation in the nicotinic receptor system 
associated with chronic exposure to tobacco may be a temporary neuroadaptation. Notably, 
these results coincide with the finding that self-reported withdrawal symptoms begin to 
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improve at around three to five weeks post-cessation (Hughes, 2007b). However, Mamede et 
al.’s (2007) study was limited as it was conducted in a small, all male sample. 
 
Brody and colleagues (2010) aimed to determine whether treatment for smoking cessation 
induced change in intrasynaptic dopamine concentration in 43 smokers who attempted to quit. 
Each participant underwent positron emission tomography (PET) scanning sessions at pre-
treatment and eight weeks post-treatment. In this study, five of the 11 quitters had one 
cigarette-free week at the time of the second scan, the remainder having quit earlier and 
remained abstinent; the quit group as a whole had a mean of 19.9 days abstinence. The results 
indicated that DA release was not significantly affected by reductions in daily smoking or 
cessation treatment. This suggests that helping smokers to stop does not alter intrasynaptic 
dopamine levels. However, a longer follow-up period or a larger sample may be required to 
determine significant changes.  
 
There are few studies investigating the influence of cessation on neurological functional, and 
the available studies report mixed findings. There is some evidence to suggest that 
neuroadaptations in nicotinic pathways reverse, and the timeframe in which these changes 
occur coincides with self-reported reduction in tobacco withdrawal symptoms. However, 
studies which have assessed change in dopamine release following cessation treatment have 
not found any significant associations, though it is possible that a longer follow-up or larger 
sample is needed. Importantly, none of the available evidence can determine if 
neurotransmitter systems return to their previous state prior to tobacco use. It is possible that 
some systems return to previous functioning and others remain damaged after cessation. 
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1.7. Surveys of smoking, smoking cessation and mental health 
 
Population surveys have examined the association between smoking and mental health. The 
Surgeon General (2004) collected evidence from a combination of sources (previously 
discussed in section 1.3) to investigate the mental health status of smokers. The review found 
15 studies that compared mental health of smokers with non-smokers, some of whom had 
medical and mental health disorders. These studies consistently found that smokers reported 
worse mental health than non-smokers including; lower life-satisfaction, lower well-being, 
poorer mental health, more psychological symptoms and higher depression scores. The report 
also found there was some evidence of a dose-response relationship, in that higher 
consumption was linked to a worse psychological status. The report concluded there was 
“…direct evidence of the relationship of smoking to a diminished health status.” This report 
highlights the association between smoking and poor mental health outcomes, however the 
direction of causation could not be established. 
 
Cross-sectional studies in general populations have also examined the association between 
cessation and mental health. In a cross-sectional survey of approximately 250,000 smokers 
and quitters, McClave et al. (2009) found that stopping smoking was associated with reduced 
lifetime depression and anxiety compared with continuing smoking, OR=0.7 (95% CI: 0.6 to 
0.8). Survey data from 7000 UK participants indicated that quitters reported greater life 
enjoyment, life satisfaction and happiness compared to smokers and never smokers (Shahab 
and West, 2012). Other analyses of survey data from over 60,000 participants found quitters 
had a slightly elevated odds of depression and anxiety, compared with never smokers, 
OR=1.13 (95% CI: 1.0 to 1.2) (Mykletun et al., 2008), however results also suggested that the 
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longer one remained abstinent the odds of depression and anxiety became significantly 
reduced. A European survey of over 10,000 smokers found that lower stress was not 
associated with cessation in men, OR=1.0 (95% CI: 0.7 to 1.4) or women, 0.9 (0.7 to 1.2), 
however better mood was associated with cessation in women, but not in men; and an 
increase in interest was significantly associated with cessation in men, but not in women (Van 
Loon et al., 2005).  
 
In summary, according to various sources of cross-sectional data there is a strong association 
between smoking and poor mental health and some evidence for an association between 
quitting and better mental health. These studies however, do not determine if smoking is a 
risk factor in development of poor mental health, if having a poor mental health is a risk 
factor for continuing to smoke, or if a third common factor is involved in the development of 
both smoking and poor mental health.  
 
1.8. Mental health inequalities in smoking prevalence  
 
It is possible that results from general population surveys are influenced by an over-
representation of smokers with mental health problems. The Royal College of Psychiatrists 
and Royal College of Physicians (2013) examined smoking and mental health data from three 
UK population surveys with a combined total of 2.5 million residents; The Health Survey for 
England (HSE) (The NHS Information Centre, 2011), The Health Improvement Network 
(THIN) (Epidemiology and Pharmacology Information Core, 2014), and the Adult Psychiatric 
Morbidity Survey (AMPS) (McManus et al., 2009). The report found that out of the 10 
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million UK smokers, approximately three million reported evidence of mental disorder, up to 
two million had been prescribed a psychoactive medication and a further one million had a 
longstanding mental illness.  
 
The HSE (The NHS Information Centre, 2011) reported smoking prevalence in those with a 
long standing mental health disorder was 37% compared with 20% in the general population 
(Dunstan, 2012), and moreover that smoking prevalence in this subgroup has changed very 
little over the last 20 years compared with the decline observed in the general population 
(Figure 1.2). Similar findings have been replicated in the US (Cook et al., 2014). This 
population also smoke a disproportionate amount of the total cigarette consumption per 
annum. In 2010 it was estimated that about 33% of all cigarettes smoked in England were 
smoked by people with a mental health disorder (McManus et al., 2010; Royal College of 
Physicians and Royal College of Psychiatrists, 2013) and estimates are similar in the US and 
Australia (Access Economics, 2007; Lasser et al., 2000).  
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Figure 1.2 Changes in smoking prevalence between 1993 and 2010 in participants with 
or without longstanding mental health conditions (with 95% confidence intervals (CIs); 
data from the HSE)
1
 
 
Data from APMS found that 34% of people with any common mental health disorder (e.g. 
depression, anxiety) were smokers, this survey also estimated that out of the 11% of adults in 
England to have consulted with a GP in the past year for a mental health or emotional 
complaint, one third of these were smokers and approximately half of the 0.7% of adults who 
attempted suicide in the last year were also smokers. Data from THIN indicated that out of the 
4% of patients reporting one or more mental health diagnoses, 30% of these patients smoked. 
Data from these surveys suggested that rates of smoking ranged from 44.6% to 56% for those 
with a psychotic disorder, 31.4% to 39.8% for those with depression, and 31.1% of people 
with anxiety disorders (Royal College of Physicians and Royal College of Psychiatrists, 
2013).  
 
                                                 
1 Replicated with copyright permission granted from Royal College of Physicians in May 2014 
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Moreover, people with mental health disorders are more heavily dependent upon tobacco. In a 
longitudinal cohort study John et al. (2004) examined the association between nicotine 
dependency, daily cigarette consumption (cigarettes per day, CPD) and withdrawal 
symptoms, with odds of psychiatric disorder in a sample of 4000 European participants. They 
found significant dose-response relationships in that increasing consumption levels predicted 
greater odds of affective disorder, and greater nicotine dependency was associated with 
increased odds of both affective and anxiety disorders. Secondly, severity of withdrawal 
symptoms was associated with greater nicotine dependence, and there was a dose-response 
relationship between number of withdrawal symptoms and affective and anxiety disorders. 
Additionally, higher nicotine dependence was associated with increased odds of relapsing, 
OR=2.6 (95% CI: 1.2 to 5.3), and more severe withdrawal was associated with increased odds 
of relapse, 3.3 (1.5 to 7.4). However, for those who attempted cessation, having a psychiatric 
diagnosis was not associated with success of quit attempt. Similar findings have been noted 
elsewhere (Fergusson et al., 1996; Hitsman et al., 2003), however recent updates suggest 
smokers with a history of major depression are less likely to quit compared with smokers with 
no history of depression (Hitsman et al., 2013).  
 
Although the mental health population has higher smoking rates compared with other groups, 
they are just as motivated to quit as general population smokers (Lasser et al., 2000). The 
ONS reported that 69% of smokers with a likely mental health problem stated that they 
wished to stop smoking (Coultard et al., 2002), other UK surveys have reported similar data 
(The NHS Information Centre, 2011), and estimates are similar in Australia and Canada 
(Addington et al., 1997; Stockings et al., 2013). Recent evidence suggests those with mental 
health disorders have a life expectancy of eight to 20 years shorter than the general 
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population, and much of this difference could be because of smoking (Chang et al., 2011; 
Chesney, Goodwin, and Fazel 2014). However, this population is less much likely to receive 
treatment for their smoking (Szatkowski and McNeill, 2013). As a result of these health 
inequalities, UK and US policy makers are currently targeting smoking in this population to 
reduce overall smoking prevalence (Hedden et al., 2012; Royal College of Physicians and 
Royal College of Psychiatrists, 2013). 
 
1.9. Explanatory models for the association between smoking, cessation and mental 
health 
 
The first part of this chapter has demonstrated that many smokers continue smoking because 
they feel that smoking offers mental health benefits. This notion is supported by some 
neurobiological evidence suggesting that tobacco may have some therapeutic properties, 
however most neurobiological evidence suggests smoking can lead to mood disturbances. 
Cross-sectional data indicates a strong association between smoking and poor mental health, 
and quitting and better mental health, moreover, the smoking population is over-represented 
by people with mental health disorders. However, from these studies, it is unknown if 
smoking is a risk factor in development of poor mental health, having poor mental health is a 
risk factor for smoking, or if a third common factor is involved the development of both 
smoking and mental illness. The next section will examine three opposing hypotheses which 
have attempted to explain the association between smoking and mental health.  
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1.9.1. The misattribution hypothesis 
 
The misattribution hypothesis explains the association between smoking and poor mental 
health through the effects of the nicotine withdrawal cycle (Parrott, 1999; 1994; 2003). The 
model recognizes that chronic exposure to nicotine leads to periods of withdrawal which are 
characterized by restlessness, depressed mood, irritability and anxiety (Hughes, 2007b); and 
that these withdrawal effects are reliably relieved by smoking another cigarette (previously 
discussed in section 1.6). These psychological symptoms are also a hallmark of many mental 
health disorders. Accordingly, Parrot (1999; 1994; 2003) proposes that fluctuation in these 
symptoms and associated neuroadaptations (previously discussed in section 1.6) lead the 
smoker to have poor mental health. The hypothesis further suggests that after sustained 
cessation, withdrawal-induced negative affect dissipates and the smokers’ mental health will 
improve. Moreover, the model suggests that smokers misattribute the ability of smoking to 
relieve withdrawal symptoms to its ability to relieve other negative emotional states 
(Benowitz, 1999; 2010; Parrott, 1999), thus, also explaining why smokers report therapeutic 
effects from smoking. This section discusses evidence from psychological neurobiological 
and prospective studies which form the basis of this hypothesis. 
 
1.9.1.1. Experimental studies 
 
Parrott (1994) examined self-rated feelings of stress and arousal, before and after each 
cigarette over a day of normal smoking in 105 smokers. He found that smokers reported high 
stress levels before smoking and low stress immediately after smoking, with stress developing 
in-between periods of smoking. The study concluded that smoking reliably relieves stress, 
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although there were individual differences in this ‘effect’. Parrott and Garnham (1998) 
assessed mood outcomes in regular smokers, over-night deprived smokers and non-smokers, 
before and after a smoking/rest period. Smokers who were deprived overnight reported 
greater negative affect and stress before smoking compared with non-deprived smokers and 
non-smokers. After smoking, deprived smokers reported the greatest benefits from smoking, 
which reduced their negative mood to a similar level of non-deprived smokers, and non-
smokers reported no significant changes in their mood after smoking. These findings suggest 
that smoking reverses the psychological symptoms of withdrawal, and has no effect on mood 
in non-smokers, studies with similar designs have replicated these findings (Adan and 
Sanchez-Turet, 2000; Herbert et al., 2001; Parrott and Kaye, 1999). Parrot (1999; 1995) 
argues smokers misattribute the ability of smoking to relieve these withdrawal symptoms to 
its ability to relieve stress and other negative emotion. 
 
There are significant individual differences in the withdrawal effect. Parrott (1994) found the 
degree of change in negative affect was modulated by self-reported sedative effect of 
smoking, such that those who rated smoking as very relaxing displayed the greatest reduction 
in stress, and those who reported smoking as minimally relaxing reported little change in 
stress. Furthermore, withdrawal symptoms have been found more intense in heavier and more 
dependent smokers (Adan et al., 2004) and can vary over time, in that they normally peak 
during the first days of abstinence and remain for a few weeks (Hughes, 2007b). However, 
some symptoms such as depression may last longer for some individuals, and some have 
argued this may be a permanent effect of tobacco abstinence (Hughes, 2007a; 2007c). Thus, 
there is replicable evidence for the withdrawal cycle, however there are some individual 
differences between smokers in the severity of withdrawal effects. 
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1.9.1.2. Longitudinal cohort studies 
 
The second part of the misattribution hypothesis suggests smoking can cause poor mental 
health. This notion can be explored through prospective longitudinal studies which have 
followed people’s smoking and mental health over time.  
 
Johnson et al. (2000) followed approximately 700 teenagers from the age of 16 to 22, to 
determine if uptake of smoking was associated with onset of anxiety disorder in later life. 
They found that heavy cigarette smoking during adolescence was associated with increased 
odds of anxiety disorder in adulthood, OR=5.5 (95% CI: 1.8 to 16.7), occurrence of anxiety 
disorder during adolescence was not associated with uptake of smoking during adulthood, and 
these findings were not altered by adjustment for covariates. In a similar study, Jamal and 
colleagues (2011) found that younger age of smoking onset was associated with shorter 
duration to onset of anxiety disorder. Wu and Anthony (1999) followed children over time 
and examined the association between smoking and onset of depression during the teenage 
years. Results indicated that smoking during early adolescence was associated with increased 
odds of depression in the teenage years. Another prospective longitudinal cohort found that 
those who began smoking at age 15 had an increased odds of any mental health disorder at 18 
years, OR=2.8 (95% CI not reported) (McGee et al., 2000), however, after adjustment for 
environmental covariates and other substance use the association became weaker, 1.6 (95% 
CI not reported), suggesting that environmental factors contribute to the comorbidity of both 
smoking and mental health disorder. 
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Boden et al. (2010) prospectively analysed a longitudinal cohort study to assess the 
association between nicotine dependency and depressive symptoms in young adults. They 
followed over 1000 smokers’ mental health from ages 18 to 25. Analyses were adjusted for 
genetic and environmental factors and time-dynamic covariates such as employment and drug 
use using structural equation modelling. This study found that time-varying environmental 
and genetic factors could not explain the longitudinal relationship between smoking and onset 
of depression. Furthermore, there was a strong relationship between dependency and 
depressive symptoms, such that those who were more dependent experienced more depressive 
symptoms. Other research has found a dose-response relationship in individuals with anxiety 
disorders, such that those who are heavier smokers have more symptoms of anxiety and 
depression, and have worse recovery outcomes (Jamal et al., 2012).  
 
In contrast, an epidemiological study exploiting Mendelian randomisation examined the 
causal link between current smoking and current anxiety and depression (Bjorngaard et al., 
2013). This study showed some evidence that the genetic variant associated with nicotine 
dependence was associated with anxiety in never and former smokers, but not in current 
smokers. If there was a causal link between smoking and mental disorder, one would expect 
the association to be prevalent in current smokers, therefore, as a whole the study did not 
support a causal link between smoking status and current mental health problems, arguing 
against the misattribution hypothesis. Whereas, other studies have found nicotine dependency 
and mental illness have a common genetic basis (previously discussed in section 1.9.3.2). 
 
In sum, there is consistency between experimental and longitudinal studies. Experimental 
evidence shows that smoking reliably reverses negative affect in smokers and that longer 
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periods of abstinence are linked to worse withdrawal, and furthermore, non-smokers do not 
appear to display any mood benefits from smoking. Longitudinal data shows that smoking is 
related to onset of mental health disorder later on in life, which lends some support to the 
misattribution theory; although longitudinal data do not clarify whether poor mental health is 
the result of neuroadaptations. There is however, some evidence showing the reverse 
association (discussed in next section), and the possibility of a common cause threatens the 
strength of this unidirectional hypothesis. Importantly, these studies highlight the presence of 
individual differences, in that the most addicted smokers experience worse withdrawal and 
also seem to experience worse mental health later in life.  
 
1.9.2. The self-medication hypothesis 
 
The self-medication hypothesis was originally developed to help understand the aetiology and 
treatment of drug and alcohol addiction (Khantzian, 1974; 1975; 1978; 1997); and more 
recently this model has been adapted to explain the association between smoking and poor 
mental health (Khantzian, 1997). The hypothesis suggests that smokers use the chemical 
properties of tobacco to alleviate cognitive and emotional symptoms common in mental 
disorders. The model ascertains that people with mental health disorders are more likely to 
use tobacco for its therapeutic properties, and those with more severe disorders are more 
likely to be highly dependent. This model is supported by some neurobiological evidence 
suggesting that tobacco produces psychological effects independent of the withdrawal cycle 
and that these effects likely reinforce smoking behaviour (previously discussed in section 
1.6). It is possible this model is mediated by neurobiological disposition (previously discussed 
in section 1.6) and social beliefs about smoking’s therapeutic effects (previously discussed in 
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sections 1.4 and 1.5). To explore the self-medication model this section reviews evidence 
from experimental studies in humans and animals and from longitudinal cohorts. 
 
1.9.2.1. Experimental evidence  
 
Cognitive symptoms are common in many mental disorders therefore the model proposes that 
those with mental health disorders take up smoking to alleviate these symptoms in addition to 
other symptoms of their disorder. The effect of nicotine on cognitive performance has been 
examined in experimental studies of general population smokers and non-smokers. Foulds et 
al. (1996) conducted a placebo-controlled experimental study and compared cognitive 
performance between smokers and never smokers, before and after nicotine injection. Results 
demonstrated that nicotine enhanced attention, memory recall, verbal memory and reasoning 
performance in smokers, and attention and memory recall in never smokers. Smokers’ 
enhanced performance was likely due to reversal of nicotine withdrawal (previously discussed 
in sections 1.6 and 1.9.1). In contrast the findings in never-smokers suggest there are some 
cognitive benefits from nicotine which may act independently from the withdrawal cycle. 
Similar studies have replicated the benefits of nicotine on memory and reaction times in both 
smokers and non-smokers, and have found dose-dependent improvements on memory tasks in 
both smokers and non-smokers (Ernst et al., 2001; Perkins et al., 1994). On the other hand, 
other experimental placebo-controlled studies have produced null findings suggesting there is 
no effect of smoking or nicotine on cognitive performance (Heishman et al., 1993; Petrie and 
Deary, 1989; Sakurai and Kanazawa, 2002).  
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Deficits in cognition function are a common characteristic of schizophrenia (and classed as a 
negative symptom), and it is thought that nicotine is especially therapeutic for people with 
this mental illness (Kumari and Postma, 2005). A review summarised experimental studies in 
humans and animals, which examined the effects of nicotine on nicotinic cholinergic systems 
involved in negative symptoms of schizophrenia (Levin et al., 2006). Animal studies showed 
consistent evidence that nicotine enhanced performance during memory, learning and 
attention tasks in animal models of schizophrenia. In seven studies assessing cognitive 
performance in people with schizophrenia, nicotine was found to improve performance on 
sensory gating, spatial information processing, attention and memory tasks, in two studies a 
null effect on memory performance was found. Similar evidence has been found in other 
disorders with cognitive deficits, such as ADHD (Gehricke et al., 2006; 2009). In sum, there 
is consistent evidence from experimental studies which support the self-medication model and 
suggest there may be a cognitive benefit from nicotine for people with certain mental 
disorders.  
 
People with depression are thought to be more sensitive to cholinergic agonists (a chemical 
which binds to a receptor in turn activating a biological response) (Dagyé et al., 2011); 
therefore depressed individuals may be more responsive to nicotine’s effects. In studies using 
animal models of depression rats exhibit a reversal of depressed behaviour after 
administration of nicotine compared with nicotine administration to non-depressed rats, 
whose behaviour shows no change and this therapeutic effect has been found to last up to 14 
days in animals (Andreasen et al., 2011; Tizabi et al., 2010; Vieyra-Reyes et al., 2008). 
Several studies in humans have examined the effect of nicotine patches on depression 
symptoms in non-smokers with and without depression (Salin-Pascual et al., 1995; 1996; 
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1998). Results showed that nicotine patches relieved symptoms of depression over four days 
in non-smokers with major depression versus placebo, but had no mood effects in non-
depressed participants. These findings have been replicated up to four weeks (McClernon et 
al. 2006). Thus, results from human and animal studies show that nicotine has therapeutic 
effects on symptoms independent of the withdrawal-cycle and these effects seem to be 
prominent in those with depression. 
 
Cholinergic pathways are also impaired in anxiety disorders (Gray, 1982), it has been 
suggested that tobacco can produce anxiety-relieving effects during activation of the 
cholinergic system. In animal models of anxiety, some studies have reported a therapeutic 
effect of nicotine on anxiety, whereas other studies have reported nicotine exacerbates anxiety 
(Balfour et al., 1986; Irvine et al., 1999; Jonkman et al., 2008; Ouazana et al., 1999). File et 
al. (2000) found the effects of nicotine depended on location of administration, or on the type 
of animal model used, for example, nicotine may be more therapeutic in a generalised anxiety 
model compared with a social phobia model of anxiety. In summary, it is possible that 
nicotine may alleviate or worsen anxiety disorders however certain types of disorders may be 
more predisposed to these effects. 
 
1.9.2.2. Longitudinal cohort studies 
 
The self-medication hypothesis suggests people with mental health disorders are more 
susceptible to the effects of tobacco and evidence from neurobiological and experimental 
studies (previously discussed in sections 1.6 and 1.9.1.1 to 1.9.2.1) lend support to this. The 
hypothesis also suggests that smokers with poor mental health use smoking to alleviate 
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symptoms of their disorder. To further examine this notion, longitudinal studies can be used 
to determine if people with mental health disorders are more likely to begin smoking after 
onset of disease.  
 
In a US cohort study Swendsen et al. (2010) followed 5000 participants aged 15 to 54, over 
10 years to determine if having a mental disorder at baseline was associated with onset of 
smoking at follow-up. Results demonstrated that those with a mental disorder had an 
increased odds of smoking in later life; odds for major depression were, OR 1.4 (95% CI: 1.0 
to 1.9), bipolar, 3.1 (1.9 to 5.1), phobias, 1.4 (1.0 to 1.9), any anxiety disorder, 1.5 (1.1 to 
2.0), obsessive-compulsive disorder, 2.2 (1.4 to 3.4), ADHD, 1.8 (1.2 to 2.8), anti-social 
personality disorder, 2.0 (1.2 to 3.2).  
 
Similarly, a meta-analysis of five longitudinal studies showed that people with ADHD were 
more likely to start smoking, compared to those without ADHD, RR=1.9 (95% CI: 1.3 to 2.3) 
(Royal College of Physicians and Royal College of Psychiatrists, 2013). However, analyses of 
ADHD subtypes demonstrated that hyperactivity–impulsivity was not associated with 
smoking initiation; and smoking initiation was only significantly increased in those with 
hyperactivity-inattention. As ADHD is characterised by cognitive deficits, it may be that 
those with the disorder smoke to alleviate these symptoms. Experimental evidence suggests 
tobacco offers cognitive benefits to those with schizophrenia, there are no prospective studies 
examining schizophrenia at baseline and later uptake of smoking. However, a systematic 
review of 42 cross-sectional studies showed there was a strong association between smoking 
and schizophrenia, OR=7.2 (95% CI: 6.1 to 8.3) (de Leon and Diaz, 2005). 
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Murphy and colleagues (2003) analysed data from a 40 year longitudinal cohort study and 
found subjects who became depressed during the study were more likely to start smoking, and 
there was no evidence for the reverse association. Escobedo et al, (1998) prospectively 
assessed the relationship between symptoms of depression and anxiety in early adolescence 
and uptake of smoking four years later. Results indicated that those who reported depressive 
symptoms at baseline were more likely to be smokers at follow-up, OR=1.3 (95% CI: 1.1 to 
1.6). In contrast, another prospective study found that depressed mood during pre-teen years 
was not associated smoking initiation 20 months later (Polen et al., 2004), although the age of 
the sample may have been too young to predict smoking onset. Fergusson et al. (2003) found 
young people with major depression at baseline had elevated rates of smoking at multiple 
follow-ups during young adulthood, however those who smoked at baseline were also more 
likely to have depression in later years. Moreover the strength of these associations was 
greatly reduced after adjusting for factors associated with both smoking and depression, for 
example peer-group. Peer-group and other environmental factors have also been found 
associated with both smoking and mental health in other longitudinal studies (Killen et al., 
1997; Patton et al., 1998). A similar pattern of results has been found for smoking and onset 
of anxiety disorders (Patton et al., 1998). 
 
There is a clear link between mental health disorder and smoking in later life. These 
longitudinal associations, in combination with neurobiological and experimental evidence 
support the self-medication model. However, there is some evidence showing the reverse 
association, and the possibility of confounding from a common cause threatens the strength of 
this hypothesis.  
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1.9.3. The common cause hypothesis 
 
Some research has found no significant association between smoking and mental health, or 
has identified confounding factors to be associated with both directions of the association. 
This suggests that the association between smoking and mental health may not be causal. It is 
possible that a third common factor which leads to both smoking and poor mental health may 
exist, the evidence exploring this hypothesis suggests that psychosocial, genetic or 
environmental factors may play a role in the development of co-morbid smoking and poor 
mental health. 
 
1.9.3.1. Personality factors 
 
Some personality traits may act as a shared vulnerability to both smoking and mental health 
problems. Neuroticism is characterized by anxiety, moodiness and worry (Goldberg, 1993; 
McCrae and Costa, 1987) and smokers consistently score higher on measures of neuroticism 
compared with never smokers (Spielberger and Jacobs, 1982; Terracciano and Costa, 2004). 
In a longitudinal cohort study Byrne and colleagues (1995) followed adolescents over 12 
months and found that those who smoked at baseline and follow-up scored significantly 
higher on neuroticism compared with non-smokers. High neuroticism is also associated with 
poor psychological quality of life and with mood, neurotic and psychotic disorders (Graaf et 
al., 2000; Khan et al., 2005; Lahey, 2009; Weinstock and Whisman, 2006). Goodwin et al. 
(2002) found that neuroticism independently predicted the co-occurrence of smoking and 
panic attacks, but neuroticism did not predict either factor alone. Furthermore, there is some 
evidence that stopping smoking may be associated with reductions in neuroticism (Parrott, 
32 
 
1998). However, it is also possible that co-occurrence of smoking and mental disorder is a 
risk factor for the development of a neurotic personality. On the same note there are other 
personality traits which are related to mental illness such as low extraversion (Bienvenu et al., 
2001; 2004) and conscientiousness (Terracciano and Costa, 2004), thus a multitude of traits 
may contribute to the co-occurrence, or vice-versa. 
 
1.9.3.2. Common genetics and/or environment 
 
Family studies have aimed to examine the co-occurrence of smoking and mental illness in 
probands (i.e. exposed participant, ascertained independently from their relatives) and their 
first degree relatives. If the association is strong across probands and their relatives this 
indicates a familial association. Family studies have shown that smoking and mental health 
disorder commonly co-occur in individuals within families, suggesting the contribution of 
shared environment or genetics and evidence is strong for depression, anxiety (Dierker et al., 
2002; Swendsen and Merikangas, 2000), schizophrenia (Lyons et al., 2002) and ADHD 
(Rohde et al., 2004). However, these studies do not show the independent contribution of each 
factor to the association.  
 
Studies in twins can be used to determine the contribution of genetics and environment on 
smoking behaviour and mental health (phenotypic characteristics). These studies typically 
compare phenotypic similarities between monozygotic twins who share 100% of the same 
genotype, with dizygotic twins who share 50% of the same genotype. One can assume 
substantial genetic contribution if monozygotic twins display similar traits or behaviours 
compared with dizygotic twins.  
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A cross-sectional study examined the association between smoking and depression in 
monozygotic and dizygotic twins discordant for depression history (Kendler et al., 1993). Co-
twin analyses indicated that depression history did not significantly predict ever-smoking, and 
that smoking did not predict depression history. The best fit model indicated that common 
environment accounted for 27% of the variance in liability to smoking, but none for 
depression; and the association between co-morbid smoking and depression was highly 
correlated with genetic factors (r=0.56). This study suggests that common genes influence the 
association between depression and smoking, and results from similar twin studies support 
these findings (Edwards et al., 2011). Conversely, other twin studies have found that non-
shared environment is dominant (McCaffery et al., 2003).  
 
Research has examined if specific genes are associated with smoking and depression. 
Audrain-McGovern et al. (2004) analysed a longitudinal cohort study to determine if specific 
polymorphisms (in DRD2) were associated with smoking and depression in adolescents. 
Results showed there was a dose-response relationship between the number of DRD2-A1 
alleles and depression symptoms, such that as number of alleles increased so did depression 
symptoms. Furthermore, there an association between the number of DRD2-A1 alleles and 
increased likelihood of progressing from at least ‘one puff’ at baseline to regular smoking two 
years later, OR=1.9 (95% CI: 1.2 to 2.9). However, this association became non-significant 
when adolescents who had not ever smoked “even a puff” were included in the model. Next 
the researchers investigated if depression moderated the association between DRD2-A1 
alleles and smoking progression, and found that an increase of one standard deviation in 
depression symptoms almost doubled the effect of A1 alleles on smoking progression. The 
authors concluded that having at least one DRD2-A1 allele indicated a vulnerability to 
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depression, and that this genetic disposition to depression may have a synergistic effect on 
progression to smoking. Importantly, this model became non-significant when people who 
had never smoked were added, suggesting that perhaps smoking at least one-puff activates the 
DRD2 allele. Thus, smoking and depression share a common genetic pathway, however 
exposure to smoking may activate certain pathways. 
 
Other studies have examined the impact of environment on smoking and depression and 
anxiety. Audrain-McGovern and colleagues (2009) prospectively analysed a longitudinal 
cohort study and measured adolescents’ smoking behaviour and depression symptoms over 
four years. They found a bidirectional relationship such that depression symptoms during 
mid-adolescence predicted smoking progression in late adolescence, and smoking in mid-
adolescence predicted depression in later adolescence. However, peer-group smoking 
mediated the association, such that more depression symptoms predicted an increase in the 
number of smoking peers, which in turn, predicted smoking progression. Other longitudinal 
cohort studies have similarly found peer group to be a mediating factor in the association 
between smoking and depression (Fergusson et al., 2003) and smoking and anxiety (Patton et 
al., 1998). These studies suggest that environmental factors influence the strength of the 
association.  
 
Rates of smoking in people with schizophrenia are much higher than in other disorders 
(previously discussed in section 1.8), suggesting a stronger association in this disorder 
compared with other disorders or with the general population. People with schizophrenia have 
abnormal expression of certain genes which are implicated in both schizophrenia and nicotine 
dependence (Mexal et al., 2010; Riley et al., 2000). Lyons et al. (2002) conducted a co-twin 
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analysis of smoking behaviour in a sample of discordant twins (i.e. one with schizophrenia 
and the other without schizophrenia), versus a control group of twins (i.e. pairs without 
schizophrenia). They found that probands with schizophrenia had an increased odds of 
smoking, OR=2.6 (95% CI: 0.9 to 7.6), versus control twins without schizophrenia, and 
probands without schizophrenia also had an increased odds of smoking, 3.7 (1.1 to 12.3), 
versus control twins. The authors stated that smoking was influenced by familial vulnerability 
to schizophrenia. Alternatively, it is possible that family stresses associated with having a co-
twin with schizophrenia might lead to adverse emotional consequences, in turn, increasing the 
risk of smoking. There are few twin studies in people with schizophrenia, however, the 
existing evidence suggests there is a genetic contribution to both smoking behaviour and the 
disorder. 
 
There is a strong case for the contribution of a common cause to the co-occurrence of mental 
health problems and smoking. Personality traits are a possible risk factor, although the 
direction is uncertain. It appears that genetics may contribute more to the co-morbidity 
compared with environment; however there are some studies presenting null results or a 
strong environmental influence. Furthermore, it is possible that smoking ‘one puff’, activates 
certain genetic pathways which may dispose individuals to further smoking behaviour and/or 
mental health problems.  
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1.10. Smoking cessation and mental health 
 
Each of the hypotheses discussed above have important implications for smokers, smoking 
cessation specialists and cessation interventions. The misattribution hypothesis suggests that 
after sustained cessation withdrawal induced negative affect will diminish and in turn 
smokers’ mental health will improve. The self-medication hypothesis suggests that smoking 
alleviates symptoms of psychological distress, therefore after cessation the quitter will 
experience worse mental health. The common cause hypothesis suggests that quitting is 
unlikely to change mental health unless the true causal factors that maintain poor mental 
health also change. A literatures search using terms related to “mental health” “smoking” and 
“cessation” was conducted to find longitudinal studies and systematic reviews which have 
examined the influence of smoking cessation on mental health. 
 
1.10.1. Longitudinal studies 
 
The search strategy produced five longitudinal cohort studies which examined dichotomous 
mental health outcomes in smokers who stopped smoking compared to smokers who 
continued smoking. Three of these studies have not been reviewed elsewhere, two (Glassman 
et al., 2001; Tsoh et al., 2000) have been previously reviewed by both Hughes’ (2007c) and 
Ragg et al. (2013) (as discussed ahead, in section 1.10.2).  
 
Khaled et al. (2012) estimated the risk of major depression over nine years in 1184 self-
reported heavy smokers who quit and 479 heavy smokers who continued smoking. 
Participants with a history of depression were excluded. They found that smokers were 
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significantly more likely to report onset of major depression compared with quitters, and this 
association remained significant after adjustment for common causes of both smoking and 
depression, including personality traits, family history of depression and stress, hazard ratio 
(HR)=3.3 (95% CI: 1.8 to 6.2). Secondly, the researchers categorised quitters according to the 
number of years they had been abstinent and compared risk of depression with those who 
continued smoking. Before and after adjustment for covariates there was a dose-response 
relationship between duration of abstinence and risk of depression; in that those who quit for 
longer periods showed less risk than those who had remained abstinent for shorter periods. 
For example, quitters who remained abstinent for one to five years showed a decreased risk, 
HR=0.5 (95% CI: 0.3 to 0.9) relative to smokers, and those who had remained abstinent for 
≥21 years showed a five-fold protection against depression compared with continuing 
smokers, HR=0.2 (95% CI: 0.1 to 0.5). These findings suggest that quitting itself is protective, 
or that people who quit are more likely to have other protective traits than do people who 
continue smoking. However, this study was missing the depression status for one third of the 
participants and this may have introduced selection bias. It is also possible that reverse 
causality was operating, i.e. that improved mood facilitated quitting. Moreover, the largest 
threat to the association is bias arising through differences in participants’ propensity to 
achieve abstinence, and in this analysis covariates associated with propensity to quit were not 
adjusted for, for example nicotine dependency, or receipt of smoking cessation treatment 
(Stead et al., 2012; Vangeli et al., 2011). 
 
Sanchez-Villegas (2008) examined data from a cohort of university students who were 
followed-up every two years from 1999 to 2005. Data were analysed from 8556 participants 
who had no initial psychiatric diagnoses, and analyses were adjusted for major confounders 
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such as age, sex, marital status, and physical activity. Adjusted and unadjusted estimates were 
similar and indicated that those who were quit for more than 10 years were significantly less 
likely to report a new diagnosis of depression compared with those who continued smoking, 
adjusted HR=0.4 (95% CI 0.2 to 0.9), though outcome was not meticulously accessed. These 
data are similar to those reported above by Khaled et al. (2012), and this suggests there is 
some consistency in the association, and are further supported by studies showing that quitters 
are more likely to stop using anti-depressants after cessation, compared with continuing 
smokers (Shahab et al., 2014). However, interpretation of these studies remains inconclusive 
due to the possibility of reverse causation. Moreover, it is possible that there are systematic 
differences between quitters and continuing smokers, thus risk of bias through group 
membership cannot be ruled out. 
 
Bolam et al. (2011) prospectively analysed data from an international general population 
cohort study. They examined whether or not cessation was associated with change in 
incidence of depression and anxiety nine months after stopping smoking. Smoking data were 
available for 1565 participants and 3% of these (N=42) reported being quit for six or more 
months. They reported no association between cessation and change in symptoms of 
depression or anxiety from baseline to nine months post-cessation, OR=1.0 (95% CI 0.4 to 
2.6) and 1.1 (0.4 to 2.8), respectively. These data, however, were limited by the small number 
of people who maintained cessation, compared to those who continued smoking. Importantly, 
there was some evidence that those with poor mental health at baseline were more likely to 
drop-out by follow-up.  
 
39 
 
Tsoh et al. (2000) conducted a secondary analysis of two randomised controlled trials of 
smoking cessation treatment which included participants with and without a history of major 
depression. One trial was of nortriptyline (medication for cessation), plus cognitive 
behavioural therapy for smoking cessation (Hall et al., 1998), and the second trial was of 
nicotine replacement therapy (NRT), plus mood management for smoking cessation (Hall et 
al., 1996). At follow-up Tsoh et al. (2000) reported the incidence rate for major depression 
was 14.7% amongst quitters, and 13.4% amongst smokers. The depression rate for quitters 
was higher, however logistic regression models adjusted for depression history indicated that 
stopping smoking was no longer associated with onset of depressive episodes, OR=1.3 (95% 
CI: 0.6 to 2.6). In a similar study Glassman et al. (2001) conducted a secondary prospective 
analysis of RCT data in which participants with depression history were excluded. One 
hundred participants were randomised to receive sertraline (medication for cessation) or 
placebo for 11 weeks and were followed-up at six months, at follow-up 34 participants 
continued smoking and 6% of these had symptoms of major depression, compared with 42 
participants who had quit by follow-up, of whom 31% reported major depression. Before and 
after adjustment for receipt of smoking treatment, quitting smoking was associated with an 
increased risk of depression compared with those who continued smoking, OR=7.2 (95% CI: 
1.5 to 34.5). However, one must account for differential loss to follow-up between groups, 
39% of smokers were lost to follow-up and their depression status was undetermined and only 
5% of quitters were lost to follow-up. These studies indicate that quitting may be associated 
with increased risk of depression, and reverse causality may be less likely to arise in these 
studies as everyone attempted to quit and depression was measured shortly before the quit 
attempt and at follow-up, therefore cessation was less likely to be contingent on mood. 
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Though ultimately, interpretation of these studies’ results is not straightforward due to 
confounding and attrition bias. 
 
In sum, studies which have estimated the risk of disorder in people who stopped smoking 
compared with those who continued smoking present mixed results. Two studies were from 
general population cohorts. One study assessed change in risk, by measuring mental health 
before and after people stopped, compared with those who continued and found no 
association (Bolam et al., 2011), whereas another cohort study indicated a decreased risk at 
follow-up for quitters (Sanchez-Villegas et al., 2008). Two studies which excluded people 
with a history of depression were dissimilar. One of these reported that cessation was 
associated with increased risk of depression, although loss to follow-up was an issue here 
(Glassman et al., 2001). Whereas the other study reported that stopping smoking was 
associated with a decreased risk in depression, however the association was weaker for 
smokers more recently quit (Khaled et al., 2012). In all of these studies attrition was a 
problem, with one study displaying evidence that depressed participants may have been more 
likely to drop-out (Bolam et al., 2011), and in many population cohorts ascertainment of 
outcome was not strong. Overall, these studies are also at risk of unmeasured confounding 
and direction of causation is questionable, especially in population cohort studies. Moreover, 
the largest threat to the association is bias arising through participants’ propensity to achieve 
abstinence. If bias through group membership occurs comparison of the groups is likely 
unjustified (Grimes and Schulz, 2002; Rosenbaum and Rubin, 1984). Covariates associated 
with propensity to quit (e.g. nicotine dependency) were rarely adjusted for in these studies 
therefore one cannot be sure if group membership was an issue. In conclusion, the results 
from these studies are uncertain.  
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1.10.2. Systematic reviews 
 
The search strategy produced three systematic reviews which have examined the association 
between smoking cessation and mental health. 
 
Hughes (2007c) conducted a review of seven cessation intervention studies of medication 
versus placebo for cessation and aimed to determine the onset of depression after cessation in 
those with depression history. All included studies excluded people with current major 
depression and reported cases of depression among subjects during follow-ups ranging from 
two to 12 months, however only one study statistically tested the association. Across the 
studies the incidence of major depression among smokers who tried to quit was 0% to 14%, 
those with a past history of major depression who tried to quit the rate was 3% to 25%, and 
among successful quitters the rate was 1% to 31%. In every trial the depression rate was 
highest in the quit group compared to the whole study cohort. Hughes (2007a; 2007c) argued 
the results supported self-medication hypothesis (Khantzian, 1997), or alternatively that 
depression after cessation may have been caused by long-term use of tobacco (previously 
discussed in section 1.6). Hughes (2007c) review could not provide a formal estimate for 
onset of major depression as comparison groups were not available. Importantly, in this 
review Hughes (2007c) highlighted the possibility that smokers and quitters may be 
inherently different, therefore any formal comparison would at risk of bias. 
 
Banham and Gilbody (2010) systematically reviewed eight RCTs of smoking cessation 
interventions in people with severe mental illness (i.e. psychoses, bipolar disorder). All trials 
measured mental health outcomes during the intervention period with follow-ups ranging 
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from two to 24 months. Two studies measured anxiety, one of these found the intervention 
group significantly improved and the other reported no significant difference between trial 
arms. Eight studies measured depression, one reported a significant improvement in the 
intervention arm, and seven reported non-significant differences between trial arms. Three 
trials reported an improvement in psychotic symptoms in the treatment arm, and five reported 
no change. Furthermore, there were minimal psychiatric adverse events; only in one trial two 
participants had suicidal ideation, however the arm in which these occurred was not reported. 
These data were analysed by treatment group rather than by comparing data between people 
who quit or continued smoking, therefore do not directly estimate the effect of cessation on 
mental health. However, importantly this review did not find any evidence to suggest that 
helping people to stop smoking causes harm to mental health.  
 
A systematic review aimed to investigate the impact of smoking cessation on schizophrenia 
and major depression (Ragg et al., 2013). The authors reviewed incidence and mean change 
data from RCTs of treatment for smoking, and cohort studies conducted in people with 
diagnoses of depression or psychotic-disorders. The clinical trials of smoking cessation 
treatment for people with psychosis were previously reviewed by Banham and Gilbody 
(2010). Six studies examined the impact of cessation in people with depression. Three of 
these studies reported change scores and two studies reported only descriptive data for 
quitters; none of these reported cessation was linked to psychological harm. One study, 
however found that those who quit had an increased risk of depression (Glassman et al., 
(2001) reviewed above). In sum, results from this review were mixed and there was 
significant heterogeneity between study design and summary statistics, therefore a formal 
estimate could not be calculated.  
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These reviews reported varied findings. Hughes (2007c) concluded there was evidence that 
those with depression history are at risk of depression after cessation. Banham and Gilbody 
(2010) found that helping people with severe mental illness to quit was not associated with 
psychological harm. Ragg et al. (2013) reported that cessation was not harmful to the mental 
health of people with psychotic illnesses, but for people with depression there was mixed 
evidence. Thus, based on these reviews the “effect” of smoking cessation on mental health is 
inconclusive.  
 
1.11. Chapter summary and aim of thesis 
 
This literature review has highlighted that smoking is major risk factor in the development of 
fatal or life-changing disease and by stopping smoking one can avoid the majority of this risk. 
However, the association between smoking, smoking cessation and mental health is less clear-
cut. Most smokers want to quit but fail and report the mental health benefits of smoking are a 
major reason to continue. However, survey data indicates that smokers have poor mental 
health compared with non-smokers and furthermore that the smoking population is over-
represented by people with mental health disorders. The belief that smoking has psychological 
benefits is also upheld by many health professionals, and in many cases this presents a serious 
barrier to cessation interventions in both general and clinical populations. Approximately one 
third of the smoking population show evidence of a mental health disorder; moreover, people 
with mental health disorders have a life expectancy of eight to 20 years shorter than the 
general population and much of this difference could be because of smoking (Chang et al., 
2011; Chesney et al., 2013; 2014). However, evidence for mental health benefits from tobacco 
is not clear and the impact of quitting smoking on mental health is also uncertain. If this 
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association was clarified, and smoking cessation was found to offer mental health benefits, 
this could be used to motivate smokers to stop, empower smokers with confidence in their 
ability to control unwanted emotion, educate health professionals, and potentially used to 
inform public health policies.  
 
The reviewed literature provides important information, however as discussed throughout this 
chapter these data are limited in various ways. Firstly, no systematic review has directly 
estimated change in mental health in quitters compared with continuing smokers. Secondly, 
no systematic review has examined change in mental health after cessation in those without 
diagnosed mental disorders. Overall, the vast majority of the reviewed studies are at risk of 
group membership bias and unmeasured confounding. Therefore, this thesis aims to: 
 
1) Conduct a systematic review and meta-analysis of longitudinal studies to compare 
change in mental health between quitters and continuing smokers from general, 
psychiatric and other clinical populations, and to compare effect estimates between 
populations based upon their clinical characteristics. These data are presented in 
Chapter Two. 
2) Conduct an analysis of individual level patient data to further examine the impact of 
group membership bias and confounding in the association between stopping smoking 
and mental health. Propensity score matching (PSM) will be used to create a matched 
sample of quitters and continuing smokers based upon characteristics which predict 
their propensity to achieve abstinence. Chapters Four and Five will use this method to 
examine a) change in mental health in quitters compared with those who continued 
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smoking and b) onset of psychiatric disorder after stopping smoking compared with 
those who continued smoking. 
3) It is possible some people who quit experience worse mental health therefore relapse 
back to smoking, while quitters who experience mental health benefits continue to be 
abstinent. This hypothesis will be tested in Chapter Six, via an analysis of individual 
level patient data.  
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CHAPTER TWO 
2. CHANGE IN MENTAL HEALTH AFTER SMOKING CESSATION: A 
SYSTEMATIC REVIEW AND META-ANALYSIS 
 
2.1. Introduction to Chapter Two 
 
In this chapter I present a systematic review and meta-analysis of longitudinal studies that 
reported the difference in change in mental health outcomes from baseline to follow-up 
between smokers who quit and smokers who continued smoking. The findings from this 
chapter were published in BMJ in February 2014 (Appendix 1): 
 
Taylor, G., McNeill, A. and Girling, A. et al. (2014). Change in mental health after 
smoking cessation: systematic review and meta-analysis. BMJ, 348 (g1151). 
 
This chapter has been slightly edited to avoid repetition from Chapter One, and includes a 
supplementary analysis not included in the published version. 
 
2.2. Background 
 
Although smokers believe that smoking offers mental health benefits, there is a strong 
association between smoking and poor mental health (discussed previously in sections 1.7 to 
47 
 
1.8). Three broad explanations have been proposed to explain these associations: smoking and 
poor mental health might have common causes (discussed previously in section 1.9); people 
with poor mental health smoke to regulate feelings such as low mood and anxiety (Khantzian, 
1997); or smoking might cause or exacerbate mental health problems (Parrott, 1999). 
Whatever the cause, the association between smoking and poor mental health warrants 
attention. Smokers might be less likely to stop if they believe their mental health will suffer, 
and some health professionals are reluctant to intervene with subgroups of smokers because 
they believe that this might be detrimental to their mental health (Johnson et al., 2010; 
McNally et al., 2006; Ratschen et al., 2009a).  
 
2.2.1. Study aims and hypotheses 
 
In this study the aim was to conduct a systematic review and meta-analysis of longitudinal 
data to examine the difference in change in mental health between people who stopped 
smoking and people who continued to smoke. I hypothesized that smokers who quit would 
experience an improvement in mental health because they would no longer experience 
multiple episodes of negative affect induced by withdrawal. 
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2.3. Methods 
 
2.3.1. Eligibility criteria  
 
A broad eligibility criterion was used to capture all potentially relevant data and then 
sensitivity and subgroup analyses were conducted to investigate clinical and methodological 
heterogeneity. Eligibility was decided on based on the following criteria: 
 
Population — Studies of smokers in the general population or any that had selected smokers 
from populations defined by the presence of a clinical diagnosis;  
 
Exposure — Studies that reported data on those who had continued smoking and those who 
had quit smoking during the study period;  
 
Outcome — Any study that had measured mental health immediately before quitting and at 
least six weeks after quitting;  
 
Language — No exclusions were made based on language;  
 
Study design — Only longitudinal studies (that is, randomised controlled trials and cohort 
studies). 
 
When data on change in mental health were available from different follow-ups within a 
single study the longest was used. Any type of measure of mental health was included (i.e. 
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self-report and clinician scored). Only studies that provided sufficient data to calculate the 
standardised mean difference (SMD) and its variance in change in mental health score from 
baseline to follow-up between quitters and continuing smokers were included. The 
standardised mean difference is the difference in change in mental health between baseline 
and follow-up divided by the standard deviation (SD) of the change. It is used to overcome 
the issue that depression, for example, can be measured by different questionnaires with 
different scoring systems. The questionnaires all measure depression but the different scoring 
means that they cannot be combined by using a simple mean. A SMD of 1 represents a 
difference in change in depression score of 1 SD. About 4 SD encompasses 95% of the 
population (Higgins and Green, 2011). 
 
2.3.2. Information sources and searches 
 
The following databases were searched for studies: Web of Science, Cochrane Central 
Register of Controlled Trials, Medline, Embase, and PsycINFO for studies published from 
inception to April 2012, a combination of text words and indexed terms related to “mental 
health,” “smoking cessation,” and “smoking reduction” were used (Appendix 2). Study 
authors were contacted to obtain relevant missing data. Reference lists of included studies 
were also searched. All non-English language studies were translated.  
 
2.3.3. Study selection 
 
The aim was to maximise sensitivity by including studies in initial screens even if data 
directly relevant to the study question were not presented in the abstract. One researcher (GT) 
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screened titles of retrieved studies for eligibility. The abstracts of eligible titles were screened 
twice for inclusion (GT, NL, PA). The researchers met after independently screening abstracts 
to discuss inclusion/exclusion of each article. If there were disagreements, two researchers 
obtained and read the full text article (GT, PA, AG, AM). 
 
2.3.4. Data collection process 
 
Two researchers piloted the data extraction form, and appropriate changes were then made 
(GT, AM). The same two researchers independently extracted data from each paper and 
agreed on final data extraction in the case of disagreement (GT, AM). The corresponding 
authors of studies were contacted for additional data when necessary. Studies were excluded 
only if data on the change in mental health and its variance could not be obtained. 
 
2.3.5. Data items 
 
The following data items were recorded: 
 
Participants — Tobacco dependence and number of cigarettes smoked a day (CPD), age, sex, 
and motivation to quit, all at baseline. 
 
Exposure — Classification and biological-validation of abstinence from tobacco. 
 
Comparator — The same data items were extracted for continuing smokers. 
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Outcomes — Data on the change in mental health between baseline and follow-up. When such 
data were not available, relevant data were extracted to calculate this (see Appendix 3 for 
formulas). To categorise mental health outcomes each measure’s key reference and 
questionnaire was examined to determine what it was designed to measure. The change in 
mental health unadjusted for confounding, and estimates which had been adjusted for 
confounding using multivariable techniques were extracted. 
 
Other items — Additional data were extracted to investigate clinical and methodological 
heterogeneity within and across studies (see sensitivity analyses for justification and 
methods). These items included study design, study quality score (Newcastle-Ottawa scale) 
(Wells et al., 2010), evidence of outcome reporting bias, follow-up length, covariates adjusted 
for, mental health management used in the intervention, and number of participants analysed 
at baseline and follow-up. 
 
2.3.6. Statistical methods 
 
2.3.6.1. Data extraction 
 
The summary measure was the SMD in change in mental health from baseline to follow-up 
between continuing smokers and people who managed to stop. Some studies reported either 
the difference in change or the standardised difference in change between continuing smokers 
and quitters, and hence data extraction of the effect estimate was straightforward. In some 
cases studies presented the mean change for each group and therefore permitted calculation of 
the differences. In other cases, studies reported the mean at baseline and at follow-up for each 
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group. The change and its variance was calculated using a standard formula (Follmann et al., 
1992), imputing a correlation coefficient taken from one of the largest studies included in the 
review (formula reported in Appendix 3). In all cases, the variance was also extracted. If the 
variance was not presented it was calculated from P values, confidence intervals, or F values 
following standard formula as recommended by the Cochrane Collaboration (Higgins and 
Green, 2011).  
 
2.3.6.2. Meta-analysis method 
 
A generic inverse variance random effects model was used to pool the SMD between change 
in mental health in quitters and continuing smokers from baseline to follow-up. A random 
effects model was used as it incorporates heterogeneity both within and between studies. 
Statistical heterogeneity was assessed with Chi
2
 and I
2
 tests. The meta-analyses and 
sensitivity and subgroup analyses were all conducted using Review Manager 5. 
 
Studies’ effect estimates (SMD) were pooled by using the following outcome categories: 
anxiety, depression, mixed anxiety and depression, positive affect, psychological quality of 
life, and stress. The SMD was calculated because the scales used to measure each outcome 
varied within category. This is standard practice for meta-analyses as outlined within the 
Cochrane Collaboration Handbook of Systematic Reviews and Meta-Analyses (Albrecht et 
al., 2000) and as used in other high quality meta-analyses of continuous mental health 
outcomes (Bower et al., 2013; Hunot et al., 2007; Smith et al., 2010). 
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Studies with different follow-up periods were combined. Each study’s longest follow-up 
period was used, as suggested by the Cochrane Collaboration. Heterogeneity between studies’ 
follow-up length was accounted for by use of a random effects model. This is standard 
practice as outlined by the Cochrane Collaboration (Higgins and Green, 2011), and as used in 
other high-quality meta-analyses of continuous mental health, with varying follow-up periods 
(Bower et al., 2013; Hunot et al., 2007; Smith et al., 2010). 
 
If studies provided sufficient data the standardised average mean change in mental health 
outcomes was calculated for quitters and smokers (formula presented in Appendix 3). These 
data were plotted for descriptive purposes only. 
 
2.3.7. Quality assessment 
 
The quality of the evidence in each study on the association of change in smoking status with 
change in mental health was assessed using the Newcastle-Ottawa quality scale (Wells et al., 
2010), adapted for this study (Appendix 4), this assesses the quality of evidence based on the 
selection of the comparison groups, the comparability of the groups, and the quality of the 
measurement of exposure and outcome. The adapted scale rated studies from 0 to 5, and 
studies with a rating of 3 or lower were deemed as at higher risk of bias. 
 
2.3.8. Assessment of publication and outcome reporting bias 
 
Funnel plots were examined for evidence of asymmetry and Egger tests were conducted for 
evidence of small study bias using STATA 13 (Egger et al., 1997). 
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In some studies, data on change in mental health were presented incidentally and the aim was 
to report on other data. In others, the aim of the report was to present data on change in mental 
health, therefore the decision to publish might have been contingent on the results. The effect 
estimates were compared between studies in which mental health was the primary outcome 
and those in which it was not to assess if there was evidence of publication bias. 
 
When studies had relevant data on change in mental health but did not report sufficient data 
for meta-analysis, attempt to estimate the direction of association to and compare this with 
included studies was made, as this could indicate reporting bias. 
 
2.3.9. Sensitivity analyses and assessment of risk of bias within and across studies 
 
Multiple sensitivity analyses were conducted to examine if the pooled effect estimate was 
influenced by including studies in which the risk of bias was greater or was influenced by 
characteristics of the study design or population. Either subgroup analyses were performed or 
studies presenting a risk of bias were removed and the pooled estimates were compared with 
and without the excluded studies. 
 
2.3.9.1. Adjustment for covariates 
 
It is possible that change in mental health could be confounded by other differences between 
continuing smokers and quitters. To account for this, some studies adjusted their data for 
covariates thought to be associated with change in smoking status or mental health. A 
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subgroup analysis was conducted to compare the effect estimate between studies that 
presented adjusted and unadjusted data. 
 
2.3.9.2. Loss to follow-up 
 
Some studies reported on change in mental health only in participants who were followed up, 
thus eliminating from the analysis those who were lost to follow-up. Other studies reported 
data on all participants who were present at baseline and the smaller number present at 
follow-up; it may be that people with poor mental health at baseline are more likely to drop 
out of studies (e.g. Bolam et al., 2011), thus possibly creating spurious changes in mental 
health through loss to follow-up. The convention in smoking cessation studies is to regard 
participants who are lost to follow-up as smokers, so loss to follow-up selectively affects the 
continuing smoker group. Whether or not studies reported data from a different number of 
participants at baseline and follow-up was recorded. 
 
2.3.9.3. Ascertainment of smoking status 
 
Some studies might misclassify exposure by using point-prevalence smoking abstinence. This 
could include participants who had been abstinent for only a week in the group were classed 
as having been abstinent for at least six weeks, though most smokers who are point prevalent 
abstinent for a week may have been abstinent for longer (Hughes et al., 2003; 2010). Recently 
abstinent smokers are likely to experience withdrawal symptoms including low mood 
(Hughes, 2007b). Thus, whether studies used a measure of prolonged or continuous 
abstinence (when misclassification could not have occurred) was recorded or if they used a 
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point-prevalence measure of abstinence. Likewise, particularly in smoking cessation trials, 
there is a danger that participants claim abstinence when this is not the case; therefore it best 
practice to biologically-validate smoking status (Hughes et al., 2003). Accordingly, whether 
or not self-reported abstinence was biologically-validated was recorded. 
 
2.3.9.4. Motivation to quit 
 
The hypothesis was that cessation improved mental health, but the outcome measure was the 
difference in change in mental health between those who stopped smoking and those who 
continued. It could be that such a difference would be evident if those who continued smoking 
had a worsening in mental health rather than those who stopped experiencing an 
improvement. Trying and failing to quit could worsen mental health, and some studies in the 
review derived data from smoking cessation trials. In these trials, all continuing smokers had 
tried but failed to achieve abstinence, and this disappointment could lead to worse mental 
health. In population cohorts, however, many continuing smokers would not have tried to 
achieve abstinence and therefore not have experienced this failure. Therefore studies were 
classified as selected or not selected by motivation to quit. Populations in which participants 
were not selected by motivation to quit were less likely to create this spurious difference 
between quitters and continuing smokers. 
 
2.3.9.5. Psychotherapeutic component within cessation intervention 
 
Having a psychotherapeutic intervention can improve mental health. Some smoking cessation 
interventions include mood management. Successful quitters often attend smoking cessation 
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clinics, while relapsers cease attending, meaning that one group might have had more 
counselling than the other. Trial protocols and the main report for smoking cessation 
intervention trials in which counselling had taken place were searched - to assess whether 
mood management was part of the intervention. 
 
2.3.10. Additional analyses 
 
2.3.10.1. Clinical population comparison 
 
The studies included in the review enrolled the general population, pregnant women, or 
patients who were postoperative, had a chronic physical condition, a psychiatric condition, or 
chronic psychiatric or physical conditions. Effect estimates were compared between these 
populations to determine whether there was evidence of a difference in size or direction. 
 
2.3.10.2. Study design 
 
The hypothesis was that stopping smoking improved mental health but any association 
between cessation and improved mood could be caused by reverse causation—that is, that 
improved mood caused successful cessation. The studies in this review fell into two groups: 
those recruiting a general population of smokers and those in which all participants were 
enrolled in smoking cessation trials. In trials, all participants attempted to quit, furthermore, in 
these studies mental health was assessed shortly before quit attempt (baseline), and six weeks 
or more after; therefore any detected change in mental health occurred after achieving 
abstinence. If improved mental health led to cessation, change in mood would have occurred 
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before the trials baseline assessment and therefore would not have been detected by change 
scores. Thus, secondary analyses from trials exclude the possibility that improved mood led to 
cessation.  
 
2.3.10.3. Length of follow-up 
 
Studies were examined for evidence of a difference in effect estimates between studies in 
which change in mental health was assessed from six weeks to six months or more than six 
months after baseline. 
 
2.4. Results 
 
2.4.1. Study selection 
 
The database and reference list searches resulted in 13,050 references. After initial screening 
219 full text articles were accessed for eligibility, of which 166 were excluded before data 
extraction (references and reasons for exclusion are presented in Appendix 5) Twenty seven 
were then excluded during data extraction (references and reasons for exclusion are presented 
in Appendix 6), 15 of which provided sufficient descriptions to include in a narrative 
synthesis of the direction and/or significance of change in mental health (Appendix 7). 
Twenty-six studies were included in the meta-analyses and for six of these studies authors 
supplied additional data (Appendix 8). See Figure 2.1 for flow of records. 
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Figure 2.1 Flow and identification of studies to include in review of change in mental 
health after smoking cessation 
 
2.4.2. Outcome categories 
 
The included studies examined six different measures of mental health: anxiety, depression, 
mixed anxiety and depression, positive affect, psychological quality of life, and stress (Table 
2.1).  
 
2.4.3. Extraction 
 
Several studies presented data on more than one outcome. Sixteen effect estimates were 
calculated from groups’ mean mental health scores, which were reported at both baseline and 
follow-up. Seven were calculated from studies that presented each groups’ mean change in 
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mental health score from baseline to follow-up. Two were calculated from a non-standardised 
difference in change. Three were extracted from other types of effect estimates. 
 
61 
 
Table 2.1 Included study and population characteristics 
Outcome 
category 
First author, and 
year of publication 
Study design Outcome measure(s) Follow-
up(s) 
Population Percentage 
male 
Mean (SD) age 
Anxiety Becona, 2002 Secondary analysis of 
cessation intervention 
State Trait Anxiety Inventory (state 
anxiety subscale) 
12 months General 53% 37.3 
Dawkins, 2009 Randomized experimental 
trial 
Hospital Anxiety and Depression Scale 
(anxiety subscale) 
3 months General 47% 68.9 
McDermott, 2013 
(in submission 
during search) 
Secondary analysis of 
cessation intervention 
State Trait Anxiety Inventory-6 6 months General 45% Abstainers 51.5, 
smokers 47.7 
Solomon, 2006 Cohort Brief Symptom Inventory (anxiety 
subscale) 
7 weeks Pregnant 0% 24.3 
Depression Berlin, 2010 Secondary analysis of 
cessation intervention 
The Hamilton Rating Scale for 
Depression 
11 weeks Psychiatric 37% 44.5 
Blalock, 2008 Secondary analysis of 
cessation intervention 
Beck Depression Inventory 3 months Psychiatric 19% 48 
Busch, 2011 Secondary analysis of 
cessation intervention 
Centre for Epidemiologic Studies 
Depression Scale 
6 and12 
months 
General 10% 32.9 
Dawkins, 2009 Randomized experimental 
trial 
Hospital Anxiety and Depression Scale 
(depression subscale) 
3 months General 47% 68.9 
Kahler, 2002 Secondary analysis of 
cessation intervention 
Beck Depression Inventory 6 and 12 
months 
Psychiatric 41% 45.1 
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Kahler, 2011 Secondary analysis of 
cessation intervention 
Centre for Epidemiologic Studies 
Depression Scale 
26 months General 55% 41.5 
Kinnunen, 2006 Cohort Minnesota Multi-phasic Personality 
Inventory 2 (depression subscale) 
5 years General 100% 42 
Munafo, 2008 Cohort Edinburgh Postnatal Depression Scale 4 months, 
3 years 
Pregnant 0% 29 
Solomon, 2006 Cohort Brief Symptom Inventory (depression 
subscale) 
7 weeks Pregnant 0% 24.3 
Vasquez, 1999 Secondary analysis of 
cessation intervention 
Beck Depression Inventory 12 months  General 35% 34.9 (9.4) 
Mixed anxiety 
and depression 
Blalock, 2008 Secondary analysis of 
cessation intervention 
Positive and Negative Affect Schedule 
(negative affect subscale) 
3 months Psychiatric 19% 48 
Chassin, 2002 Cohort Negative affect scale (non-
standardised) 
6 years General 48% 27.0 
Kahler, 2009 Secondary analysis of 
cessation intervention 
Multidimensional Personality 
Questionnaire (stress reaction 
subscale) 
6 months General 57·6% 40.9 (12.7) 
Mino, 2000 Cohort General Health Questionnaire-30 6 and 12 
months 
General 100% Abstainers 33.3, 
smokers 36.1 
Steinberg, 2011 Cohort Kessler Psychological Distress Scale 6 months Chronic physical and/or 
psychiatric condition 
47% Median 40 to 64 
Positive affect Blalock, 2008 Secondary analysis of Positive and Negative Affect Schedule 3 months Psychiatric 19% 48 
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cessation intervention (positive affect subscale) 
Croghan, 2005 Cohort Short Form Health Survey-36 (energy 
and vitality subscale) 
12 months General 52% Abstainers 52.8 
(11.2), smokers 54.6 
(15.6) 
Mitra, 2004 Cohort Short Form Health Survey-36 (energy 
and vitality subscale) 
3 to 4 
years 
Chronic physical and/or 
psychiatric condition 
42% 43.8 (13.3) 
Psychological 
quality of life 
Balduyck, 2011 Cohort European Organisation for Research 
and Treatment of Cancer Quality of 
Life Questionnaire (emotional 
functioning subscale) 
6 and12 
months 
Post-surgical 71% 59.3 
Croghan, 2005 Cohort Short Form Health Survey-36 (mental 
health composite) 
12 months General 52% Abstainers 52.8 
(11.2), smokers 54.6 
(15.6) 
Longmore, 2007 Cohort Short Form Health Survey-12 (mental 
health composite) 
12 months Chronic physical 
conditions 
Not 
reported 
18+ 
McFall, 2006 Secondary analysis of 
cessation intervention 
Short Form Health Survey-36 (mental 
health composite) 
2 months Psychiatric 91.6% 52.1 (6.8) 
Mitra, 2004 Cohort Short Form Health Survey-36 (mental 
health subscale) 
3 to 4 
years 
Chronic physical and/or 
psychiatric condition 
42% 43.8 (13.3) 
Quist-Paulsen, 2006 Secondary analysis of 
cessation intervention 
Cardiac Arrhythmia Suppression Trial 
Inventory (mental health subscale) 
12 months Chronic physical 
conditions 
73% 56.5 
Sarna, 2008 Cohort Short Form Health Survey-36 (mental 8 to 9 General 0% Range 29 to 71 
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health composite) years 
Stewart, 1995 Secondary analysis of 
cessation intervention 
Short Form Health Survey-36 (mental 
health subscale) 
6 months General 58% 40.6 
Stress Chassin, 2002 Cohort Stress (non-standardised composite) 6 years General 48% 27.0 
Hajek, 2010 Secondary analysis of 
cessation intervention 
Non-standardised measurement of 
perceived stress 
12 months Chronic physical  
conditions 
77% 56.0 
Manning, 2005 Secondary analysis of 
cessation intervention 
Perceived Stress Scale-14 6 months General 31% 44.4 
Beck’s Depression Inventory (Beck et al., 1988), Brief Symptom Inventory (Derogatis, 1993), Cardiac Arrhythmia Suppression Trial Inventory (Wiklund et al., 1992), Centre For Epidemiological 
Studies Depression Scale (Ross and Mirowsky, 1984), European Organization For Research And Treatment Of Cancer Quality Of Life Questionnaire (The European Organization for Research and 
Treatment of Cancer, 2001), Edinburgh Postnatal Depression Scale (Cox et al., 1987), Fagerström Test For Nicotine Dependence (Fagerström et al., 1990), General Health Questionnaire – 30 Item Form 
(Japanese Version) (Nakagawa and Daibo, 1985), Kessler Psychological Distress Scale (Kessler et al., 2002), Hospital Anxiety And Depression Scales  (Zigmond and Snaith, 1983), Hamilton 
Depression Inventory (Hamilton, 1960), Minnesota Multi-Phasic Personality Inventory (Butcher, 1989) , Multidimensional Personality Questionnaire (Tellegen, 1982), Positive And Negative Affect 
Scales (Watson et al., 1988), Perceived Stress Scale – 14 Item Form (Cohen et al., 1983), Short Form Health Survey-36 (Ware et al., 1993) (Ware, 1993), State Trait Anxiety Inventory – 6 Item Form 
(Marteau and Bekker, 1992) , State Trait Anxiety Inventory (Spielberger et al., 1983). 
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2.4.4. Study characteristics 
 
Eleven of the studies were cohort studies, 14 were secondary analyses of cessation 
interventions, and one was a randomised trial. Study enrolment included the general 
population (14 studies), populations living with a chronic physical condition (three), pregnant 
women (two), postoperative patients (one), people with either a chronic physical and/or 
psychiatric condition (two), and people with psychiatric conditions (four). The median age 
was 44, and on average 48% were male. On average, participants smoked 20 cigarettes a day 
and scored 5.4 on the Fagerström test for nicotine dependence (FTND), indicating moderate 
dependence. The median length of follow-up was six months (Table 2.2). 
 
In 11 studies, abstinence was measured as continuous abstinence from a point soon after 
baseline assessment, and in 18 studies abstinence was biologically-validated. In seven studies 
participants received a psychological intervention as part of the cessation intervention. In 17 
studies participants were motivated to quit (Table 2.3).  
 
2.4.5. Study quality 
 
Twenty studies had high quality scores on the Newcastle-Ottawa scale, and five had medium 
to low scores; for one study there was insufficient information to determine a score 
(conference abstract) (Table 2.3). 
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Table 2.2 Characteristics of populations' tobacco use and cessation intervention  
First author, 
year of 
publication 
Behavioural support and medication Baseline FTND scores M (SD) Difference between 
groups P-value for 
FTND 
Baseline cigarettes per day (CPD) M 
(SD) 
Difference 
between groups 
P-value for CPD 
Balduyck, 
2011 
No behavioural support. No mood management. Not measured Not reported Abstainers (smoking pack-years (SD)) 
36.6 (17.3), smokers 41.3 (16.9) 
Not reported 
Becona, 2002 Six weekly behavioural support sessions.  No mood management. Cohort 5.4 (2.4) Not reported Cohort 26.4 (10.4) Not reported 
Berlin, 2010 Sertraline plus behavioural support or placebo sertraline plus 
behavioural support. Participants received mood management 
counselling. 
Abstainers 6.6 (2.8), smokers 
6.7 (2.4) 
P=0.88 Abstainers 23.3 (8.6), smokers 26.0 
(10.6) 
P=0.27 
Blalock, 2008 Behavioural support and mood management counselling Abstainers 3.9 (1.5), smokers 
5.6 (2.4) 
P>0·05 (non-
significant) 
Abstainers 23.1 (7.0), smokers 23.5 
(5.3) 
P>0.05 (non-
significant) 
Busch, 2011 Some participants received standard support and some received 
mood management. Participants who reported readiness to quit 
were provided nicotine replacement therapy (NRT) (patches). 
Cohort 4.6 (1.4) Not reported Cohort 15.1 (8.6) Not reported 
Chassin, 2002 No behavioural support provided. No mood management Not measured Not reported Abstainers median 10 to 14, smokers 
median 10 to 14 
P=0.68 
Croghan, 
2005 
Behavioural support, mood management, and/or pharmacological 
support. 
Not measured Not reported Cohort median 20 to 39 Not reported 
Dawkins, 
2009 
No behavioural support but received financial incentive for 
maintaining smoking or abstinence status as allocated. No mood 
management. 
Abstainers 4.6 (1.7), smokers 
5.29 (1.81) 
P=0.11 Smokers 18.5 (6.3) 
 
P=0·68 
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Hajek, 2010 Single brief support. No mood management. 75.3% of the cohort smoked 
within 30 minutes of waking. 
Not reported Cohort 21 (13) Not reported 
Kahler, 2002 Some participants received standard smoking cessation treatment 
(ST) and some received ST plus cognitive behavioural therapy. 
Cohort  6.4 (1.8) Not reported Cohort 27.3 (11.3) Not reported 
Kahler, 2009 Behavioural support, NRT and mood management plus brief 
alcohol intervention. 
Cohort  5.0 (2.0) Not reported Cohort 22.0 (10.9) Not reported 
Kahler, 2011 Counselling plus NRT (nicotine patch) or counselling plus NRT 
(patch) plus brief alcohol intervention. No mood management. 
Cohort 5.0 (2.2) Not reported Cohort 21.3 (9.4) Not reported 
Kinnunen, 
2006 
No behavioural support. No mood management Not reported Not reported Not reported Not reported 
Longmore, 
2007 
No behavioural support. No mood management. Not reported Not reported Not reported Not reported 
Manning, 
2005 
Eight weekly sessions of motivational interviewing. No mood 
management. 
Not measured Not reported Cohort 17.1 (8.5) Not reported 
McDermott, 
2013 (in 
submission 
during search) 
Seven weekly behavioural support sessions. No mood 
management. 
Abstainers 4.8 (2.0), smokers 
5.7 (2.2) 
P<0.01 Abstainers 18.7 (7.8), smokers 21.0 
(8.9) 
P<0.01 
McFall, 2006 Behavioural, pharmacological and mood management. Cohort 6.2 (2.2) Not reported Cohort 26.0 (14.5) Not reported 
Mino, 2000 No behavioural support. No mood management. Not measured Not reported Abstainers 15.7 (10.1), 
Smokers 20.0 (8.4) 
Not reported 
Mitra, 2004  No behavioural support. No mood management. Not measured Not reported Not reported Not reported 
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Munafo, 2008 No behavioural support. No mood management. Not reported Not reported Not reported Not reported 
Quist-Paulsen, 
2006 
Behavioural support with no mood management, plus NRT. Not measured Not reported Abstainers 14.0 (6.0), smokers 16.0 
(7.0) 
P=0·42 
Sarna, 2008 No behavioural support. No mood management. Not measured Not reported Cohort 16.8 (10.3) Not reported 
Solomon, 
2006 
Abstinence-monitoring schedule plus TAU. Participants were 
allocated to receive a financial incentive after successful 
biologically-validation or to receive a financial incentive 
independent of smoking status. No mood management. 
Not measured Not reported Abstainers 9.7 (6.0), smokers 22.4 (9.6) P< 0·01 
Steinberg, 
2011 
Behavioural support, no mood management. Plus combination 
pharmacotherapy of NRT and or bupropion or varenicline 
Not measured Not reported Cohort 19.0 (SD not reported) Not reported 
Stewart, 1995 Self-help booklet with no mood management described plus NRT 
(gum) and a financial incentive. 
Not measured Not reported Cohort 19.7 (11.1) Not reported 
Vasquez, 
1999 
Multi component behavioural treatment. No mood management. Cohort 4.8 (2.3) Not reported Cohort 24.6 (8.9) Not reported 
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Table 2.3 Study characteristics that may present a risk of bias 
First 
author, year 
of 
publication 
Publicatio
n status 
Measurement 
of abstinence 
Bio-
validation of 
smoking 
status 
Newcastle-
Ottawa Scale 
score (Range 
0 to 5, 0=low) 
Same N of 
participants at 
baseline and 
follow-up? 
Motivated to 
quit? 
Psychotherapeutic 
component in 
cessation 
intervention? 
Statistical adjustment for 
covariates 
Any 
evidence of 
outcome 
reporting 
bias? 
Was 
publication 
based on 
change in 
mental 
health? 
Balduyck, 
2011 
Published 
and 
unpublish
ed 
Point-
prevalence 
Not bio-
validated 
4 Different Not selected 
by motivation 
to quit 
Did not receive 
mood management 
No adjustment No No 
Becona, 
2002 
Published Point-
prevalence 
Bio-
validated 
5 Same Motivated to 
quit 
Did not receive 
mood management 
No adjustment No Yes 
Berlin, 2010 Published Continuous Not bio- 
validated 
5 Same Motivated to 
quit 
Received mood 
management 
Adjusted for treatment group 
(placebo or sertraline) 
No Yes 
Blalock, 
2008 
Published 
and 
unpublish
ed 
Continuous Bio-
validated 
5 Same Motivated to 
quit 
Received mood 
management 
Unadjusted and adjusted 
data. Adjusted for baseline 
CO, baseline, withdrawal 
measure score and treatment 
group. 
No Yes 
Busch, 2011 Published Point-
prevalence 
Bio-
validated 
4 Different Not selected 
by motivation 
Received mood 
management 
No adjustment No Yes 
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to quit 
Chassin, 
2002 
Published 
and 
unpublish
ed 
Continuous Not bio-
validated 
3 Same Not selected 
by motivation 
to quit 
Did not receive 
mood management 
No adjustment No Yes 
Croghan, 
2005 
Published Continuous Not bio-
validated 
3 Same Motivated to 
quit 
Received mood 
management 
Adjusted for age and sex 
reference norms (US) 
No No 
Dawkins, 
2009 
Published 
and 
unpublish
ed 
Continuous Bio-
validated 
4 Same Not selected 
by motivation 
to quit 
Did not receive 
mood management 
No adjustment No Yes 
Hajek, 2010 Published Continuous Bio-
validated 
4 Same Motivated to 
quit 
Did not receive 
mood management 
No adjustment No Yes 
Kahler, 2002 Published Continuous Bio-
validated 
5 Different Motivated to 
quit 
Received mood 
management 
Adjusted for baseline 
(session 1) BDI scores 
No Yes 
Kahler, 2009 Published Continuous Bio-
validated 
4 Different Motivated to 
quit 
Received mood 
management 
No adjustment No No 
Kahler, 2011 Published 
and 
unpublish
ed 
Point-
prevalence 
Bio-
validated 
5 Different Motivated to 
quit 
Did not receive 
mood management 
Unadjusted and adjusted 
data.  Adjusted for treatment 
condition, MDD history, 
gender, and FTND 
No Yes 
Kinnunen, Published Continuous Not bio- 4 Different Not selected Did not receive MMPI-2 scores were No Yes 
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2006 validated by motivation 
to quit 
mood management adjusted for age reference  
norms 
Longmore, 
2007 
Published 
(conferenc
e abstract) 
Not reported Not reported Not reported Different Not selected 
by motivation 
to quit 
Did not receive 
mood management 
Adjusted for “demographic, 
clinical, and socioeconomic 
factors  and baseline health 
status” but no further details. 
No Yes 
Manning, 
2005 
Published Point-
prevalence 
Bio-
validated 
4 Different Motivated to 
quit 
Did not receive 
mood management 
No adjustment No Yes 
McDermott, 
2013 (in 
submission 
during 
search) 
Published Continuous Bio-
validated 
4 Same Motivated to 
quit 
Did not receive 
mood management 
Adjusted for age, nicotine 
dependence and cigarette 
consumption 
No Yes 
McFall, 2006 Published Point-
prevalence 
Bio-
validated 
5 Different Motivated to 
quit 
Received mood 
management 
No adjustment Yes No 
Mino, 2000 Published 
data 
Point-
prevalence 
Does not 
report 
assessment 
of smoking 
status 
validation 
4 Different Not selected 
by motivation 
to quit 
Did not receive 
mood management 
No adjustment No Yes 
Mitra, 2004  Published Point- Not bio- 2 Same Not selected Did not receive Adjusted for gender, No No 
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data prevalence validated by motivation 
to quit 
mood management ethnicity, years of education, 
age at baseline, numbers of 
domains in which 
respondents were dependent 
in activities of daily living. 
Munafo, 
2008 
Published 
data 
Point-
prevalence 
Non bio-
validated 
3 Different Not selected 
by motivation 
to quit 
Did not receive 
mood management 
No adjustment No Yes 
Quist-
Paulsen, 
2006 
Published 
data 
Point-
prevalence 
Bio-
validated 
5 Same Motivated to 
quit 
Did not receive 
mood management 
No adjustment No No 
Sarna, 2008 Published 
data 
Point-
prevalence 
Non bio-
validated 
3 Different Not selected 
by motivation 
to quit 
Did not receive 
mood management 
Adjusted for age, BMI, living 
alone, co-morbidity and BL 
SF-36 scores 
No Yes 
Solomon, 
2006 
Published 
data 
Point-
prevalence 
Bio-
validated 
4 Same Motivated to 
quit 
Did not receive 
mood management 
No adjustment No Yes 
Steinberg, 
2011 
Published 
and 
unpublish
ed data 
Point-
prevalence 
Bio-
validated 
4 Same Motivated to 
quit 
Did not receive 
mood management 
No adjustment No Yes 
Stewart, 
1995 
Published 
data 
Point-
prevalence 
Bio-
validated 
4 Same Motivated to 
quit 
Did not receive 
mood management 
Adjusted for age, gender 
ethnicity, education, 
No Yes 
73 
 
employment status, marital 
status, number of choric 
conditions, number of 
cigarettes consumed at 
enrolment, nicotine 
dependency, nicotine gum 
intervention. 
Vasquez, 
1999 
Published 
data 
Continuous Bio-
validated 
5 Same Motivated to 
quit 
Did not receive 
mood management 
No adjustment No Yes 
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2.4.6. Results of meta-analyses 
 
If studies reported change data separately for quitters and continuing smokers (i.e. rather than 
difference in change between groups) these data were used to calculate each groups’ 
standardised average mean change in scores, for each outcome. On average, smokers who quit 
showed an improvement from baseline to follow-up, and those who continued smoking 
showed small change, if any, in mental health outcomes (Figure 2.2).  
 
 
Legend: Quitter                                     Continuing smoker 
Figure 2.2 Groups’ standardised average mean change in mental health outcomes 
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2.4.6.1. Anxiety 
 
Four studies reported change in anxiety from baseline to follow-up, with follow-ups ranging 
from seven weeks to 12 months (median six months). On average, quitters’ anxiety scores 
improved and continuing smokers did not display change from baseline to follow-up (Figure 
2.2). The difference in change was significant ((standardised mean difference) (SMD) 0.37, 
95% CI: 0.70 to 0.03; P=0.03). There was substantial statistical heterogeneity between 
studies (I
2
=71%) (Higgins and Green, 2011) (Figure 2.3). 
 
 
Figure 2.3 Difference between change in anxiety from baseline to longest follow-up in 
people who stopped smoking or continued to smoke 
 
2.4.6.2. Mixed anxiety and depression 
 
Five studies reported change in mixed anxiety and depression from baseline to follow-up, 
with follow-up ranging from three months to six years (median six months). On average, 
quitters displayed an improvement in symptoms, and continuing smokers showed a slight 
worsening in symptoms from baseline to follow-up (Figure 2.2). The difference in change 
was significant (SMD 0.31, 95% CI: 0.47 to 0.14; P<0.001; I
2
=0%) (Figure 2.4). 
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Figure 2.4 Difference between change in mixed anxiety and depression from baseline to 
longest follow-up in people who stopped smoking or continued to smoke 
 
2.4.6.3. Depression 
 
Ten studies reported change in depression from baseline to follow-up, with follow-up ranging 
from 11 weeks to five years (median 12 months). On average, quitters showed an 
improvement in depressive symptoms, and continuing smokers slightly improved from 
baseline to follow-up (Figure 2.2Error! Reference source not found.). The improvement 
as significantly larger in the quit group (SMD 0.25, 95% CI: 0.37 to 0.12; P<0.001; 
I
2
=30%) (Figure 2.5). 
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Figure 2.5 Difference between change in depression from baseline to longest follow-up in 
people who stopped smoking or continued to smoke 
2.4.6.4. Stress 
 
Three studies reported change in stress from baseline to follow-up, with follow-up ranging 
from six months to six years (median 12 months). On average, quitters displayed an 
improvement in stress and continuing smokers showed a slight improvement (Figure 2.2). The 
improvement was significantly greater in the quit group (SMD 0.27, 95% CI 0.40 to 0.13; 
P<0.001) from baseline to follow-up (I
2
=0%) Figure 2.6. 
 
 
Figure 2.6 Difference between change in stress from baseline to longest follow-up in 
people who stopped smoking or continued to smoke 
 
2.4.6.5. Psychological quality of life 
 
Eight studies reported change in psychological quality of life from baseline to follow-up, with 
follow-ups ranging from two months to nine years (median 12 months). On average, quitters 
displayed a significant improvement in psychological quality of life from baseline to follow-
up and continuing smokers showed a slight worsening (Figure 2.2). The difference in change 
was significant (SMD 0.22, 95% CI: 0.09 to 0.36; P<0.001). There was moderate statistical 
heterogeneity between studies (I
2
=63%) (Higgins and Green, 2011) (Figure 2.7). 
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Figure 2.7 Difference between change in psychological quality of life from baseline to 
longest follow-up in people who stopped smoking or continued to smoke 
 
2.4.6.6. Positive affect 
 
Three studies reported change in positive affect from baseline to follow-up, with follow-ups 
ranging from three months to four years (median 12 months). On average, quitters showed an 
improvement in positive affect, and continuing smoker’s scores slightly increased from 
baseline to follow-up (Figure 2.2). The difference in change was significant (SMD 0.40, 95% 
CI: 0.09 to 0.71; P=0.01; I
2
=49%) (Figure 2.8). 
 
 
Figure 2.8 Difference between change in positive affect from baseline to longest follow-
up in people who stopped smoking or continued to smoke 
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2.4.7. Sensitivity and subgroup analyses 
 
Numerous sensitivity and subgroup analyses were conducted to investigate clinical and 
methodological heterogeneity and to investigate risk of bias within and across studies (results 
reported in Appendix 9). 
 
2.4.7.1. Study quality 
 
Removal of studies with medium to low scores on the Newcastle-Ottawa Scale did not greatly 
change the summary estimates (Appendix 9).  
 
2.4.7.2. Publication and outcome reporting bias 
 
There were sufficient studies to create funnel plots for anxiety, depression, mixed anxiety and 
depression, and psychological quality of life. The plots were symmetrical for depression, 
anxiety, and mixed anxiety and depression and asymmetrical for psychological quality of life 
(Appendix 9). Egger tests indicated that small studies measuring psychological quality of life 
provided larger effect estimates than studies with larger samples (P=0.017). Seven out of 
eight of the pooled studies, however, had sample sizes ranging from 34 to 323. Thus, the 
result of the Egger test was likely influenced by the only large study (Sarna, 2008), which 
analysed data from 11,809 participants, and accounted for 25.7% of the pooled effect 
estimate. There was no evidence of small study bias for studies that measured anxiety 
(P=0.184), depression (P=0.064), mixed anxiety and depression (P=0.307), positive affect 
(P=0.179), or stress (P=0.705). 
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In 20 of the 26 studies, the main aim was to report on change in mental health and the 
decision to publish could have been contingent on the strength or significance of the finding 
(Table 2.3). The main aim of the six other studies was to report on other outcomes, and they 
reported only psychological quality of life and positive affect. Subgroup analysis showed no 
evidence of a difference in effect between studies that did not primarily report on change in 
mental health and those that did so for psychological quality of life (P=0.19) and positive 
affect (P=0.14). One of the 26 studies showed evidence of multiple testing and selectively 
reported the only significant result (Table 2.3). 
 
Results of narrative synthesis — Fifteen studies were excluded because there were 
insufficient data to extract an effect size or its variance, despite contact with the authors 
(Appendix 9). Nine of the 15 studies reported on the significance of the difference in change 
between quitters and continuing smokers: three reported no significant difference, five 
favoured quitters, and one study showed a difference favouring continuing smoking. Of the 
nine studies, seven reported that mental health improved in quitters, one showed no change, 
and one showed a worsening in mental health for quitters. Five of nine studies reported 
information on change in mental health for continuing smokers, three studies reported that 
mental health had worsened at follow-up and two reported that it had improved. 
 
2.4.7.3. Adjustment for covariates 
 
Two studies supplying estimates for three outcomes (anxiety, depression, and positive affect) 
provided effect sizes of the difference in change in mental health both unadjusted and 
adjusted for confounders. The confounders included demographics, information pertaining to 
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tobacco consumption, and/or treatment allocation. Comparison of these estimates indicated 
that adjustment did not greatly change the results (Table 2.4)  
 
Summary effect estimates from studies that supplied only unadjusted effect estimates were 
compared with studies that supplied only adjusted effect estimates. Studies adjusted for 
several potential confounders (Table 2.5). For anxiety one study adjusted for covariates, for 
depression four studies adjusted for covariates, for psychological quality of life five studies 
adjusted for covariates, for positive affect two studies adjusted for covariates, and for stress 
and mixed anxiety and depression no studies adjusted for covariates. The effect sizes were 
similar for studies that did and did not adjust for covariates for all outcomes except anxiety. 
Studies that adjusted for covariates showed a significantly larger difference between quitters 
and smokers than those that did not adjust.  
82 
 
Table 2.4 Comparison of unadjusted and adjusted estimates from studies in which both were presented 
Study Covariates adjusted for Outcome (measure) 
Standardised mean difference 
(95% CI) 
Unadjusted estimate Adjusted estimate 
Blalock 
(2008) 
Baseline CO expiration, baseline nicotine 
withdrawal score, treatment group 
allocation 
Beck’s depression inventory 0.54 (1.42 to 0.34) 0.58 (1.00 to 0.16) 
Positive and negative affect schedule 
(positive affect subscale) 
0.59 (0.29 to 1.47) 0.68 (0.24 to 1.12) 
McDermott 
(2012) 
Age, nicotine dependence, and daily 
cigarette consumption 
State trait anxiety inventory-6 0.62 (0.88 to 0.36) 0.74 (1.00 to 0.48) 
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Table 2.5 Subgroup analysis with comparison of effect estimates between studies that did and did not adjust for covariates 
Outcome 
Standardised mean difference (95% CI) 
Test for subgroup differences Original estimate Adjusted estimate Unadjusted  estimate 
Anxiety* 0.37 (0.70 to 0.03) 
(4 studies) 
0.74 (1.00 to 0.48) 
(1 study) 
0.34 (0.61 to 0.07) 
(4 studies) 
²=4.40, P=0.04 
Depression 0.25 (0.37 to 0.12)  
(10 studies) 
0.41 (0·65 to 0·17) 
(4 studies) 
0.15 (0.27 to 0.03) 
(7 studies) 
²=3.49, P=0.062 
Mixed anxiety and depression 0.31 (0.47 to 0.14) 
(5 studies) 
No data 0.31 (0.47 to 0.14) 
(5 studies) 
Not applicable 
Positive affect 0.40 (0.09 to 0.71) 
(3 studies) 
0.28 (0.02 to 0.57) 
(2 studies) 
0.68 (0.24 to 1.12) 
(1 study) 
²=2.22, P=0.14 
Psychological quality of life 0.22 (0.09 to 0.36) 
(8 studies) 
0.24 (0.07 to 0.40) 
(5 studies) 
0.22 (0.13 to 0.57) 
(3 studies) 
²=0.01, P=0.92 
Stress 0.27 (0.40 to 0.13) 
(3 studies) 
No data 0.27 (0.40 to 0.13) 
(3 studies) 
Not applicable 
*Please note that for anxiety and depression some studies provided both adjusted and unadjusted estimates, therefore these were compared within the corresponding 
subgroup analysis. 
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2.4.7.4. Loss to follow-up 
 
Twelve of the 26 studies reported means at baseline on a larger number than contributed to 
the mean at follow-up. Removal of these 12 did not greatly change the effect estimates 
(Appendix 9). 
 
2.4.7.5. Ascertainment of smoking status 
 
Eleven studies did not report continuous abstinence, classification of smoking status was not 
clear in four studies, and eight did not biochemically confirm abstinence, exclusion of these 
did not change the results (Appendix 9). 
 
2.4.7.6. Motivation to quit 
 
In a subgroup analysis, effect estimates from 16 studies in which participants were all 
attempting to quit were compared with the 10 studies in which participants were not selected 
by motivation to quit. There was no evidence of subgroup differences (Appendix 9), 
suggesting that deterioration in mental health as a reaction to failing to quit was an unlikely 
cause of the difference between quitters and continuing smokers. 
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2.4.7.7. Psychotherapeutic component within cessation intervention 
 
Seven studies included a psychotherapeutic element in the cessation intervention to help 
participants manage symptoms of anxiety or low mood. Removal of these studies did not 
greatly change the summary estimate (Appendix 9). 
 
2.4.8. Additional analyses 
 
2.4.8.1. Comparison of clinical population  
 
Fourteen studies enrolled smokers from the general population, four enrolled patients with 
psychiatric disorders, three enrolled patients with chronic physical conditions, two enrolled 
patients with either psychiatric or physical conditions, two enrolled pregnant women, and one 
enrolled patients after surgery. Test for subgroup differences for change in depression was 
significant due to the small effect found in pregnant women 0.07 (95% CI: 0.23 to 0.09) 
compared to the other populations where estimates ranged between 0.23 (95% CI: 0.37 to 
0.09) and 0.53 (95% CI: 0.77 to 0.29) (Table 2.6). There was no evidence of subgroup 
differences for any other outcome. 
 
Populations with psychiatric disorders were especially of interest, and data from this 
population were available on change in depression, mixed anxiety and depression, and 
positive affect. The effect estimates for this subgroup compared with the general population 
were 0.39 (95% CI: 0.63 to 0.14) versus 0.30 (0.48 to 0.12) for depression; 0.21 
(1.07 to 0.65) versus 0.32 (0.53 to 0.11) for mixed anxiety and depression; 0.40 (0.03 
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to 0.83) versus 0.15 (0.01 to 0.30) for psychological quality of life; and 0.68 (0.24 to 1.12) 
versus 0.16 (0.14 to 0.46) for positive affect.  
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Table 2.6 Subgroup analysis with comparison of effect estimates between different clinical populations 
Outcome and population Effect estimate standardised mean difference (95% CI) Test for subgroup differences 
 
Anxiety 
Overall 0.37 (0.70 to 0.03) — 
General (3 studies) 0.48 (0.81 to 0.15) 
²=2.77, P=0.10 
Pregnant (1 study) 0.06 (0.42 to 0.30) 
 
Depression 
Overall 0.25 (0.37 to 0.12)  
General (5 studies) 0.23 (0.37 to 0.09) 
²=9.74, P=0.008 Psychiatric condition (3 studies) 0.53 (0.77 to 0.29) 
Pregnant (2 studies) 0.07 (0.23 to 0.09) 
 
Mixed anxiety and depression 
Overall 0.31 (0.47 to 0.14) — 
General (3 studies) 0.32 (0.53 to 0.11) ²=0.08, P=0.96 
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Psychiatric condition (1 study) 0.21 (1.07 to 0.65) 
Chronic physical and/or psychiatric condition (1 study) 0.29 (0.57 to 0.01) 
 
Psychological quality of life 
Overall 0.22 (0.09 to 0.36) — 
General (3 studies) 0.15 (0.01 to 0.30) 
²=5.25, P=0.25 
Psychiatric condition (1 study) 0.40 (0.03 to 0.83) 
Chronic physical and/or psychiatric condition (1 study) 0.60 (0.17 to 1.03) 
Chronic physical condition (1 study) 0.16 (0.11 to 0.43) 
Postoperative (1 study) 0.62 (0.27 to 1.51) 
 
Positive affect 
Overall 0.40 (0.09 to 0.71) — 
Chronic physical and/or psychiatric condition (1 study) 0.47 (0.04 to 0.90) 
²=3.95, P=0.11 General (1 study) 0.16 (0.14 to 0.46) 
Psychiatric condition (1 study) 0.68 (0.24 to 1.12) 
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Stress 
Overall 0.27 (0.40 to 0.13) — 
General (2 studies) 0.32 (0.52 to 0.12) 
²=0.51, P=0·48 
Chronic physical condition (1 study) 0.22 (0.40 to 0.04) 
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2.4.8.2. Study design 
 
Eleven studies were cohort studies, 14 were secondary analyses of cessation interventions, 
and one was a randomised trial. There was no evidence of subgroup differences between these 
study designs (Appendix 9). 
 
2.4.8.3. Length of follow-up 
 
The effect sizes were similar for studies that assessed mental health between six weeks and 
six months and those with follow-ups longer than six months (Appendix 9). Studies were 
ordered according to follow-up length in forest plots (Figure 2.2 to 2.8) which indicated no 
clear chronological pattern in effect estimates. 
 
2.5. Discussion 
 
There was consistent evidence that stopping smoking is associated with improvements in 
depression, anxiety, stress, psychological quality of life, and positive affect compared with 
continuing to smoke. The strength of association was similar for both the general population 
and clinical populations, including those with mental health disorders. There was no evidence 
that methodological heterogeneity or short comings explained these associations nor was there 
substantial evidence of publication bias. 
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2.5.1. Limitations, strengths and potential sources of bias 
 
The strengths of this study lay in the broad search terms that were used to retrieve literature, 
including hand searching to avoid missing available literature and also checking reference 
lists of included studies. Authors of studies were contacted and data were calculated from 
papers in which, in many cases, these data were not provided in a directly usable form. 
 
In most included studies, the quality of measurement of exposure status—smoking—was 
adequate. Nearly half of the studies reported prolonged or continuous abstinence that was 
biologically-validated; this removed the threat of misclassification of exposure. Sensitivity 
analysis showed no evidence that studies that assessed smoking in other ways could have 
altered the results. Inclusion of such studies would, in general, underestimate the true strength 
of the association. Likewise, assessment of outcome was good, with participants completing 
validated self-reported mental health questionnaires before they stopped smoking and at 
follow-up. Assessors were, in that sense, blind to exposure status, and no study was set up 
primarily to investigate change in mental health on cessation. 
 
Confounding is usually a major threat to the validity of most associations based on 
observational data. However, adjustment for potential confounders, which were mostly factors 
associated with propensity to achieve cessation, had only small effects in the studies that 
reported such data. The data within each study were robust and the association was unlikely to 
arise through bias. 
 
92 
 
The validity of the review rests on whether the search retrieved appropriate literature. This 
study aimed to retrieve a large number of cohort studies that might have contained data, even 
when this was not readily apparent. Doing so, several studies were uncovered that would have 
been missed if the search was confined to studies that seemed to be about smoking cessation 
and mental health. In all cases, the data were derived from secondary analyses of studies 
investigating other hypotheses (for example, secondary analyses of cessation interventions, 
population cohorts). It could be that authors of similar studies analysed data in the same way 
but found no association so may have chosen not to publish those data. One example of this 
was located when a study reported quantitative data only for the significant (and presumably 
stronger) association and did not report other non-significant associations. Other studies that 
reported on the association but not completely enough to assess quantitatively, however, 
seemed to give similar results to those in which the data were more clearly presented. Overall, 
there was little evidence of publication bias, but this cannot be excluded. 
 
2.5.2. Possible interpretations 
 
Data in this study are valid and there are three possible explanations for the association. The 
first is that smoking cessation causes the improvement in mental health, the second is that 
improving mental health causes cessation, and the third is that a common factor explains both 
improved mental health and cessation. Observational data can never prove causality, but 
almost all that is known about the harms of smoking and the benefits of cessation derive from 
observational studies, as randomised trials to examine this have insurmountable ethical and 
practical difficulties, i.e. one cannot randomise people to smoke or quit. 
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Could a common factor explain both cessation and improved mental health? This supposes 
that a single factor—such as positive life events—can cause people to attempt or achieve 
cessation and improve mental health. There is no evidence that positive life events or any 
other single mechanism are associated with both cessation and improved mental health. In 
addition, mental health outcomes were assessed anywhere from seven weeks to nine years 
after baseline, and it seems implausible that such mechanisms are associated with positive 
mental health changes during this entire period. 
 
An obvious explanation for the association is that improvements in mental health prompt 
people to attempt cessation and that this explains the association. This is contradicted by these 
data, however. Over half the studies were secondary analyses of randomised trials. In these 
studies everyone attempted cessation and therefore the decision to quit was not contingent on 
change in mental health. Importantly, those who did achieve abstinence in these trials, any 
detected change in mental health would have occurred after cessation rather than before 
cessation (previously discussed in section 2.3.10.2). Subgroup analyses that split data by 
whether they were derived from such trials or from population cohorts, showed no evidence 
of a difference in the effect estimates between the study types. These data support the notion 
that cessation improves mood. However, it may be possible success of the quit attempt was 
dependent upon change in mood. 
 
In some, but not all, of the studies the change in mental health in quitters and continuing 
smokers could be calculated, rather than just the difference in the change as presented in the 
meta-analyses. In these studies, the average mean change was calculated separately for each 
group. These data indicated little change in mental health from baseline to follow-up in 
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continuing smokers, while smokers who quit showed reductions in adverse mental health 
symptoms and improvements in positive affect and quality of life. In support of these data, 
one of the studies in the review was a trial in which participants were randomised to continue 
smoking or quit. Obviously adherence to this instruction was not absolute, but analysis of 
these data by trial arm showed a modest benefit of cessation compared with continuing to 
smoke. The trial was not powered to detect this difference and it was not significant, but it 
does provide further evidence to support the notion that stopping smoking leads to 
improvements in mental health. 
 
Data from a systematic review of randomised trials also supports the notion that cessation 
improves mental health. Banham and Gilbody systematically reviewed eight trials of smoking 
cessation interventions in people with severe mental illnesses (Banham and Gilbody, 2010). 
All trials that assessed psychological function typically used several scales at multiple times. 
Most showed no difference between active and control groups, but the two studies that 
reported significant differences favoured the intervention groups (study details previously 
discussed in section 1.10.2). Another study reported after this review randomised people with 
serious mental illness to cessation support or usual care. It showed that cessation support 
reduced readmissions for worsening mental illness (Prochaska et al., 2013). These data do not 
directly estimate the effect of cessation on mental health because most people who were 
randomised to the intervention did not quit. But these findings, in people with serious mental 
illness, support the findings in our review that psychological outcomes improve on cessation. 
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2.5.3. Possible mechanisms 
 
The hypothesis that cessation improves mood is supported by a plausible biological 
mechanism. As discussed previously (section 1.6), chronic tobacco smoking is associated 
with neuroadaptations in nicotinic pathways in the brain. Neuroadaptations in these pathways 
are associated with occurrence of depressed mood, agitation, and anxiety shortly after a 
cigarette is smoked (Benowitz, 1999; 2010; Mansvelder and McGehee, 2002; Wang and Sun, 
2005). This is known as the withdrawal cycle and is marked by fluctuations in a smoker’s 
psychological state throughout the day (Benowitz, 1999; 2010) and could worsen mental 
health (Parrott, 1999). A study reported that the neurological functioning of quitters returned 
to the same level as non-smokers by three weeks after cessation (Mamede et al., 2007), 
consistent with reports that withdrawal symptoms abate after a few weeks (Hughes, 2007b). 
The misattribution hypothesis is that smokers attribute these symptoms as arising from stress 
or poor mental health and conclude from the ability of cigarettes to ameliorate these 
symptoms that cigarettes improve mental health. 
 
Not all data, however, support this causal interpretation. An epidemiological study exploiting 
Mendelian randomisation examined the causal link between current smoking and current 
anxiety and depression (Bjorngaard et al., 2013). This study showed some evidence that the 
genetic variant was associated with anxiety in never and former smokers; however as a whole 
the study did not support a causal link between smoking status and current mental health 
problems. These data argue against the misattribution hypothesis, whereby periods of 
psychological changes related to withdrawal from smoking are eliminated by neurological 
adaptation to permanent deprivation of nicotine. 
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2.5.4. Clinical implications 
 
If the associations observed in this review are causal then the effect size is clinically 
important. Fournier and colleagues (2010) meta-analysed trials of selective serotonin reuptake 
inhibitors and estimated the effect size. For mild to moderate depression the effect estimates 
ranged from 0.17 to 0.11; this is lower than the effect size for smoking cessation. A meta-
analysis of 34 randomised controlled trials assessed the effect of anti-depressants on 
generalised anxiety disorder (National Institute for Health and Clinical Excellence, 2011). 
These effect estimates ranged from 0.23 (0.43 to 0.13) to 0.50 (0.77 to 0.23); this is 
similar to smoking cessation at 0.37. This result is particularly important in view of the 
current findings in patients with psychiatric disorders. There was no evidence that the effect 
size differed between population subgroups based on clinical diagnosis, and the effect on 
depression, psychological quality of life, and positive affect was significant in people who had 
mental disorders. These data should reassure doctors treating patients with mental illness that 
cessation is unlikely to exacerbate their symptoms and might indeed be therapeutic. 
 
2.6. Conclusion 
 
Whether or not smoking cessation directly causes the observed improvement in mental health, 
there are direct clinical implications. Smokers can be reassured that stopping smoking is 
associated with mental health benefits. This could also overcome barriers that clinicians have 
toward intervening with smokers with mental health problems. Furthermore, challenging the 
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widely held assumption that smoking has mental health benefits could motivate smokers to 
stop. 
 
2.7. Chapter summary 
 
This chapter reported a systematic review and meta-analysis of longitudinal studies 
comparing the difference in change between those who quit and continued smoking. Meta-
analyses of 26 studies found consistent evidence showing smoking cessation was associated 
with improvements in mental health outcomes. The size of the effect was equal or greater to 
anti-depressant treatment. Within and between study heterogeneity was explored through 
multiple sensitivity analyses and found that risk of confounding to the association was low.  
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CHAPTER THREE 
3.  INTRODUCTION TO THE MCNEIL TRIAL ANALYSES 
 
3.1. Introduction to Chapter Three  
 
In this chapter I introduce a dataset obtained for the analyses presented in Chapters Four to 
Six. The data were provided by McNeil pharmaceutical company and contains individual-
level patient data from six placebo-controlled randomised trials of nicotine replacement 
therapy (NRT) for smoking reduction. This chapter describes the data application process, 
methods used to prepare these data for analysis, and presents descriptive information about 
the trials and about ascertainment of exposures and outcomes used in the subsequent chapters.  
 
3.2. Background to the McNeil trials 
 
The data supplied for the analyses presented in Chapters Four to Six were provided by 
McNeil AB, which is incorporated in Sweden and is part of Johnson and Johnson, a global 
healthcare company. McNeil AB conducts research, develops and produces medicines for 
self-care which can be purchased without prescription. In 1978 (known then as Pharmacia 
AB) McNeil AB launched NICORETTE, a brand of NRT used to treat nicotine dependence. 
NICORETTE is now available in seven variants which are currently available in over 70 
countries (McNeil AB, 2014). McNeil conducted a series of double-blind randomized 
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placebo-controlled trials of NICORETTE NRT for smoking reduction during 1997 and 2003. 
The individual patient data from these trials was provided for use in this thesis.  
 
3.3. Application process 
 
Ideally, trials of smoking cessation treatment would have been analysed to examine the aims 
of the thesis, however, due to unforeseen circumstances and time restraints the data described 
in this chapter were opportunistically selected. These data were obtained in a four stage 
process. Firstly, the trials’ protocols were examined to determine if the data were useable for 
the proposed analyses (study protocol presented in Appendix 11) and to ensure the trials were 
compatible for a merged longitudinal analysis. Each trial’s protocol was examined to ensure 
that key variables were assessed using the same measures and that there was consistency 
across trials’ follow-up points, inclusion/exclusion criteria and data collection processes. 
Secondly, a detailed request for the dataset was sent, which involved writing a summary of 
the proposed analyses and a detailed data request describing which variables were required for 
the analyses. Finally, a data-sharing agreement was arranged between McNeil AB and the 
universities involved in the analyses. To ensure these data arrived on time for use in this 
thesis, I was directly involved in managing and pursing academics and contracts’ 
administrators. 
 
3.4. Downloading, checking and combining data  
 
Please see Appendix 12 for methods used to download, clean and combine data. 
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Table 3.1 Variables recorded within each trial and their characteristics 
   Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 Trial 6 
(excluded)
1
 
Demographic  Age Continuous 
Sex Binary 
Treatment  Treatment allocation Binary (Placebo or Active) 
Nicotine 
dependency 
Fagerström Tolerance 
Questionnaire 
Continuous scale 1-10 (8> high dependence) 
Intention to 
quit 
How motivated are you to quit 
smoking?  
Not recorded Continuous 10 CM 
VAS* (10= maximum 
motivation) 
Not recorded Not recorded Not recorded Not recorded 
Do you intend to quit smoking 
completely in the next month?  
Not recorded Not recorded Not recorded Not recorded Not recorded Not recorded 
Rate the likelihood that you will 
quit smoking in the next 6 
months 
Not recorded Not recorded Continuous 10 CM 
VAS (10= maximum 
motivation) 
Continuous 10 CM 
VAS (10= maximum 
motivation) 
Continuous 10 CM 
VAS (10= maximum 
motivation) 
Not recorded 
How much would you say you 
want to stop smoking 
Categorical (not at all, 
a little, somewhat, a 
lot) 
Not recorded Not recorded Not recorded Not recorded Not recorded 
How much does a part of you 
want to go on smoking? 
Categorical (not at all, 
a little, somewhat, a 
Not recorded Not recorded Not recorded Not recorded Not recorded 
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lot) 
Rate the likelihood that you will 
not be smoking in one year. 
Not recorded Not recorded Continuous 10 CM 
VAS (10= maximum 
likelihood) 
Continuous 10 CM 
VAS (10= maximum 
likelihood) 
Continuous 10 CM 
VAS (10= maximum 
likelihood) 
Not recorded 
Intention to 
reduce 
What is your personal goal in 
terms of cigarettes per day? 
Continuous Not recorded Not recorded Not recorded Not recorded Not recorded 
How motivated are you to 
reduce your smoking from 
current level? 
Not recorded Continuous 10 CM 
VAS (10= maximum 
motivation) 
Not recorded Not recorded Not recorded Not recorded 
Rate the likelihood that you will 
make a serious attempt to reduce 
your smoking during the next 
month. 
Not recorded Not recorded Continuous 10 CM 
VAS (10= maximum 
likelihood) 
Continuous 10 CM 
VAS (10= maximum 
likelihood) 
Continuous 10 CM 
VAS (10= maximum 
likelihood) 
Not recorded 
Rate the likelihood that you will 
reduce smoking by 50%. 
Not recorded Not recorded Continuous 10 CM 
VAS (10= maximum 
likelihood) 
Continuous 10 CM 
VAS (10= maximum 
likelihood) 
Continuous 10 CM 
VAS (10= maximum 
likelihood) 
Not recorded 
Rate the likelihood that one year 
from now, be smoking at least 
50% less than what you are 
smoking now. 
Not recorded Not recorded Continuous 10 CM 
VAS (10= maximum 
likelihood) 
Continuous 10 CM 
VAS (10= maximum 
likelihood) 
Continuous 10 CM 
VAS (10= maximum 
likelihood) 
Not recorded 
How do you intend to change 
your smoking in the next month? 
Not recorded Not recorded Not recorded Categorical (stay quit, 
start smoking again, 
Categorical (stay quit, 
start smoking again, 
Categorical (stay quit, 
start smoking again, 
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quit, reduce from 
current level, keep 
current level, increase 
from current level) 
quit, reduce from 
current level, keep 
current level, increase 
from current level) 
quit, reduce from 
current level, keep 
current level, increase 
from current level) 
Smoking 
history 
 
How old were you when you 
started smoking regularly 
Continuous Not recorded 
Longest period without smoking  Categorical (<1 week, 1week-1month, >1month-3 months, >3 months) 
Times tried to quit smoking Categorical never (once, 2 to 5 times, 6 to 10 times, more than 10 times) 
How long time was the last time 
you tried to stop? 
Categorical (0-6 months, >6-12months, >12 months) 
Mental health 
  
SF-36 emotional well-being 
subscale  
Continuous 0-100 (100=better health) Not recorded 
Smoking 
status 
 
Co/ppm reading Expired CO parts per million 
How many cigarettes do you 
smoke a day as an average? 
Continuous 
Have you stopped smoking? Binary (yes, no) 
Relief from 
craving 
questionnaire 
 
Rate the feeling pepped up 
effects from your last cigarette 
Categorical (not at all, mild, moderate, strong, very strong) Not recorded 
Rate the calming effects from 
your last cigarette.  
Categorical (not at all, mild, moderate, strong, very strong) Not recorded 
What best applies to you 
experience from your latest 
Categorical (very unpleasant, somewhat unpleasant, neutral, somewhat pleasant, very pleasant) Not recorded 
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cigarette? 
Rate the frequency of urges to 
smoke. 
Not recorded Continuous VAS 
10=max effect 
Continuous VAS 
10=max effect 
Continuous VAS 
10=max effect 
Continuous VAS 
10=max effect 
Not recorded 
Rate the strengths of urges to 
smoke. 
Not recorded Continuous VAS 
10=max effect 
Continuous VAS 
10=max effect 
Continuous VAS 
10=max effect 
Continuous VAS 
10=max effect 
Not recorded 
Rate the satisfaction from 
smoking. 
Not recorded Continuous VAS 
10=max effect 
Continuous VAS 
10=max effect 
Continuous VAS 
10=max effect 
Continuous VAS 
10=max effect 
Not recorded 
Rate the unpleasant symptoms 
from your last cigarette 
Categorical (not at all, 
mild, moderate, strong, 
very strong) 
Not recorded Not recorded Not recorded Not recorded Not recorded 
Adverse events Description/code Brief description and 
World Health 
Organization code 
Brief description and 
World Health 
Organization code 
Brief description and 
World Health 
Organization code 
Brief description and 
World Health 
Organization code 
Brief description and 
MedDRA 5.1 code 
Brief description and 
MedDRA 5.1 code 
Start date Day/month/year 
*VAS= visual analogue scale 
1Reason for exclusion explained in section 3.5.2 
Please note: to ensure participant anonymity McNeil pharmaceutical could not supply education, income, ethnicity and marital status data.   
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3.5. About the trials  
 
3.5.1. Study design  
 
Data were originally collected during randomised controlled trials (RCT), with multiple 
follow-ups over a two year period (see Table 3.2 for follow-up points). The original reports of 
the five double-blind placebo-controlled RCTs of NRT for smoking reduction have been 
previously reported or published (Batra et al., 2005; Bolliger et al., 2000; Haustein, 2001; 
Rennard et al., 2006; Wennike et al., 2003). Smoking reduction is a harm-reduction approach 
to nicotine dependence, in which smokers aim to reduce their daily cigarette consumption. 
These trials were aimed at people who have found it hard to quit previously, those who 
wanted to cut-down to quit, or those who wanted to permanently reduce their smoking (Table 
3.2).  
 
3.5.2. Trials’ variables 
 
Table 3.1 presents the variables which were recorded within each trial. To protect 
participants’ anonymity McNeil did not provide ethnicity, education or income data. Most 
variables were recorded consistently across trials, some trials’ recorded a few variables 
differently from one another (i.e. one trial recorded variables as continuous, where as another 
trial recorded the same variable as dichotomous), and some trials’ did not record the same 
variables as other trials’. For the analyses presented in Chapters Four to Six the following data 
were required to ascertain outcome, exposure and confounding: Age, sex, nicotine 
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dependency, treatment received, smoking status, SF-36, adverse events. Other variables such 
as smoking behaviour and history, and intention to quit were also were relevant (discussed in 
section 4.3.4 ). Trial 6 was excluded from all analyses because the study did not record 
participants’ SF-36 scores. 
 
3.5.3. Trials’ measurement of smoking and mental health  
 
Smoking status  Participants’ self-reported, seven-day point-prevalence smoking status was 
recorded at every follow-up throughout the trials’ study periods (See Table 2.1 for follow-up 
points). Self-reported smoking was biologically validated using expired carbon monoxide 
(CO) readings of ≥10 parts per million (ppm), and self-reported cessation was biologically 
validated at CO/ppm <10.  
 
Mental health  The RAND-36/SF-36 is a short form self-report questionnaire designed to 
detect changes in physical and mental health status. This study used the “emotional 
wellbeing” subscale to assess mental health. Scores range from 0 to 100. Scores of ≤38 
indicate presence of mental health problem (Hays et al.,1993; 1998). 
 
Adverse events  During each trial’s duration, newly occurring psychiatric symptoms were 
recorded at each visit during assessment of potential adverse events. Research staff recorded a 
brief description of the event or symptoms and coded the symptoms according to terms 
provided by a regulated dictionary (see Table 3.1).  
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3.5.4. Settings 
 
These trials were conducted between 1997 and 2003 and each trial lasted about two years, on 
average. The trials were conducted in medical centres within each trial’s home country. 
Baseline and follow-up data were collected at both common and different time points (Table 
3.2).  
 
3.5.5. Interventions 
 
Each trial used a slightly different multi-component intervention for smoking reduction (Table 
3.2). NRT was prescribed to help smokers reduce their daily cigarette consumption (CPD) and 
the trials differed in the dose and delivery of NRT (i.e. gum or inhaler). Participants were 
randomised to receive either active or placebo treatment. Both active and placebo groups 
received behavioural advice to reduce their cigarette consumption, with no mood management 
advice. In each trial, participants were asked to reduce their CPD as much as possible, there 
were no agreed reduction goals (e.g. reduce 50% of baseline intake), however participants 
were advised about possible ways to achieve this, such as; increased interval between 
cigarettes, longer time to first cigarette in the morning and removal of habitual cigarettes. 
Smoking cessation was recommended as the ultimate goal, but was not mandatory. The trials 
reported a moderate effect of NRT on smoking reduction (Batra et al., 2005; Bolliger et al., 
2000; Haustein, 2001; Rennard et al., 2006; Wennike et al., 2003). 
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3.5.6. Ethics and data protection 
 
Each trial received ethical approval from the appropriate bodies within the country it was 
conducted. For the analyses presented in the thesis all data were anonymized, were accessible 
only by the named authors and were kept on encrypted computers. To ensure participant 
anonymity, data pertaining to ethnicity, education, income and marital status could not be 
provided. 
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Table 3.2 Trial and population characteristics 
Population Setting Age 
M(SD) 
FTND 
M(SD) 
% 
Male 
Year 
(enrolment 
to final 
follow-up) 
Number 
enrolled 
after 
screenin
g 
Treatment Control 
treatmen
t 
Comparison 
treatment 
Follow-
up 
periods 
(weeks) 
Where 
biological 
data were 
analysed 
Data 
collecte
d by 
 
Trial 1 Switzerland 
 
General Hospital 
outpatient 
clinic 
46.0 
(10.5) 
5.5 
(2.1) 
47.5
% 
1997 to 
1999 
400 10mg nicotine oral inhaler plus behavioural advice 
to reduce smoking at each visit. Participants did not 
receive advice to quit. 
Placebo 
inhaler 
N/a Baseline
, 1, 2, 6, 
13, 18, 
26, 52, 
78, 104 
Bio-
analytical 
research 
corporation 
Ghent 
Belgium 
Laboratories 
Study 
nurse 
 
Trial 2 Denmark 
 
General Hospital 
outpatient 
clinic 
43.8 
(10.0) 
6.4 
(1.8) 
37.7
% 
1999 to 
2001 
411 2 or 4 mg nicotine gum for up to 12 months plus 
moderate behavioural smoking reduction 
information at each visit. Participants did not 
Placebo 
gum 
N/a Baseline
, 2, 10, 
18, 26, 
Pharmacia 
AB, 
Consumer 
Study 
nurse 
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receive advice to quit. 39, 52, 
104 
Healthcare, 
Helsingborg, 
Sweden. 
 
Trial 3 Australia 
 
General Hospital 
outpatient 
clinic 
43.6 
(11.1) 
6.5 
(2.0) 
45.4
% 
1999 to 
2001 
436 2 or 4 mg nicotine gum plus advice to reduce 
smoking for up to 12 months plus behavioural 
smoking reduction information at each visit. 
Participants did not receive advice to quit. 
Placebo 
gum 
N/a Baseline
, 2, 6, 
10, 18, 
26, 39, 
52, 65 
Pharmacia, 
Consumer 
Healthcare, 
Helsingborg 
Study 
nurse 
 
Trial 4 US 
 
General Hospital 
outpatient 
clinic 
45.0 
(12.2) 
6.5 
(2.0) 
44.9
% 
1999 to 
2000 
434 10mg nicotine inhaler plus some advice to reduce 
smoking. Participants did not receive advice to quit. 
Placebo 
inhaler 
N/a Baseline
, 2, 6, 
10, 18, 
26, 39, 
52, 65 
Pharmacia, 
Consumer 
Healthcare 
in 
Helsingborg 
Investig
ator and 
study 
nurse 
 
Trial 5 Germany 
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General Hospital 
outpatient 
clinic 
41.3 
(9.4) 
5.5 
(1.9) 
50.1
% 
2000 to 
2001 
385 4mg nicotine gum plus advice to reduce smoking 
gradually. Participants did not receive advice to 
quit. 
Placebo 
gum 
10mg 
nicotine oral 
inhaler plus 
advice to 
reduce 
quickly, and 
to quit 
smoking 
within four 
weeks 
Baseline
, 2, 6, 
10, 18, 
26, 39, 
52 
Not reported Study 
nurse 
 
Trial 6 Switzerland (excluded from analyses)1 
 
General Hospital 
outpatient 
clinic 
42.6  
(10.1) 
5.8 
(1.9) 
41.6
% 
2001 to 
2003 
364 4mg nicotine gum plus behavioural advice to 
reduce smoking at each appointment. Participants 
did not receive advice to quit. 
Placebo 
gum 
N/a Baseline
, 2, 6, 
10, 18, 
26, 39, 
52 
Phizer 
Helsingborg 
Sweden; 
Exhaled air 
CO was 
measured by 
use of a 
Bedfont 
Smokerlyzer 
. 
Study 
nurse 
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1Excluded as missing mental health outcome data (SF-36) 
Fagerström Test of Nicotine Dependency (FTND) 
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3.5.7. Participants 
 
The trials recruited adult smokers from the general population via newspaper advertisements 
and those enrolled did not receive any financial incentives for their participation. After 
screening for eligibility criteria (described ahead in Table 3.3), each trial enrolled between 
350 and 450 smokers and these participants were followed-up several times over a period of 
one to two years. Participants were similar in age, sex and nicotine dependency (FTND); 
mean age range across trials was 41.3 to 46.1 years; 37.7% to 50.1% were male; and the 
nicotine dependency scores ranged from 5.5 to 6.5. Further participant characteristics are 
described in Table 3.2. 
 
3.5.8. Inclusion and exclusion criteria 
 
Each trial had similar inclusion (listed ahead) and exclusion criteria (reported in Table 3.3). 
There was some variation between trials’ terminology used to describe inclusion criteria, 
however in essence, each trial aimed to recruit the same type of participants. Each trial 
included participants aged 18 and older, who smoked daily for at least three years and 
participants were biologically-validated as smoking. All participants wanted to reduce their 
smoking, were prepared to adhere to the trial protocol and provided informed consent. 
 
Participants were excluded from the McNeil trials if they:  
 
 Were currently using NRT, or partaking in a behavioural or pharmacological smoking 
cessation/reduction program;  
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 Were using any other nicotine containing products;  
 Had unstable angina pectoris or myocardial infarction within three months before 
enrolment;  
 Were pregnant, breastfeeding, or intended to be pregnant;  
 Were under psychiatric care or taking medication which might interfere with the 
study;  
 Had an alcohol or drug problem which may interfere with the study;  
 Intended to quit smoking in the next month;  
 Had any medical conditions deemed inappropriate for study entry by the responsible 
physician (US);  
 Were living in a household where more than one member desired to participate in the 
study (US). 
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Table 3.3 Trials’ inclusion criteria 
Inclusion category Inclusion criterion Trial ID and country 
  Trial 1 
Denmark 
Trial 2 
Switzerland 
Trial 3 
Australia 
Trial 4  
US 
Trial 5 
Germany 
Trial 6 
Switzerland 
(excluded) 
Age Aged 18 or older       
Cigarettes per day (CPD) 
Smoked ≥ 15 CPD        
Smoked at least ≥ 20 CPD       
Bio-verification 
CO/ppm reading of 15 or more       
CO/ppm reading of 10 or more       
Time as smoker Had smoked for at least three years       
Attempt to stop smoking 
Had failed a quit-attempt at least once in the last 12 months       
Had failed a quit-attempt at least once in the last 24 months       
Had failed a quit attempt at least once in the last 24 months, but not 
failed in the six months before the start of the trial 
      
Want to reduce smoking 
Wanted to reduce their smoking with assistance of NRT       
Want to reduce smoking at baseline       
Likely to make an attempt to reduce smoking        
Accept use of NRT for an extended period of time       
Adhere to protocol Prepared to adhere to the trial protocol       
Informed consent Willing to provide signed informed consent       
Understanding of trial Able to understand the trial’s objectives       
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procedures Possess the ability to read write and speak English       
Blue shading: Inclusion criteria required for entry to trial  
1Trial 6 was excluded as it was missing mental health outcome data (SF-36) 
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3.5.9. Participant attrition 
 
Table 3.4 presents the number of participants who provided smoking status data at each 
follow-up. The attrition rates from baseline to final follow-up ranged from 35% to 61%. 
Overall, the risk of attrition bias is high, although these attrition rates are similar to other 
RCTs of NRT for smoking interventions (Stead et al., 2012). 
 
Table 3.4 Number of participants in each trial providing smoking status data 
Trial ID After screening 6 month follow-up 1 year % lost at final follow-up 
Trial 1 400 304 331 23% 
Trial 2 411 189 175 57% 
Trial 3 436 202 207 53% 
Trial 4 434 232 171 61% 
Trial 5 385 196 213 47% 
Trial 6 (excluded) 362 213 219 39% 
TOTAL (N=5) 2066 1123 1097 47% 
 
3.6. Risk of bias across trials 
 
Each prospective observational analysis presented in Chapters Four to Six will include a 
different set of exposure, outcome and cofounding variables; therefore each analysis 
(Chapters Four to Six) will be separately assessed for risk of bias using the Newcastle-Ottawa 
Scale (Wells et al., 2010). 
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3.7. Chapter summary 
 
Five McNeil trials were conducted according to strict protocols and had consistent inclusion 
and exclusion criteria. Data required to ascertain exposure, outcome and confounding 
variables for the prospective analyses in the thesis were measured in the same manner across 
trials. Trial 6 was excluded as it was missing mental health outcome data. Any differences 
between the way in which variables were recorded will be addressed within the subsequent 
chapters, where applicable.  
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CHAPTER FOUR 
4. THE ASSOCIATION BETWEEN SMOKING CESSATION AND CHANGE 
IN MENTAL HEALTH: A COMPARISON OF REGRESSION 
MODELLING AND PROPENSITY SCORE MATCHING 
 
4.1. Introduction to Chapter Four 
 
The results in Chapter Two showed that stopping smoking was associated with improvements 
in mental health, critics however countered that selection bias or unmeasured confounders 
were possible explanations of the findings (Sanderson et al., 2014). Thus in this chapter I will 
address these possibilities by conducting a prospective analysis of the McNeil trials data to 
examine the association between smoking cessation and change in mental health and compare 
estimates derived from regression modelling with those derived from propensity score 
matching. Although propensity score matching reduces the sample size and leads to greater 
imprecision, it offers more potential for controlling group membership bias and confounding. 
This chapter has been summarised and is currently under peer review for publication in the 
British Journal of Psychiatry (please see Appendix 13). 
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4.2. Background 
 
As discussed previously (section 1.4) many smokers continue smoking because they believe 
smoking offers mental health benefits. However, this is not consistent with data presented in 
Chapter Two, in which a systematic review and meta-analysis found consistent evidence that 
sustained smoking cessation was associated with improved mental health compared with 
continuing to smoke (Taylor et al., 2014). This evidence supports the misattribution 
hypothesis (previously discussed in section 1.9.2), such that after sustained cessation the ex-
smoker no longer experiences withdrawal-induced negative affect, thus leading to 
improvements in mental health compared with continuing to smoke. However, the study was 
of observational data and has been criticized for being susceptible to bias through unmeasured 
confounding or predisposition to group membership (Sanderson et al., 2014).  
 
Ideally a randomised study would be used to determine if the association is a true cause-effect 
relationship. One of the studies in the review was a trial where participants were randomised 
to continue or to quit smoking (Dawkins et al., 2009) and results showed a modest benefit of 
cessation on mental health compared with continuing to smoke. However, allocating people to 
continue to smoke or remain abstinent is problematic, because some people will choose to 
stop regardless of allocation, while other cannot achieve abstinence. For example, in the study 
reported by Dawkins and colleagues (2009) only 31% of participants allocated to abstinence 
could achieve this, while 18% of the continue-smoking arm chose to stop smoking. Thus, 
selection to exposure group is a major threat to the validity of data reported in Chapter Two. 
 
 
120 
 
4.2.1. Multivariate regression versus propensity score matching modelling 
 
Regression modelling is a common way to account for confounding in observational analyses, 
and aims to weaken the impact of confounding by adjusting for observed covariates. 
However, there are some downfalls to use of regression modelling in the context of smoking 
cessation and mental health. By use of “adjustment” the model is corrected based on the 
covariates’ association with both exposure (quitting or continuing smoking) and outcome 
(change in mental health), thus adjustment makes assumptions about the linearity between the 
exposure and outcome variables. During assessment of smoking status and mental health this 
method of analysis may not be the most useful, as selection bias to exposure group is very 
probable (as discussed above in section 4.2).  
 
Alternatively, propensity score matching (PSM) can be used to account for confounding in 
observational analyses. PSM involves matching individuals within a sample based upon 
characteristics which predict their propensity to belong to the exposure group. Accordingly, in 
this study, a propensity score is defined as a smokers conditional probability (odds) of 
quitting versus continuing smoking, given the observed confounders (Rosenbaum and Rubin, 
1984). The use of PSM addresses some weaknesses indentified in regression models. Firstly, 
propensity scores predict exposure selection, without consideration of the outcome, thus, by 
balancing observed confounders between groups, the effect of selection bias can be reduced. 
Secondly, to predict exposure selection one can test a multitude of covariates for statistical 
importance therefore optimizing the matching criteria. Furthermore, one can examine the 
overlap of groups’ propensity scores, to ensure that adequate matching is conducted within a 
common region. If there is sufficient overlap between groups’ propensity scores, one can 
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estimate the average treatment effect, which incorporates the possibility of unknown 
confounding (Rosenbaum and Rubin, 1984). 
 
Critics discount the validity of PSM compared with randomisation to control for unknown 
confounding (Freemantle et al., 2013). However, as noted above, in the case of smoking 
cessation and mental health, there is evidence that no randomised design is satisfactory or 
feasible because participants cannot conform to their allocated smoking status. In the case of 
PSM analyses, sensitivity of the association to unmeasured confounders can be estimated 
(Rosenbaum and Rubin, 1984) by comparing adjusted regression models between matched 
and unmatched samples, and this can be used to interpret the validity of the results (Stürmer et 
al., 2005), regression modelling alone cannot provide this information. PSM has been also 
criticised for confounding by indication, which commonly occurs when treatment and 
outcome are influenced by the expectation of prognosis (Viswanathan et al., 2014). This 
usually takes place when the participant is judged as less likely to respond to treatment due to 
an underlying condition. Thus, in this case confounding by indication may occur if a health 
professional does not recommend cessation treatment to a certain patient, because the 
professional feels cessation would not be appropriate in the patients’ circumstances. 
Confounding by indication cannot be eliminated by PSM. However, in this analysis, 
participants were included and excluded based upon the same criteria, rather by than the 
judgment of a health professional, and furthermore participants were aiming to reduce 
cigarette consumption rather than quit. Therefore, confounding by indication is unlikely to be 
an issue in this study.  
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4.2.2. Study aims and hypotheses 
 
To determine if there have been any studies which have used PSM to investigate the 
association between smoking cessation and mental health a literature search was conducted 
using a combination of search terms “cessation”, “propensity score matching”, “mental 
health”. This search did not generate any studies which investigated the association between 
smoking cessation and change in mental health using PSM. 
 
If improved mental health observed in quitters compared with continuing smokers presented 
in Chapter Two was influenced by group membership bias or other unmeasured confounding, 
effect estimates derived from PSM, in theory, should produce different results to estimates 
derived from regression modelling alone.  
 
This study aimed to:  
 
1. Estimate the strength of the association between cessation and change in mental health 
using an adjusted regression model;  
2. Match quitters and continuing smokers on their conditional probability of achieving 
abstinence, using observed baseline variables;  
3. Compare regression coefficients derived from the matched sample with those derived 
from the whole (unmatched sample).  
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4.3. Methods 
 
4.3.1. Study design and setting 
 
A prospective analysis of individual-level patient data derived from five RCTs of nicotine 
replacement therapy (NRT) for smoking reduction. These data were provided by McNeil 
pharmaceutical company as described in Chapter Three; and the trials were conducted 
separately in North America, Europe and Australia by research teams selected by McNeil 
pharmaceutical company. 
 
4.3.2. Participants and study size 
 
All participants were recruited via newspaper advertisements from the general population and 
were aged ≥18 years. Participants were included in the trials if they were daily smokers for at 
least three years, had biologically-validated smoking status at baseline and were motivated to 
reduce their smoking. Participants were followed up at multiple time points over a two year 
period. See Chapter Three for further details.  
 
After screening for eligibility criteria there were 2066 participants enrolled in the trials. At 
baseline 2059 participants provided smoking status information. Nine-hundred-and-thirty-
seven participants provided data at baseline, and six and 12 month follow-ups, of these, 757 
completed carbon monoxide (CO) tests; 68 participants were validated as quit at both follow-
ups (CO/parts per million (CO/ppm) <10) and 589 as smokers at both follow-ups (CO/ppm 
≥10).  
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4.3.3. Aim 1: Determine the association between smoking cessation and change in 
mental health in the whole sample (unmatched)  
 
Linear regression modelling was used to determine the difference in mental health at follow-
up, with adjustment for baseline values, between smokers who quit and smokers who 
continued, this model was repeated with adjustment for covariates (Table 4.1). Variables were 
ascertained as described in the following sections ahead. 
 
Table 4.1 Adjusted and unadjusted linear regression model for 
the whole (unmatched sample) 
Predictor Outcome Adjustment 
Smoking 
status 
Mental health (SF-36) at 
12 month follow-up 
Baseline mental health 
Smoking 
status 
Mental health (SF-36) at 
12 month follow-up 
Baseline mental health, treatment 
status, FTND, Trial ID, sex and age 
 
4.3.3.1. Exposure 
 
Exposure was self-reported and biologically-validated, repeated point-prevalence (seven-day) 
smoking status at both six and 12 months. Quitters were biologically validated as quit 
(CO/ppm <10) at both time-points and smokers were biologically validated as smoking 
(CO/ppm ≥10) at both time-points (see Figure 4.1). Those who reported quit, but failed 
biological-validation were excluded, and those who reported smoking but failed biological-
validation were also excluded from the analysis. 
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Figure 4.1 Timeframe for measurement of exposure and outcome variables 
 
4.3.3.2. Outcome 
 
Mental health was self-reported and measured using the RAND 36 item health survey 1.0. 
This scale is also known as the SF-36; however the RAND-36 uses slightly different scoring 
algorithms The RAND-36/SF-36 is a short form self-report questionnaire designed to detect 
changes in physical and mental health status. This study used the “emotional wellbeing” 
subscale to assess mental health. Scores range from 0 to 100 and a score of ≤38 indicates 
presence of a mental health problem (Hays et al., 1993; 1998). In the general population the 
subscale’s mean and standard deviation are 70.4 (22.0). A minimally important difference on 
the emotional wellbeing subscale can be determined by effect size (standardised mean 
difference) between 0.09 and 0.28 equivalent to 2.0 to 6.2 points difference on the scale (Hays 
and Morales, 2001). 
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Outcome was change in mental health at 12 month follow-up, with adjustment for baseline 
values (Figure 4.1). Participants mean change scores were not used to measure change in 
mental health from baseline to follow-up, because of regression to the mean when using 
within-person, repeated measures data. Regression to the mean occurs when extreme 
measurements tend to be followed by measurements which are closer to the group mean 
(Barnett et al., 2005). Therefore, use of mean change scores can exaggerate extreme effects 
and compromise statistical precision. For these reasons, Vickers et al. (2001) suggest when 
using a regression model to compare change in a continuous outcome between two groups, 
follow-up scores should be adjusted for baseline values. 
 
4.3.3.3. Confounding variables 
 
The adjusted regression model (conducted using the whole sample) included nicotine 
dependency (FTND), treatment allocation (placebo or active), Trial ID, sex and age as 
covariates.  
 
4.3.4. Aim 2: Match participants on propensity scores 
 
A propensity score was calculated for each participant representing the conditional probability 
(odds) of quitting smoking (versus continuing to smoke), and was developed using observed 
baseline covariates found to predict repeated point-prevalence smoking status. PSM intended 
to balance the distribution of demographic, psychological and behavioural covariates between 
the groups (Rosenbaum and Rubin, 1983). 
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The McNeil trials were conducted in different countries, and this could introduce systematic 
differences between the participants if trial was not a matching criterion. In addition, while 
the measurement of some variables was consistent across trials, other measures differed by 
trial. Therefore to account for systematic differences between trials and to include as many 
baseline covariates as possible in the matching procedure, participants were matched within 
trials (see Appendix 1 for variables). The matching procedure is described in detail below. 
 
4.3.4.1. Step 1: Determine which baseline covariates should contribute towards 
propensity scores  
 
The following two methods were used to determine which covariates should be used to 
develop propensity scores. 
 
Literature search — A literature search was conducted to find systematic reviews of 
characteristics which predict cessation success. A combination of the following search terms 
were used “cessation” “quit” “predict$” “success” “associa$” “characteristic$” “variable” 
“covariate”. The search produced two major reviews2. Vangeli and colleagues (2011) 
systematically reviewed 17 prospective studies of adults, which aimed to examine predictors 
of achieving cessation. The review found that only nicotine dependency consistently predicted 
cessation success across studies. A review by the Cochrane group (Stead et al., 2012) pooled 
results from 111 RCTs comparing NRT with placebo/non-NRT control, and the results 
indicated that NRT increases success of quitting by 50% to 70%. Accordingly, nicotine 
                                                 
2
 Another review by Hitsman et al (2013) identified that depression history predicted failed cessation; however 
participants’ depression history data were not available for these analyses. 
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dependence scores (FTND) (Fagerström et al., 1990) and NRT treatment status (active or 
placebo) were forced into propensity score models. 
 
Logistic regression model — To determine which baseline variables predicted repeated point-
prevalence smoking status, behavioural, psychological and demographic baseline covariates 
(Table 3.1 presents a detailed list of covariates) were entered into a forward stepwise logistic 
regression model, after forced entry of FNTD scores and treatment status. P<0.10 was used to 
determine entry into the model.  
 
4.3.4.2. Step 2: Calculate participants’ propensity scores 
 
PSMATCH2 command in STATA 13 was used to calculate propensity scores (Leuven and 
Sianesi, 2003). Participants’ propensity scores were estimated using a logistic regression  
(Rosenbaum and Rubin, 1984) in which smoking status was the outcome variable and 
baseline covariates (as identified during Step 1) were entered as the predictors. The estimated 
propensity score was the participants’ predicted probability (odds) of achieving abstinence 
derived from the fitted regression model. 
 
Participants’ propensity scores were matched using 1:1 nearest neighbour matching, with no 
replacements, and matching was conducted within the common support region (see Step 3 
ahead for further details about the common support region). Thus each participant in the quit 
group was matched to a single participant in the continuing smoker group with the closest 
estimated propensity score. Nearest neighbour 1:1 matching uses a greedy algorithm which 
sorts the observations in the quit group by their estimated propensity score, then matches each 
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observation sequentially to an observation in the continuing smoker group that has the closest 
propensity score, within the common support. Once a participant was matched, they were not 
re-entered into the algorithm. 
 
4.3.4.3. Step 3: Model adequacy checks 
 
The main PSM model was checked for adequacy using the following checks as recommended 
by Thoemmes and Kim (2011): 
 
Checking covariate balance before and after matching — The propensity score model was 
checked to ensure that a balance of means and variances was achieved for covariates after 
matching (Thoemmes and Kim, 2011). The standardised differences were examined and T-
tests were conducted to analyse distribution of covariates between groups, before and after 
matching.  
 
The standardised % bias before and after matching was calculated to assess bias reduction. 
The standardised percent bias is the percent difference of the sample means in the quitters and 
continuing smokers (whole or matched sample), as a percentage of the square root of the 
average of the sample variances in each group. The achieved percentage of reduction in bias 
(Rosenbaum and Rubin, 1985) was calculated. After matching bias should be between 5% 
(Rosenbaum and Rubin, 1985) and 10% (Heinze and Juni, 2011) to determine an adequate 
model. 
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Common support — Matching was restricted within the common support region. The 
common support region is defined as the area in which the groups’ propensity score 
distributions are commonly observed. If the overlap between the distributions is broad, this 
allows for causal estimates over the full range of propensity scores in the sample (King and 
Zeng, 2005). However, small common support regions restrict the estimation of a causal 
effect and can result in bias by changing the observed population (King and Zeng, 2005). This 
can be examined diagrammatically; plots of Kernel density estimations of groups’ propensity 
scores were examined by group, before and after matching as recommended by Thoemmes 
and Kim (2012). Kernel density estimation is a non-parametric method of estimating the 
probability density function of a continuous variable.  
 
4.3.5. Aim 3: Determine the association between smoking cessation and mental 
health in the matched sample 
 
4.3.5.1. Linear regression modelling in the matched sample 
 
Linear regression modelling was conducted in the matched sample to examine the association 
between smoking cessation and mental health. Exposure and outcome were ascertained in the 
same manner as discussed in sections 4.3.3.1 and 4.3.3.2, adjustment for confounding is 
discussed ahead. Linear regression modelling compared follow-up mental health scores 
between groups, with adjustment for baseline values (Table 4.2).  
 
Confounding — Using the matched sample, the linear regression model was only adjusted for 
age and sex. The model was not adjusted for FTND and treatment allocation, because these 
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covariates were forced into propensity scores, nor was the model adjusted for Trial ID, as 
participants were matched within trials to account any systematic differences between trials. 
 
Table 4.2 Linear regressions models conducted in matched 
sample 
Predictor Outcome Adjustment 
Smoking status 
Change in mental 
health 
Baseline mental health, 
sex, age 
 
4.3.5.2. Main PSM model and sensitivity analyses 
 
The trials measured key baseline variables consistently; however each trial also measured 
some variables in different ways. Therefore participants were a) matched within trials using 
all relevant variables (see Appendix 1 for variables), and in another model participants were 
b) matched across trials using variables which were measured consistently. Matching was 
repeated within or across trials, with and without common support restrictions, and regression 
coefficients were compared between the sensitivity models (See Table 4.3 for analysis 
breakdown). 
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Table 4.3 Analysis breakdown: PSM analyses and linear regressions conducted after 
matching 
Primary or 
sensitivity 
analysis 
Matching 
within or 
across trials 
Within/without 
common support 
restrictions 
Predictor Outcome  Covariates 
Primary Within trials 
Within common 
support 
Smoking status 
Mental health 
(SF-36) 
Baseline mental 
health, sex, age 
Sensitivity 
Within trials 
Without common 
support 
Smoking status 
Mental health 
(SF-36) 
Baseline mental 
health, sex, age 
Across trials 
Without common 
support 
Smoking status 
Mental health 
(SF-36) 
Baseline mental 
health, Trial ID, 
sex, age 
Across trials 
Within common 
support 
Smoking status 
Mental health 
(SF-36) 
Baseline mental 
health, Trial ID, 
sex, age 
The primary analysis is indicated by blue text  
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4.3.6. Clinically important change 
 
A minimally clinically important difference on the SF-36 emotional well-being subscale is 
determined by an effect size (SMD) of 0.09 to 0.28 (Hays and Morales, 2001). To determine 
if the association between smoking cessation and mental health was a clinically important 
change the SMD was calculated using Cohen’s d (Cohen, 1988). Cohen’s d was calculated 
before and after matching, whereby the mean follow-up mental health score for smokers      
was subtracted from that of quitters (   , and this difference was divided by the cohort’s 
standard deviation (McGough and Faraone, 2009): 
  
     
 
 
4.3.7. Missing data 
 
If participants were missing any relevant data they were excluded from the analysis. The 
number of participants excluded for missing outcome data are reported in the results. 
 
4.3.8. Risk of bias 
 
An adapted version of the Newcastle-Ottawa Scale was used to assess risk of bias in 
observational studies (Appendix 4). The measure rates studies on a scale of 1 to 5: 1 indicates 
a high risk of bias and 5 indicates a low risk of bias. 
 
4.3.9. Ethics and data protection 
 
Please see Chapter Three for details pertaining to ethics and data protection. 
134 
 
4.4. Results 
 
4.4.1. Participants in the whole (unmatched) sample 
 
In the whole sample 68 participants were biologically validated as quit at both six and 12 
month follow-up, and 589 as smokers at both six and 12 month follow-up. Three smokers and 
one quitter were excluded due to missing baseline mental health scores. Twenty-six smokers 
were missing mental health data at 12 month follow-up and no quitters were missing mental 
health outcome data at follow-up. Smokers excluded for missing follow-up data had a M (SD) 
baseline SF-36 mental health score 74.0 (15.7), this was similar to the mean baseline score of 
included smokers 71.2 (17.5) and those excluded were psychologically healthy (scores of ≤38 
indicate health problem (Hays et al., 1998)). After exclusion for missing mental health data, 
67 participants were biologically validated as repeated point prevalence quitters and 560 
biologically validated as repeated point prevalence smokers. 
 
Table 4.4 Baseline characteristics of whole sample 
 Smokers 
(N=560) 
Quitters 
(N=67) 
Test of 
significance P-value 
Age, M (SD) 45.6 (10.6) 46.2 (10.2) T = 0.52 0.607 
Sex, % male (N) 48% (258) 52% (35) Chi
2 
= 0.42 0.515 
FTND, M(SD) 6.2 (1.9) 5.3 (2.5) T = 3.42 0.0007 
SF-36 Mental health, 
M (SD) 
71.2 (17.5) 74.8 (13.6) T = 1.64 0.101 
Treatment status, % 
received active (N) 
50% (280) 72% (48) Chi
2 
= 11.42 0.001 
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Table 4.4 displays baseline characteristics for smokers and quitters in the whole sample. 
There were significant baseline differences between the groups’ FTND scores, and the 
proportion who received active treatment, there were no differences between groups’ age, sex 
or baseline mental health.  
 
4.4.2. Aim 1: Determine the association between smoking cessation and change in 
mental health in the whole (unmatched) sample 
 
The first aim was to determine the difference in change in mental health from baseline to 12 
month follow-up between smokers and quitters in the whole sample. Both groups showed an 
improvement in SF-36 mental health scores, and the improvement was greater in the quit 
group 4.90 (95% CI: 1.14 to 8.65) compared with continuing smokers 0.98 (-0.43 to 2.39) 
(Figure 4.2). SF-36 mental health outcome scores were compared between groups with 
adjustment for baseline mental health, and the mean difference was significant, 5.48 (95% CI: 
1.62 to 9.35; P<0.001). After adjusting for FTND scores, trial ID, sex, age and treatment 
status the adjusted mean difference between groups remained significant, 4.50 (3.56 to 8.50; 
P= 0.025). 
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Figure 4.2 Means and standard errors: unmatched groups’ change in mental health over 
time 
 
4.4.3. Aim 2: Match participants on propensity scores 
 
The first objective of the PSM procedure was to determine which covariates should be used to 
develop propensity scores. Covariates were selected based upon their association with 
smoking status, within each trial, after forced entry of FTND and treatment status. Table 4.5 
presents odds ratios and 95% CIs for covariates which predicted cessation at the P<0.10 
significance level. In the main PSM model the following baseline covariates were included in 
the propensity scores: FTND scores, NRT treatment status, age started smoking, report of 
calming effects from smoking, report of unpleasant symptoms from smoking, length of time 
to last cessation attempt, experience from last cigarette, longest period without smoking, SF-
36 mental health (one trial) (Table 4.5).  
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Table 4.5 Main PSM model: Odds ratios and 95% CI for baseline predictors of smoking status at six and 12 month 
follow-up 
Trial ID Covariate 
OR 
(quit=1) 
95% CI P-value 
1 
FTND (high score = more dependent) 0.52 0.36 to 0.74 <0.001 
NRT treatment (active=1) 0.41 0.09 to 1.86 0.25 
Age started smoking 1.38 1.18 to 1.62 <0.001 
Calming effect from smoking (high score = maximum effect) 2.15 1.15 to 4.00 0.016 
Number of unpleasant symptoms from smoking (more symptoms = higher score) 2.17 1.12 to 4.20 0.021 
Time to last cessation attempt 3.74 0.85 to 16.38 0.80 
2 
FTND (high score = more dependent) 0.87 0.59 to 1.27 0.460 
NRT treatment (active=1) 11.65 1.38 to 98.17 0.024 
Pleasant experience from last cigarette (high rating = maximum enjoyment) 2.36 1.0 to 5.41 0.043 
3 
FTND (high score = more dependent) 0.98 0.74 to 1.30 0.907 
NRT treatment (active=1) 3.06 0.77 to 12.14 0.112 
Longest period without smoking 1.87 1.07 to 3.26 0.028 
4 FTND (high score = more dependent) 0.80 0.55 to 1.16 0.241 
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NRT treatment (active=1) 2.91 0.50 to 16.79 0.232 
5 
FTND (high score = more dependent) 0.85 0.62 to 1.16 0.316 
NRT treatment (active=1) 6.07 1.75 to 21.05 0.004 
Pleasant experience from last cigarette (high rating = maximum enjoyment) 0.43 0.24 to 0.77 0.005 
SF-36 mental health (high score=better mental health) 1.05 1.01 to 1.09 0.021 
Age started smoking 0.77 0.59 to 1.00 0.046 
Age 1.07 1.00 to 1.15 0.043 
139 
 
4.4.3.1. Variables used to develop propensity scores in sensitivity models 
 
Slightly different covariates contributed towards propensity scores in sensitivity models 
where participants were matched across trials. Table 4.6 displays a summary of the covariates 
used to develop propensity scores during matching across trials; the odds and 95% CIs for the 
association between these variables and propensity to quit are reported in Appendix 15. The 
covariates were similar to the main model, and baseline mental health did not predict smoking 
status in sensitivity models where participants were matched across trials. 
 
Table 4.6 Which covariates are important predictors of 
smoking status in sensitivity models 
 Kept in model at P<0.1 level 
Forced into 
regression 
Across Trials 
Demographic, Intention to quit/reduce, 
Smoking history, CPD, Relief from smoking 
questionnaire 
FTND, 
treatment 
status 
Within Trials Same as main analysis 
 
4.4.3.2. Main model adequacy checks 
 
The main PSM model matched participants within each trial therefore adequacy checks were 
conducted within trials. 
 
Checking covariate balance before and after matching — Means of variables entered into 
propensity scores were compared between groups, and were examined before and after 
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matching (presented in Appendix 16). In all cases, variables which were significantly 
imbalanced before matching became balanced after matching (Heinze and Juni, 2011; 
Rosenbaum and Rubin, 1985). No variables became significantly imbalanced after matching. 
The percent difference in bias between groups before and after matching was also examined 
(Appendix 16). In Trial 1, after matching, three (out of six) variables were adequately 
matched; in Trial 4, zero (out of two) variables were adequately matched; in Trial 5, three (out 
of six) variables were adequately matched. In Trials 2 and 3, after matching all variables were 
adequately matched (six out of six). In sum, matching led to a ≥90% reduction in bias for 
13/20 variables. Please see Appendix 16 for further details.  
 
Common support — The distribution of smokers’ and quitters’ propensity scores before 
matching were examined for a common support region (overlap in score distributions). Figure 
4.3 shows the common support region was not large, but the overlap was sufficient for 
matching within common region. Figure 4.4 displays that smokers and quitters were 
predominately matched within a common region. 
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Figure 4.3 Overlay of Kernel density distributions of quitters’ and smokers’ propensity 
scores in the whole sample 
 
 
 
 
 
Figure 4.4 Overlay of Kernel density distributions of quitters’ and smokers’ propensity 
scores in matched sample 
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4.4.4. Aim 3: Compare the association between smoking cessation and mental health 
between matched and unmatched samples 
 
4.4.4.1. Participants after PSM 
 
The PSM model included 67 biologically validated continuous quitters who were matched to 
67 smokers with similar propensity scores. Sixteen participants (12%), eight per matched 
sample, were lost as they did not fall within the common support. Those who were excluded 
for this reason had similar baseline mental health scores to those included, M (SD)s for 
excluded smokers were 77.0 (14.6) and 73.5 (16.4) for excluded quitters; FTND scores of 
excluded smokers were 4.0 (2.4) and 3.4 (1.9) for excluded quitters. Six excluded smokers 
and seven excluded quitters received active NRT. Thus, baseline data for those excluded due 
to common support restrictions were similar to baseline data of those included. 
 
Table 4.7 Matched participants’ baseline characteristics  
Characteristic 
Smokers (N=59) 
M (SD) 
Quitters (N=59) 
M (SD) 
Test of 
significance 
P-value 
Age 48.3 (10.4) 45.8 (9.0) T=1.44 0.152 
Sex (% male) 46% 53% Chi
2
= 0.54 0.461 
FTND 5.6 (2.1) 5.6 (2.4) T=0.04 0.968 
SF-36 Mental health 77.5 (15.1) 75.0 (13.3) T=0.95 0.340 
Treatment status (% 
received active) 
29% 31% Chi
2
=0.04 0.840 
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Table 4.7 displays baseline characteristics for smokers and quitters matched within the 
common support. In the whole sample there were significant differences between the groups’ 
FTND scores and the number of people receiving active treatment (Table 4.4). After matching 
a balance between groups’ baseline characteristics was reached. 
 
4.4.4.2. Regression analysis after PSM 
 
In the main PSM model participants were matched within trials and common support 
restrictions were used. Quitters showed an improvement in SF-36 mental health scores (mean 
change) 4.54 (95% CI: 0.35 to 8.74) and smokers displayed a slight worsening in mental 
health scores 0.23 (4.75 to 4.34) (Figure 4.5). After adjustment for baseline mental health, 
age and sex the difference in outcome scores was not significant (B=3.37; 95% CI: 2.15 to 
8.90; P=0.229). Similar to the adjusted mean difference in the unmatched sample (section 
4.4.2), the change remained in favour of the quit group, but the estimate was no longer 
precise. 
  
144 
 
 
Figure4.5 Means and standard errors: matched groups’ change in mental health over 
time 
 
4.4.4.3. Main model and sensitivity models 
 
Three additional PSM models (described in detail in Table 4.3) were conducted based on 
different methodological decisions, these included matching participants across trials, and 
matching without common support restriction. The association between stopping smoking and 
change in mental health was examined in these sensitivity models after adjustment for age, 
sex, baseline mental health and Trial ID, where applicable (Appendix 17). In each sensitivity 
model smokers and quitters presented balanced baseline mental health scores. At follow-up 
smokers’ mean scores indicated either a slight improvement or slight worsening, and in all 
analyses quitters showed a moderate improvement in mental health. The adjusted mean 
differences (95% CI), ranged from, 3.97 (1.00 to 8.93) to 3.55 (1.29 to 8.40) (Appendix 17), 
suggesting the association observed was not influenced by any methodological decisions 
made.  
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4.4.5. Minimal clinically important difference 
 
As described above, a minimally important difference on the SF-36 mental health subscale is 
indicated by an effect size (SMD) of 0.09 to 0.28 (Hays and Morales, 2001). The standardised 
effect size was d=0.42 (95% CI: 0.16 to 0.67) in the whole sample, after matching the effect 
estimate declined and became imprecise 0.14 (0.22 to 0.50). 
 
4.4.6. Risk of bias 
 
The study’s risk of bias was assessed using the Newcastle-Ottawa Scale, and scored 4/5, 
indicating a low risk of bias. The study lost one point because of high loss to follow-up 
(Appendix 18). 
 
4.5. Discussion 
 
4.5.1. Summary of key results 
 
Regression modelling showed evidence that smoking cessation was associated with improved 
mental health compared with continuing smoking and this finding was not altered by 
adjustment for confounding. Propensity score matching offers potential to control group 
membership bias, as well as confounding. Using this technique a good match between 
smokers that continued smoking and those that stopped smoking was achieved. Doing so, the 
regression coefficient for the difference between smokers and quitters was similar to that 
achieved by regression methods alone, but it was no longer significant.  
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Comparison of the two statistical approaches shows that the regression analysis in the whole 
sample was more powerful, however there was more potential for bias. The regression 
analysis after matching participants on their propensity scores was less powerful, however 
there was less potential bias. The effect estimates were similar from both analyses giving 
confidence that the significant effect seen in the unmatched sample was less likely to be due 
to confounding. 
 
4.5.2. Limitations, strengths and potential sources of bias 
 
PSM is a valuable tool for causal inference in observational research, however it has its 
limitations and these will be addressed in relation to this study. Firstly, PSM is argued to 
balance unobserved confounding between groups (Rosenbaum and Rubin, 1983a; 1983b), 
however one cannot be completely certain this has been achieved, limiting inferences drawn 
from these findings. Secondly, there was a moderately sized common support region, and this 
somewhat restricts estimation of a causal effect, and may introduce bias by changing the 
observed population (King and Zeng, 2005). However, only 12% of quitters were lost, and 
those excluded did not differ on baseline characteristics compared with the remainder of the 
sample, and moreover estimates derived from models using common support restrictions were 
similar to those derived from models with no common support restrictions.  
 
The size of the cohort was an obvious issue in this study as it gives rise to considerable 
imprecision. The largest analysis in the unmatched sample included 67 quitters, and the final 
matched analysis included 59 in each group, and this was not large enough to produce 
statistically significant evidence of a clinically important difference. 
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To ensure patient anonymity, demographic characteristics such as ethnicity, social class and 
education could not be used in analyses. These demographics are possible predictors of 
change in smoking status, however a recent systematic review did not find consistent 
evidence to support this (Vangeli et al., 2011). In support of this, adjustment for potential 
confounders such as age, sex and Trial ID (which accounts for country of participant), had 
only a small effect on the regression model. Importantly, the strongest predictor of mental 
health at follow-up is mental health at baseline (Asendorpf, 1992; Burns et al., 2014) and 
these analyses measured mental health change, within individuals using adjustment for 
baseline values. However, confounding via interactions between covariates may be a 
possibility. 
 
There was significant loss to follow-up in the McNeil trials, although these rates were similar 
to other trials of NRT (Stead et al., 2012). The association between mental health and drop out 
is not clear and may bias the association. Studies in depressed individuals have found that 
worse baseline mental health was associated with dropout at follow-up (Bolam et al., 2011; 
Munoz et al., 1997), whereas another study found no association (Borrelli et al., 2002). Bias 
would only occur, however, if drop out differed by exposure group, which is not necessarily 
implied by drop out being associated with change in mental health. 
  
148 
 
4.5.3. Strengths of study 
 
The strengths of this observational study lay in its ascertainment of exposure and outcome. 
Stringent criteria for assessment of exposure were adopted, therefore in this study there was a 
minimal chance of misclassification. Participants were biologically validated as either quit or 
smoking, at both follow-up periods. These are highly accepted evidence-based cut-off criteria 
(Hughes et al., 2003; West et al., 2005), and repeated point-prevalence is likely to produce 
results similar to those from a continuously abstinent group (Hughes et al., 2003; 2010), 
therefore exposure misclassification is unlikely to be an issue. The outcome mental health was 
measured using the RAND-36/SF-36 “emotional well-being subscale”. This measure of 
mental health is psychometrically sound in general and clinical populations, is highly 
validated and sensitive to change (Hays et al., 1998; Hays and Morales, 2001). Secondly, risk 
of bias was assessed using a tool purposefully modified to rate studies which investigate the 
association between smoking cessation and mental health; the study’s rating suggests a low 
risk of bias to the association.  
 
Sensitivity analyses were examined to address heterogeneity in these data and bias from 
methodological decisions made. The association was examined after matching participants 
across and within trials, and after matching participants with and without common support 
restrictions. The association at its weakest, remained favourable for quitters. 
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4.5.4. Interpretation  
 
As was the case in Chapter Two, there are three possible explanations for the association. The 
first is that smoking cessation improves mental health; the second is that improving mental 
health leads to cessation; and the third is that a common factor caused both improved mental 
health and cessation. 
 
The third explanation, the common cause, would require that the common factor would have 
had to occur within the first six months of follow-up, be common across cultures (Europe, US 
and Australia), and have persisting effects on mental health that could be observed at the 12 
month follow-up. There is no evidence that positive life events, for example, are associated 
with sustained cessation. The possibility of a single event leading to both cessation and 
improved mental health seems less plausible, particularly considering the evidence presented 
in Chapter Two, where improved mental health was seen nine years after cessation. 
 
There is a plethora of data which support the notion that cessation improves mental health. 
Firstly, data in Chapter Two display consistencies in this association and through sensitivity 
analyses weaken reverse causation and confounding (Appendix 9). Furthermore, this notion is 
supported by a study in which participants were randomised to quit or continue smoking, 
which showed a modest benefit of cessation (Dawkins et al., 2009). Thus there is adequate 
evidence to support the notion that stopping smoking may likely lead to improvements in 
mental health. However, these trials were of people who wanted to reduce their smoking 
rather than quit smoking, thus these participants were not selected based on their desire to 
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stop. It is possible that mood improved from baseline to six months, which then initiated a 
cessation attempt
3
. Therefore, reverse causation is possible in this analysis. 
 
4.5.5. Biological explanation 
 
The notion that stopping smoking improves mental health is supported by a biological model 
(previously discussed in section 1.6). Chronic tobacco smoking is associated with 
neuroadaptations in nicotinic pathways in the brain (Benowitz, 1999; 2010; Mansvelder and 
McGehee, 2002; Wang and Sun, 2005), these changes induce a withdrawal cycle, and are 
marked by fluctuations in a smoker’s psychological state throughout the day (Benowitz, 1999; 
2010) and could worsen mental health (Parrott, 1999). It has been found that the neurological 
functioning of quitters returns to the same level as non-smokers at three weeks after cessation 
(Mamede et al., 2007), which is consistent with reports that psychological withdrawal 
symptoms subside after a few weeks (Hughes, 2007b). It is possible that smokers assume that 
because smoking alleviates these feelings, that smoking a cigarette has improved their mental 
health when in fact it was smoking that caused these problems.  
 
4.5.6. Clinical implications 
 
If the association is causal, then this study shows that the ‘effect’ of cessation on mental 
health is likely clinically important, although after reduction in sample size after PSM this 
estimate became imprecise, somewhat smaller, and of borderline clinical significance. These 
data should be used in conjunction with other observational studies and should reassure health 
                                                 
3
 This hypothesis could not be tested due to missing mental health data at six month follow-up. 
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care professionals and smokers that smoking cessation is not likely to cause psychological 
harm. 
 
4.6. Conclusion 
 
Overall, this study suggests that the association between smoking cessation and improved 
mental health was not altered by matching smokers and quitters on their propensity to achieve 
abstinence, therefore results derived from regression modelling alone are unlikely to be 
influenced by disposition to group membership or confounding. This study is in agreement 
with other data which suggest that cessation may lead to improved mental health, and is 
supported by a plausible biological pathway.  
 
4.7. Chapter summary 
 
The findings in Chapter Two may have been biased by group membership and unmeasured 
confounding. Therefore in this chapter the association between cessation and mental health 
was assessed using PSM to control for these biases and produce causal effect estimates. 
Estimates derived from PSM and regression modelling produced similar estimates compared 
to regression modelling alone, suggesting the findings were associated with cessation, rather 
than arising through other bias.   
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CHAPTER FIVE 
5. ASSESSING THE ASSOCIATION BETWEEN SMOKING CESSATION 
AND ONSET OF PSYCHIATRIC DISORDER, USING PROPENSITY 
SCORE MATCHING 
 
5.1. Introduction to Chapter Five 
 
It has been suggested that after cessation some quitters’ may experience psychiatric disorder 
as a result of cessation. If this hypothesis is true, analysis of means, as reported in Chapters 
Two and Four may have concealed the uncommon occurrence of psychiatric disorder. 
Therefore, this Chapter reports a secondary analysis of the McNeil trials, in which the 
association between smoking cessation and onset of psychiatric disorder is assessed by 
comparing risk-difference estimates between smokers and quitters, before and after using 
propensity score matching (PSM) techniques.  
 
5.2. Background 
 
It has been suggested that some psychological withdrawal symptoms from tobacco may 
display a permanent deterioration after cessation, known as an offset effect (Hughes, 2007a) 
(previously discussed in sections 1.6.3, 1.9.2 and 1.10.2). If an offset effect occurs, the level 
of symptom is abnormal and permanent. For example, if a quitter experiences an offset effect, 
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this would mean that become depressed as a result of cessation. Hughes (2007c) argues that 
there are two interpretations of the offset effect. Firstly, the person’s mental health may have 
been poor before they began to use tobacco, and that tobacco use improved the symptoms of 
their disorder; this notion is supported by the self-medication hypothesis (Khantzian, 1997) 
(previously discussed in section 1.9.2). Another explanation is that the onset of disorder after 
cessation results from neuropsychological damage caused by chronic tobacco use (previously 
discussed in section 1.6). 
 
Chapters Two and Four examined the difference in change in mental health between people 
who quit and people who continued smoking, these chapters displayed that stopping smoking 
was associated with improvements in mental health outcomes, and that continuing smoking 
was associated with little change (Figures 2.2, 4.2, and 4.5). If there were uncommon 
occurrences of psychiatric disorder, analysis of group means may have not revealed this 
(McCaffery and Elliott, 2008). 
 
Three reviews (Banham and Gilbody, 2010; Hughes, 2007c; Ragg et al., 2013) and three other 
studies not reviewed elsewhere (Bolam et al., 2011; Sanchez-Villegas et al., 2008; Khaled et 
al., 2012) have examined risk of depression or anxiety after cessation, or other psychiatric 
symptoms (all reviews and studies previously discussed in detail in section 1.10). In 
summary, the findings from these reviews and studies are mixed, some suggest that cessation 
was not associated with risk of depression, anxiety or other disorders in psychiatric or general 
populations (Banham and Gilbody, 2010; Bolam et al., 2011); one review reports cessation 
was linked to increased risk of depression in smokers with depression history (Hughes, 
2007c); another review suggests cessation was associated with a possible risk of depression in 
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those with depression history (Ragg et al., 2013), whereas other studies report cessation was 
associated with decreased risk of depression in the general population (Khaled et al., 2012; 
Sanchez-Villegas et al., 2008). In most of these studies attrition was a problem, with one 
study showing some evidence that depressed people were more likely to drop-out (Bolam et 
al., 2011) and in population cohort studies ascertainment of outcome was not strong. Another 
major problem within these studies is the risk of group membership bias, which is a likely 
source bias in observational studies of quitters and smokers, but also in randomised designs 
(as previously discussed in sections 1.10, 2.5 and 4.2.1). 
 
5.2.1. Study aims  
 
No previous study has used propensity score matching (PSM) to address group membership 
bias when investigating the association between cessation and risk of psychiatric disorder (as 
assessed by literature review reported in section 4.2). Therefore in this chapter the association 
between smoking cessation and risk of psychiatric disorder was assessed by comparing risk 
estimates derived from the whole sample with estimates derived from a sample matched on 
their propensity to achieve abstinence. This study aimed to:  
 
1) Determine the risk of psychiatric disorder onset during a six month period after 
cessation compared with continuing smoking during the same period;  
2) Calculate propensity scores for quitters and continuing smokers using observed 
baseline covariates;  
3) Recalculate the risk difference in the matched sample.  
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5.3. Methods 
 
5.3.1. Study design 
 
A prospective observational analysis of individual level patient data derived from the McNeil 
trials (see Chapter Three for further trial details).  
 
5.3.2. Setting 
 
The trials’ settings have been previously reported in sections 3.5 and 4.3.1 to 4.3.2. 
 
5.3.3. Participants and study size 
 
Participant characteristics have been previously reported in sections 3.5 and 4.3.2. After 
screening there were 2066 participants enrolled in the trials. At baseline 2059 participants 
provided smoking status information, of these, 937 participants provided smoking data at both 
six and 12 month follow-ups. Sixty eight participants were biologically-validated as repeated 
point-prevalence (seven day) quitters (carbon monoxide/parts per million (CO/ppm <10) and 
589 as repeated point-prevalence smokers (CO/ppm ≥10).  
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5.3.4. Variables 
 
5.3.4.1. Exposure 
 
Exposure was self-reported and biologically-validated, repeated point-prevalence (seven-day) 
smoking status at both six to 12 months. Groups were biologically-validated as quit (CO/ppm 
<10) or smoking (CO/ppm ≥10). Those who failed biological-validation were not included in 
this analysis. 
 
5.3.4.2. Outcome  
 
Outcome was onset of psychiatric disorder between six and 12 month follow-up points, 
during which time repeated point-prevalence cessation or continued smoking was self-
reported and biologically-validated (Figure 5.1). 
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Psychiatric 
adverse event
Baseline 6 Months 12 Months
Smokers
Smokers
Bio-verified 
quit 
Bio-verified 
smoking
 
Figure 5.1 Timeframe for measurement of exposure and outcome variables 
 
Psychiatric disorder was ascertained by coding each trial’s adverse event data according to the 
MedDRA database (version 16.1) (Medical Dictionary for Regulatory Activities, 2013). 
MedDRA is an internationally used set of terms relating to medical conditions and was 
purposely designed to assist clinicians and researchers communicate medical information, 
including adverse event data. The trials’ adverse event data comprised of brief descriptions 
and key terms recorded by trial researchers (previously discussed in section 3.5). Each 
adverse event key term was entered into the MedDRA 16.1 online database to determine its 
classification according to the ‘Lowest Level Term’ (i.e. symptom). Adverse events were 
considered to be psychiatric if the ‘Lowest Level Term’ mapped on to the classification of 
‘Psychiatric Disorder’. The corresponding ‘High Group Level Term’ (e.g. ‘mood disorders’) 
was recorded to determine the type of disorder. There were no cases where a ‘Lowest Level 
Term’ could be classed under two different psychiatric disorders. If the  ‘Lowest Level Term’ 
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fell under two ‘System Organ Classes’ (i.e. Psychiatric conditions) PA and GT read the 
adverse event description in detail to decide if the event was likely to be psychiatric-related or 
otherwise. Any remaining key terms which did not meet ‘Psychiatric Disorder’ criteria were 
coded as ‘No psychiatric disorder.’ GT and PA were blinded to participants’ smoking status. 
 
5.3.5. Risk of bias 
 
An adapted version of the Newcastle-Ottawa Scale was used to assess risk of bias in 
observational studies (Appendix 4). The measure rates studies on a scale of 1 to 5: 1 indicates 
a high risk of bias and 5 indicates a low risk of bias. 
 
5.3.6. Statistical methods 
 
5.3.6.1. Calculation of difference before and after PSM 
 
To assess the association between smoking cessation and onset of psychiatric disorder, the 
risk of psychiatric disorder was compared between quitters and continuing smokers, by 
calculating Pearson’s Chi2 and the risk-difference in the whole (unmatched) sample. To see if 
the association was altered by use of PSM McNemar’s Chi2 and risk difference were 
calculated after matching participants on their propensity scores. 
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5.3.6.2. Propensity score matching procedure 
 
Matching participants on their propensity to quit aims to balance the distribution of 
demographic, psychological and behavioural characteristics between quitters and continuing 
smokers (Rosenbaum and Rubin, 1984). The PSM procedure and methods were previously 
described in detail in section 4.3.4. Each participant’s propensity score was developed using 
covariates which were identified as important predictors of achieving abstinence (previously 
reported in section 4.3.4.2). The analyses described in this Chapter used the same PSM 
models as described in Chapter Four.  
 
5.3.6.3. Primary model and sensitivity analyses 
 
To determine if the results were influenced by heterogeneity between trials measurement of 
variables or by methodological decisions made, three additional PSM models were developed 
(outlined in Table 4.3). In these models, participants were matched either within or across 
trials, and models were repeated with and without common support restrictions (previously 
discussed in section 4.3.5.2), estimates derived from these sensitivity models were compared 
with those derived from the main PSM model. 
 
5.3.6.4. Adequacy checks 
 
All methods used to determine model adequacy were previously reported in section 4.3.4.3. 
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5.3.6.5. Missing data 
 
If participants were missing data they were excluded from the analysis. The number of 
participants excluded for missing data and corresponding missing information is reported in 
the results. 
 
5.3.6.6. Post-hoc power 
 
To determine the study’s achieved power at the p<0.05 significance level a post-hoc power 
calculation was made using a standard formula (e.g. Rosner, 2011). 
 
5.3.7. Ethics and data protection 
 
Please see Chapter Three for details pertaining to ethics and data protection. 
 
5.4. Results 
 
5.4.1. Participants in the whole (unmatched) sample 
 
The study included 68 participants biologically validated as repeated point-prevalence (seven 
day) quitters and 589 as repeated point-prevalence smokers. No smokers or quitters were 
missing outcome data. Table 5.1 displays baseline characteristics for smokers and quitters, 
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there were significant differences between the groups’ nicotine dependency scores (FTND) 
and the proportion receiving active nicotine replacement treatment (NRT).  
 
Table 5.1 Baseline characteristics of whole sample 
Characteristic Smokers (N=589) Quitters (N=68) Test of significance P-value 
Age 45.6 (10.6) 46.2 (10.2) T = –0.52 0.607 
Sex, % male (N) 48% (283) 52% (35) Chi
2
= 0.42 0.515 
FTND 6.2 (1.9) 5.3 (2.5) T = 3.42** 0.0007 
SF-36 Mental health 71.2 (17.5) 74.8 (13.6) T = -1.64 0.101 
Treatment status,  
% received active (N) 
50% (295) 72% (49) Chi
2
=11.42** 0.001 
 
Table 5.2 shows that quitters did not report any incidences of psychiatric disorder between six 
and 12 month follow-ups. In the smoking group, there were seven cases of depressed mood 
disorders and disturbances, and three cases of anxiety disorders and symptoms between six 
and 12 month follow-ups. There were no cases of any other type of disorder (e.g. 
schizophrenia) during this six month period. 
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Table 5.2 Frequency of onset of psychiatric disorder during biologically-validated 
smoking or quit period 
MedDRA 16.1 High level group term Smokers (N=589) Quitters (N=68) 
No psychiatric disorder 579 68 
Anxiety disorders and symptoms 3 0 
Changes in physical activity 0 0 
Depressed mood disorders and disturbances 7 0 
Manic and bipolar mood disorders and disturbances 0 0 
Mood disorders and disturbances not elsewhere classified 0 0 
Personality disorders and disturbances in behaviour 0 0 
Psychiatric disorders not elsewhere classified 0 0 
Schizophrenia and other psychotic disorders 0 0 
Sleep disorders and disturbances 0 0 
Somatoform and factitious disorders 0 0 
Suicidal and self-injurious behaviours not elsewhere classified 0 0 
 
5.4.2. Pearson’s Chi2 and risk difference in whole (unmatched sample) 
 
Pearson’s Chi2 and risk difference were calculated to determine the difference in risk of onset 
of psychiatric disorder, between continuing smokers and quitters. Ten (1.7%) smokers and 
zero quitters reported evidence of a psychiatric disorder between six and 12 month follow-up, 
the risk difference between groups was not significant, -0.017, P=0.28 (Table 5.3). The 
confidence intervals for this estimate were unreliable as they do not take in to account zero 
variability in risk in the quit group.  
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Table 5.3 Risk difference of onset of psychiatric disorder during 
biologically-validated smoking or quit period in the whole sample 
 Smokers (N=589) Quitters (N=68) 
No psychiatric disorder reported  579 68 
Psychiatric disorder reported  10 0 
Risk 0.017 0 
Risk difference (95% CI) -0.017 (-0.03 to -0.01)* 
Pearson Chi
2
 1.17 
P-value 0.28 
* The confidence interval is unreliable as it does not take in to account zero variability in risk in the quit group. 
 
5.4.3. Propensity score matching results 
 
Matching variables and model adequacy were previously reported in section 4.4.3. 
 
5.4.4. Participants after PSM 
 
The PSM analysis included 68 repeated point-prevalence quitters, who were matched to 68 
smokers with similar propensity scores. Sixteen participants, eight per group could not be 
matched within the common support. Quitters who were excluded for this reason presented 
similar baseline characteristics to included quitters (Table 5.4); the mean (SD) mental health 
score (SF-36) of excluded quitters was 71.4 (15.2), mean FTND score was 3.9 (2.0) and all 
received active NRT. Smokers who were excluded for this reason also had similar baseline 
characteristics compared with included smokers (Table 5.4); the mean (SD) mental health 
score for excluded smokers was 77.0 (14.6); Mean FTND scores was 4.1 (2.4), and 6 
excluded smokers received active NRT. 
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Table 5.4 displays baseline characteristics for smokers and quitters matched within the 
common support. Before PSM there were significant differences between the groups’ FTND 
scores and the proportion of people receiving of active treatment (Table 5.1), after matching, 
groups’ baseline characteristics became balanced. 
 
Table 5.4 Baseline characteristics in matched sample 
Characteristic Smokers 
(N=60) 
M(SD) 
Quitters 
(N=60) 
M(SD) 
Test of 
significance 
P-value 
Age 48.0 (10.7) 46.0 (8.8) T = 1.11 0.2674 
Sex, % male (N) 48% (29) 53% (32) Chi
2 
= 0.30 0.584 
FTND 5.5 (2.2) 5.5 (2.5) T = 0.12 0.9073 
SF-36 Mental 
health 
76.9 (15.1) 75.2 (13.4) T = 0.63 0.5244 
Treatment status, 
% received 
active (N) 
73% (44) 68% (41) Chi
2 
= 0.36 0.547 
 
5.4.5. McNemar’s Chi2 and difference after PSM 
 
McNemar’s Chi2 and risk difference were calculated to determine the difference in risk of 
psychiatric disorder between six and 12 month follow-ups, between matched groups. In the 
matched sample, one smoker (1.7%) (depressed mood disorder) and no quitters reported 
evidence of a psychiatric disorder during this period. The risk difference between matched 
groups was not significant, -0.017, P = 1.0 (Table 5.5), and the results were very similar to 
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those calculated from the whole sample (Table 5.3). The confidence intervals for this effect 
were unreliable as they do not take in to account zero variability in risk in the quit group.  
 
Table 5.5 Risk difference of onset of psychiatric disorder 
during biologically-validated smoking or quit period in the 
matched sample 
 Smokers (N=60) Quitters (N=60) 
No psychiatric report  59 60 
Psychiatric AE report  1 0 
Risk difference (95% CI) -0.017 (-0.07 to 0.03)* 
McNemar’s Chi2 1.00 
P-value 1.00 
* The confidence interval is unreliable as it does not take in to account zero variability in risk 
in the quit group. 
 
5.4.6. Model adequacy checks 
 
Model adequacy checks were previously reported and discussed in section 4.4.3.2. 
 
5.4.7. Sensitivity analyses 
 
Matching participants across trials resulted in zero psychiatric diagnoses between six and 12 
month follow-up in both groups, therefore differences could not be calculated. Matching 
participants within trials resulted in a maximum of three diagnoses (all depressed mood 
disorders) in the continuing smoker group, and none in the quit group. Sensitivity analyses 
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displayed that the estimates were all non-significant and ranged from -0.017 to -0.030 
indicating a slightly elevated risk for continuing smokers (Appendix 19).  
 
5.4.8. Risk of bias 
 
Risk of bias was assessed using the Newcastle-Ottawa Scale and this study received 4/5 stars 
indicating a low risk of bias (Appendix 20). The study lost one point because of high attrition. 
 
5.4.9. Post-hoc power 
 
This study achieved 0.5% power to detect significant differences at the p<0.05 level. 
Therefore a sample size of 3076 per arm would be required to detect a difference of 1.5% to 
2.5% between exposure groups, with 80% power.  
 
5.5. Discussion 
 
In this study of smokers from the general population, no one who stopped smoking reported 
onset of psychiatric disorder six months following cessation. By contrast, several people who 
continued to smoke did so, resulting in an estimate of a higher risk in continuing smokers 
compared with quitters, this estimate was not altered by use of PSM within-trials. However, 
the results in this study were inconclusive and the study was not adequately powered to detect 
statistical significance. 
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The findings of this study were not likely to be influenced by methodological decisions, as 
assessed during sensitivity analyses. Our primary model matched participants within trials to 
increase the number of characteristics that were matched, including variables that would be 
difficult to adjust for in regression models, such as country. Our model also used common-
support restrictions to ensure that participants' propensity scores fell within the same 
distributions. Most importantly this model matched participants on emotional-wellbeing 
where it was found to predict group membership. This model was least susceptible to bias and 
was therefore used as the primary model.  
 
However, in sensitivity analyses where participants were matched across trials this resulted in 
zero psychiatric diagnoses in both quitters and smokers between six and 12 month follow-up, 
this is likely to be the result of inadequate sample size required to detect a true incidence of 
psychiatric disorder. Furthermore, the results of these sensitivity analyses were influenced by 
matching participants on fewer covariates, and by matching participants across trials 
participants from different countries were matched with one another, therefore it is likely 
groups’ were not adequately matched.  
 
5.5.1. Limitations, strengths and potential sources of bias 
 
As this study used the same matched sample as in Chapter Four, the issues surrounding the 
use of PSM were the same in this chapter and have been previously discussed in section 4.5. 
Briefly, PSM can theoretically account for unmeasured bias (Rosenbaum and Rubin, 1983a; 
1983b), but one cannot be completely sure. The area outside the common region was large 
(Figure 4.3) and this may have restricted estimation of a causal effect and in bias by changing 
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the observed population (King and Zeng, 2005). However, only 12% of quitters were lost due 
to common support restrictions and those excluded did not differ on baseline characteristics 
compared with the remainder of the sample.  
 
The size of the cohort was an issue in this study. In the whole sample there were only 68 
quitters, and the matched sample only had 60 participants per group, thus this study was 
underpowered and was likely too small to detect a dichotomous outcome such as psychiatric 
disorder (McCaffrey and Elliott, 2008). Accordingly, the lack of report of disorder in the quit 
group was an artefact of the small sample. It is possible that the incidence of psychiatric 
disorder is very rare for quitters; however a larger sample would be needed to determine this. 
 
As discussed in the previous chapter (section 4.5.2), due to patient confidentiality certain 
demographic data, such as ethnicity, social class and education were not supplied, and 
therefore participants were not matched on these characteristics. However, a recent systematic 
review did not find consistent evidence to suggest that demographic characteristics were 
associated with cessation (Vangeli et al., 2011). Therefore it is unlikely that exclusion of these 
characteristics influenced the association greatly, although interactions between covariates 
may be possible.  
 
This study adopted stringent criteria for assessment of exposure which limits misclassification 
of smoking status (previously discussed in section 4.3.3.1). The outcome of psychiatric 
disorder was ascertained from trial reports of patients symptoms, and these were coded 
according to the MedRA database (Medical Dictionary for Regulatory Activities, 2013). The 
MedRA database is a standardised tool designed to guide categorisation of trial adverse 
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events. This study used this tool to code pre-existing event descriptions by researchers 
originally involved in the treatment trials; this may have introduced bias, although as those 
researchers were blinded to the hypotheses of this analysis, it is hard to see a mechanism for 
such bias. Furthermore, overall risk of bias in this study was low according to the NOS and 
sensitivity analyses produced similar results. Finally, as no quitters reported a psychiatric 
disorder a regression model could not be fitted to compare adjusted and unadjusted models. 
Importantly though, the largest risk to this association was group membership bias (Dawkins 
et al., 2009; Hughes, 2007c), which can be greatly accounted for by nicotine dependency and 
receipt of treatment (Stead et al., 2012, Vangeli et al., 2011), this study was able to account 
for these factors and other confounding through PSM, and the study’s findings were not 
altered by matching participants on these characteristics.  
 
5.5.2. Interpretation of findings 
 
Although data presented in this study are inconclusive, they are supported by other studies 
which report smokers have an increased risk of mood disorder compared with quitters 
(Khaled et al., 2012). Cautiously, it may be concluded that cessation reduced the incidence of 
disorder, and this is supported by a recent study reporting that after cessation quitters were 
more likely to stop anti-depressant treatment (Shahab et al., 2014). The misattribution 
hypothesis recognises that chronic exposure to nicotine leads to periods of low mood and 
anxiety (previously discussed in sections 1.6.1 and 1.9.1). These psychological symptoms are 
also a hallmark of many mood disorders, thus Parrot (1999; 2003) proposes that after 
sustained cessation, the smokers’ mental health will return to a more desired state and risk of 
disorder will be reduced (previously discussed in section 1.9.1). This model is supported by 
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longitudinal data, neurobiological evidence and experimental neurological functional imaging 
studies (previously discussed in sections 1.6 and 2.5.3). Although this model appears to 
support the findings in this study, one cannot be certain, and a study with a larger sample 
should investigate this in the future. Importantly, it is equally possible that the incidence of 
psychiatric disorder in the continuing smoking group could be a consequence of partaking in a 
reduction study. In the original trials all participants attempted to reduce their smoking, and it 
may be that reducing daily smoking, or failing to do so induces periods of depression or 
anxiety. This is an area for future research.  
 
5.6. Conclusion 
 
The results from this study were inconclusive and the study design should be replicated in a 
larger sample. 
 
5.7. Chapter summary 
 
In Chapters Two and Four the use of means to examine the association between mental health 
and smoking cessation may have concealed evidence of psychiatric disorder, therefore the 
onset of psychiatric disorder after quitting compared with continuing smoking was examined 
using PSM and risk difference methodology. Results showed no one who stopped smoking 
reported onset of psychiatric disorder six months following cessation, whereas several people 
who continued to smoke did so, resulting in an estimate of a higher risk in continuing smokers 
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compared with quitters, although this was not significant. Due to lack of variability in the quit 
group the results in this chapter were inconclusive and should be replicated in a larger study.  
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CHAPTER SIX 
6. DOES WORSE MENTAL HEALTH AFTER SMOKING CESSATION 
PREDICT RELAPSE? 
 
6.1. Introduction to Chapter Six 
 
It is possible that some quitters experience improved mental health after smoking cessation 
and therefore remain abstinent, whereas, other quitters may experience worse mental health 
after cessation, and therefore be more likely to relapse. If this hypothesis is true, it may 
explain the association between smoking cessation and mental health reported in Chapters 
Two and Four. To test this hypothesis, in Chapter Six I present a prospective analysis of the 
McNeil trials to examine the association between change in mental health and risk of relapse.  
 
6.2. Background 
 
Chapters Two and Four report a strong association between stopping smoking and improved 
mental health. Hughes (2007c) suggests that some smokers experience a permanent 
worsening in mental health after cessation, resulting from either chronic exposure to tobacco 
or from abstinence of tobacco’s therapeutic properties, and as a result, are at risk of relapse 
(previously discussed in sections 1.6, 1.9.2 and 1.10.2). This hypothesis, if true, could explain 
the findings in Chapters Two and Four.  
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A literature review was conducted to determine if any previous studies have examined this 
association. A series of terms related to “smoking” “relapse” and “mental health” were used 
to search “MEDLINE”, “PsycINFO” and “PsycARTICLES” “EMBASE”. The search strategy 
produced 1520 articles, the titles and abstracts were examined narrowing these articles down 
to 52 relevant articles. Examination of the full-texts resulted in two systematic reviews of 
predictors of relapse, however neither presented relevant data (Hitsman et al., 2013; Vangeli 
et al., 2011), and three studies which investigated the association between change in mental 
health (after the withdrawal period) and relapse (Gruder et al., 2013; Manning et al., 2005; 
Yong et al., 2010). 
 
Yong et al. (2010) prospectively examined the association between emotional experiences 
after quitting and odds of relapsing versus remaining abstinent over a four year period. After 
cessation, participants were asked to rate questions such as, “Since you quit, has your ability 
to calm down when you feel stressed or upset improved, gotten worse or stayed the same?” 
Results indicated that the perception of worsened emotional control after cessation was 
associated with increased odds of relapse at follow-up, OR (95% CI), 1.6 (1.3 to 2.1); these 
results are supported by other studies in which smokers report the mental health benefits of 
smoking deter them from achieving abstinence (previously discussed in section 1.4). 
However, in Yong et al.’s study (2010) mental health was not assessed using a validated tool, 
and the data were based on participants’ recollections of events, both of these study features 
may introduce bias (Coughlin, 1990; Hassan, 2006; Wood et al., 2007). Ideally, to measure an 
accurate account of mental health during the transition from smoker to quitter, scores would 
be recorded using a validated measure at a time of regular smoking and then compared to a 
time after cessation.   
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Gruder et al. (2013) prospectively examined change in depression scores from baseline, when 
participants were smoking, to two year follow-up, when participants had either relapsed or 
quit. Results indicated that change in depression scores was not associated with odds of 
relapse versus remaining abstinent, OR=0.9 (95% CI 0.7 to 1.4). In a similar study, Manning 
et al. (2005) analysed data from a cessation treatment trial to determine if change in stress 
from baseline (before quitting) to six month follow-up was associated with relapse at six 
month follow-up. Analyses indicated that there was no association between change in stress 
scores and odds of relapse at follow-up, 1.0 (0.9 to 1.1). Both studies reported no association 
between change in mental health outcomes and relapse. However, in these studies final mental 
health score was measured after relapse had occurred, thus the data do not clearly assess 
whether change in mental health contributed to relapse. 
 
Therefore, to assess the association I conducted a prospective analysis using logistic 
regression modelling to determine if change in mental health during the cessation period was 
associated with odds of relapsing versus remaining abstinent at a later follow-up. 
 
6.3. Methods  
 
6.3.1. Study design 
 
A prospective observational study of individual level patient data derived from the McNeil 
trials (trials’ characteristics previously discussed in Chapter Three).  
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6.3.2. Participants and study size 
 
Seven-hundred-and-forty-one participants provided smoking data at both four and 12 month 
follow-ups. At four month follow-up 107 participants were biologically-validated as quit, of 
these, 80 participants provided sufficient data at 12 month follow-up to determine their 
relapse status. 
 
6.3.3. Variables 
 
6.3.3.1. Exposure  
 
Exposure was defined as change in mental health score from when the person was a smoker, 
at baseline, to after they had reported biologically-validated, seven day, point-prevalence 
cessation at four month follow-up. Mental health scores were measured using the “emotional 
wellbeing” subscale from the RAND-36/SF-36 item health survey 1.0. Scores range from 0 to 
100 and scores of ≤38 indicates presence of a mental  health problem. In the general 
population the subscale’s mean and standard deviation are 70.38 (21.97) (Hays et al., 1993; 
1998). Further information about the scale has been previously reported in section 4.3.3.2. 
 
6.3.3.2. Outcome  
 
The outcome was biologically-validated, self-reported point-prevalence (seven-day) smoking 
status at four and 12 months. Relapse was defined as biologically-validated (carbon 
monoxide/parts per million (CO/ppm) <10) point-prevalence abstinence at four months 
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follow-up, and return to smoking at 12 months follow-up. Repeated point-prevalence 
cessation was defined as biologically-validated (CO/ppm <10) self-reported cessation at both 
four and 12 month follow-up. Those whose carbon monoxide did not confirm either smoking 
or quitting at four or 12 month follow-ups were not included in the analysis. Quitters who did 
not provide smoking status data at 12 months were excluded from the analysis. See Figure 6.1 
for visualization of measurement of exposure and outcome. 
 
Baseline 4 Months 12 Months
Bio-verified 
quit 
Smoker Bio-verified 
Relapse vs. quit
Mental health
 
Figure 6.1 Timeframe for measurement of exposure and outcome variables 
 
6.3.3.3. Confounding variables 
 
The following variables were entered into the adjusted logistic regression model: nicotine 
dependency, as measured using the Fagerström Test of Nicotine Dependence (FTND) 
(Fagerström et al., 1990) and NRT treatment status (placebo or active) (Stead et al., 2012), 
sex, age and baseline mental health score (SF-36 ) (Asendorpf, 1992; Barnett et al., 2005; 
Niaura et al., 2001).  
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6.3.4. Statistical methods 
 
Individual level patent data from five trials of NRT for smoking reduction were pooled 
according to methods described previously in Chapter Three. Logistic regression modelling 
was used to assess the association between change in mental health and relapse. Exposure was 
change in mental health from baseline (pre-cessation) to four month follow-up (time point of 
biologically-validated abstinence). The outcome variable was biologically-validated relapse 
(coded as 1) or repeated point-prevalence abstinence (coded as 0). The regression model was 
repeated with and without adjustment for FTND score, NRT treatment status, baseline mental 
health (SF-36), sex and age. 
 
6.3.5. Sensitivity analysis 
 
Ideally change scores would have been calculated for participants who had remained abstinent 
for six weeks minimum to ensure they were no longer experiencing psychological withdrawal 
symptoms from tobacco abstinence (Hughes, 2007b). To address the issue that those who 
reported point-prevalence cessation at four month follow-up may have been recently quit, a 
sensitivity analysis was conducted to include participants who had likely been quit for at least 
six weeks up to the four month follow-up
4
. 
 
The analysis included quitters who reported point-prevalence cessation (biologically-
validated) at both 10 week and four month follow-ups. It is likely these quitters were 
                                                 
4
 NB. This analysis was not used as the main analysis because there were limited data available due to 
differences between trials’ follow-up points. 
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continuously abstinent over this six week period (Hughes et al., 2003; 2010); the logistic 
regression model described in section 6.3.5 was repeated using this group of quitters. 
 
6.3.6. Missing data 
 
Participants with any missing data were excluded from the analysis. The number of 
participants excluded for missing outcome data and their characteristics are presented in the 
results. 
 
6.3.7. Risk of bias 
 
An adapted version of the Newcastle-Ottawa Scale was used to assess risk of bias in 
observational studies (Appendix 4). The measure rates studies on a scale of 1 to 5: 1 indicates 
a high risk of bias and 5 indicates a low risk of bias. 
 
6.3.8. Ethics and data protection 
 
See Chapter Three for further information pertaining to ethics and data protection. 
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6.4. Results 
 
6.4.1. Participants 
 
One-hundred-and-seven participants were biologically-validated as quit at four months, of 
these 80 reported smoking status at 12 months. Twenty-seven did not provide smoking data at 
12 months and were excluded from the analysis; these participants were on average 
psychologically healthy, according to the SF-36 (Hays et al., 1998), with a mean (M) and 
standard deviation (SD) of 71.7 (21.2). Of the 80 participants reporting outcome data at four 
and 12 months, two quitters were excluded for missing mental health data. The baseline score 
for the quitter missing data at follow-up was 56, and the follow-up score of the quitter missing 
data at baseline was 82, neither scores indicate poor mental health (Hays et al., 1993). After 
excluding for missing data, the analysis included 17 quitters classified as relapsed at 12 month 
follow-up, and 61 as quit at 12 month follow-up  
 
6.4.2. Characteristics of quitters and relapsers 
 
Baseline characteristics of quitters and relapsers are presented in Table 6.1. T-tests indicated 
that groups were not significantly different in age, sex, nicotine dependency (FTND), baseline 
mental health (SF-36) or receipt of active NRT.  
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Table 6.1 Baseline characteristics of relapsers and quitters  
Characteristic 
Quitter 
(N=61) 
Relapser 
(N=17) 
Test of 
significance 
P-
value 
Age, M (SD) 46.9 (9.6) 45.3 (11.9) T = 0.55 0.58 
Sex, % male (N) 49% (30) 71% (12) Chi
2
= 2.45 0.12 
FTND, M (SD) 5.5 (2.4) 5.6 (1.5) T = - 0.25 0.803 
SF-36 Mental health, 
M (SD) 
74.5 (14.7) 69.6 (18.0) T = 1.18 0.24 
Treatment status, % 
received active (N) 
72% (44) 71% (12) Chi
2
=0.02 0.901 
 
 
6.4.3. Unadjusted logistic regression analysis  
 
Twenty-one percent (n=17) of those who reported cessation at four months, reported relapse 
at 12 month follow-up. The mean change and SD in mental health scores from baseline to 
four month follow-up for repeated point-prevalence quitters was 2.22 (14.77), and the mean 
change in mental health scores for quitters who had reported relapse at 12 month follow-up 
was 3.05 (17.64). 
 
The unadjusted model indicated that change in mental health was not associated with odds of 
relapsing, compared with staying quit, odds ratio and 95% confidence intervals (OR; 95% CI) 
were 1.00 (0.97 to 1.04), P=0.84. After adjustment for baseline mental health, FTND scores, 
NRT status, age and sex, the association remained non-significant, 0.99 (0.95 to 1.03), P=0.58 
(Table 6.2).  
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Table 6.2 Adjusted logistic regression model  
Variable OR (95% CI) (relapse=1) P-value 
Change in mental health (baseline to follow-up) 0.99 (0.95 to 1.03) 0.58 
Baseline mental health 0.97 (0.93 to 1.01) 0.19 
Treatment status (1=active) 1.00 (0.28 to 3.61) 0.99 
FTND  1.02 (0.79 to 1.32) 0.86 
Sex (female) 0.39 (0.12 to 1.28) 0.12 
Age 0.99 (0.93 to 1.05) 0.65 
 
 
6.4.4. Sensitivity analysis 
 
A sensitivity analysis was conducted to determine if change in mental health was influenced 
by possible withdrawal symptoms. This analysis examined if change in mental health scores 
from baseline to after repeated point-prevalence cessation at both 10 weeks and four months, 
was associated with relapse at 12 month follow-up. In this sensitivity analysis there were five 
relapsers, whose mean change (SD) in mental health scores was 0.00 (23.83) and 45 repeated 
quitters whose mean change in mental health scores was 2.67 (16.05). There was no 
association between change in mental health from baseline to four month follow, and relapse 
at 12 month follow-up, OR=0.99 (95% CI: 0.94 to 1.05), P=0.73. Adjustment for covariates 
did not change the association 0.99 (0.93 to 1.07), P=0.85 (see Appendix 22 for full adjusted 
and unadjusted models).   
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6.5. Discussion 
 
Change in mental health during the transition from smoker to quitter was not associated with 
future relapse, and this association was not altered by adjustment for covariates or during 
sensitivity analyses.  
 
6.5.1. Limitations, strengths and potential sources of bias 
 
The cohort’s size was small and is therefore an issue. However, the purpose of the analysis 
presented in this chapter was to examine the possibility that worsened mental health may lead 
to relapse and mental health was measured using the SF-36 which was purposefully designed 
to detect changes in mental health and is psychometrically sound (Hays et al., 1998). Using 
this validated tool there was no evidence of worsened mental health for quitters or relapsers. 
 
Pre-cessation scores were measured at baseline while everyone was a smoker and had no 
immediate plans to quit, only to reduce. Post-cessation mental health scores were obtained at 
four month follow-up, after biologically-validated, point-prevalence cessation, thus it is 
possible that some quitters were recently abstinent and were therefore experiencing 
psychological withdrawal symptoms (Hughes, 2007b). However, use of repeated point-
prevalence criteria to ascertain abstinence is likely to produce results similar to continuous 
abstinence (Hughes et al., 2003; 2010), therefore a sensitivity analysis was conducted and 
included only those who reported repeated point-prevalence abstinence at both 10 week and 
four month follow-up. Results from the sensitivity analysis were similar to the main analysis. 
As the sensitivity analysis replicated the non-significant association, it is likely that those who 
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were identified as quit using seven day, point-prevalence criteria at four month follow-up 
were quit for much longer than one week. 
 
Biologically-validated, point-prevalence smoking status at both four and 12 months was used 
to ascertain outcome (relapse or quit). It is possible that those who were biologically-validated 
as quit at both time-points may have relapsed in between the four and 12 months follow-ups. 
However, it would be uncommon to find a smoker who was quit at both time points but 
smoked in between (Hughes et al., 2003; 2010). Therefore in this study outcome 
misclassification was a potential issue, but it is unlikely. 
 
6.5.2. Interpretation  
 
Hughes (2007c) suggests that some smokers experience a permanent worsening in mental 
health after cessation, resulting from either chronic exposure to tobacco or from abstinence of 
tobacco’s therapeutic properties, and as a result are at risk of relapse (previously discussed in 
sections 1.6, 1.9.2 and 1.10.2). This hypothesis is supported by Yong et al.’s (2010) study 
which found relapsers’ perception of reduced ability to cope with low mood and stress after 
cessation was associated with increased odds of relapse, and is further supported by smokers’ 
reports that smoking’s mental health benefits deter cessation (previously discussed in 1.4). 
However, data from observational studies that psychometrically measured mental health have 
failed to replicate these findings (Gruder et al., 2013; Manning et al., 2005). Direction of 
causation was questionable in these studies because the follow-up measures of mental health 
and cessation/relapse were measured simultaneously (e.g. did relapse cause worse mental 
health?), however reverse causation was less questionable in this study, and likewise, it found 
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no significant association with relapse. Thus, to summarise, studies which rely on 
participants’ perceptions of mental health after cessation report a significant association 
between worsened mental health after cessation and relapse; whereas studies which 
scientifically measure mental health change show no evidence of such an association. 
 
Understanding the cognitive processing involved in memory recall may be key to interpreting 
this association, or lack thereof. The disparity between peoples’ reports about symptoms 
based on memory versus symptoms which have been scientifically measured is a commonly 
observed phenomenon (Coughlin, 1990; Hassan, 2006; Henkel and Mather, 2007). When 
participants report on past symptoms they depend on their memory, and research has 
consistently found that beliefs about the condition in question and other socially-derived 
information present during recall, can alter the way in which memories about symptoms are 
reconstructed (Koriat et al., 2000; Robinson and Clore, 2002a; 2002b). Moreover, memory 
becomes less accurate and increasingly biased by personal and social belief systems overtime 
(Henkel and Mather, 2007). These notions have been confirmed in a study which compared 
participants’ real-time reports of mood and smoking lapses (recorded via a portable diary), 
with their memory of the event recorded 12 weeks later (Shiffman et al., 1997). Results 
indicated that at follow-up participants over-estimated the causal role of negative affect as a 
reason for lapse. Thus, if memory recall theories are correct, it may not be change in mental 
health which leads the person to relapse; rather it is the belief that smoking will cure 
unwanted emotion which biases recollection about reason for relapse. 
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6.5.1. Implications for cessation treatment 
 
There are many multi-component interventions designed to promote smoking cessation in the 
UK and it is NHS standard to include an element of relapse prevention (McEwen, 2014). 
Usually, patients are helped to identify smoking cues and discuss strategies to cope during 
times of temptation. When applicable, patients are also provided with advice on methods to 
cope during times of stress or unwanted emotion. Interventions should target belief systems 
and their influences on decision to relapse during times of stress, and participants should be 
encouraged to identify previous experiences when their memory about emotions may have 
been influenced by their own beliefs or the beliefs of others.  
 
6.6. Conclusion 
 
This prospective study reported that change in mental health was not associated with odds of 
relapse compared with remaining abstinent. Sample size was an issue in this, however the 
findings are consistent with similar studies which have assessed the association using 
validated measures; and oppose data reported from studies which rely on relapsers’ memories 
of reasons for relapse. These findings do not support the notion that cessation-induced 
worsened mental health leads to relapse.  
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6.7. Chapter summary 
 
It is possible that some smokers experience worse mental health after smoking cessation, 
compared with when they smoked, therefore they may be more likely to relapse back to 
smoking; this notion is supported by studies examining relapsers’ reports of poor mental 
health after cessation. To investigate this possibility I conducted a prospective analysis using 
logistic regression modelling to determine if change in mental health scores from pre-
cessation to post-cessation was associated with odds of relapsing, versus maintaining 
cessation at follow-up. Results displayed no association between change in mental health and 
this finding was not altered by adjustment for confounding or through sensitivity analyses, 
however the sample was small in this study which may give rise to imprecision. One 
interpretation of the null association is that beliefs about the benefits of smoking bias belief 
systems during recall of relapse. 
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CHAPTER SEVEN 
 
7. IMPLICATIONS, RECOMMENDATIONS FOR FUTURE RESEARCH 
AND CONCLUSIONS OF THE THESIS 
 
7.1. Introduction to Chapter Seven 
 
In Chapter Seven I discuss the findings of the thesis, and contextualise the findings in relation 
to current knowledge and according to Bradford Hill’s criteria for inferring causal 
associations. Secondly, clinical and public health implications of the thesis are discussed and 
suggestions for future research are made. I conclude the chapter summarising the overall 
contribution of the thesis. 
 
7.2. Interpretation of findings 
 
Due to the impracticalities of randomizing smokers to stop or to continue smoking, all that is 
known about the physical health hazards of smoking and the benefits of quitting are from 
observational data, and these data are considered legitimate. I argue the same attitude should 
be applied to the use of epidemiological data when considering the mental health harms and 
benefits of smoking and quitting. This thesis provides evidence that smoking cessation is 
associated with mental health benefits. The research was observational and is weakened by 
188 
 
the possibility of confounding and other biases. However, methods were adopted to reduce 
these risks and in turn strengthened the findings.  
 
The thesis aimed to clarify areas of uncertainty arising from the current literature and the 
chapters in this thesis are novel contributions to the field. No previous systematic review has 
been able to provide a summary estimate for the impact of cessation on mental health (section 
1.10.2), thus Chapter Two presents the first study to combine effect estimates from 
longitudinal studies comparing change in mental health over time between quitters and 
smokers. The study showed that cessation was associated with improvements in mental health 
of a comparable size to anti-depressant treatment, and this study was published in a peer-
reviewed journal (Taylor et al., 2014). Another major issue in the current literature is the 
possibility of bias and unknown confounding, therefore in Chapter Four propensity score 
matching (PSM) and regression modelling was used to reduce group membership bias and 
confounding. This technique provided further evidence that smoking cessation was associated 
with improved mental health; and PSM methodology strengthened a causal interpretation. The 
analysis of means presented in Chapters Two and Four may have concealed incidences of 
psychiatric disorder, and previous research examining onset of psychiatric disorder in quitters 
may have also been biased by group membership (section 5.2). Therefore in Chapter Five use 
of PSM and risk difference estimates examined the risk of psychiatric disorder after stopping 
smoking compared with continuing smoking. The study found that six months after quitting 
ex-smokers did not display evidence of psychiatric disorder whereas some continuing 
smokers did, this finding was replicated after matching participants on their propensity to 
quit; however all estimates were inconclusive. Finally, the findings in Chapters Two, Four 
and Five could be explained by the possibility that some people who quit experience worse 
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mental health and therefore relapse back to smoking, while quitters who experience mental 
health benefits continue to be abstinent. Interpretations of previous studies which have 
examined this hypothesis have been restricted by possible reverse causation or reliance on 
patients’ memory about reasons for relapse (section 6.2). Therefore, in another novel study, 
Chapter Six tested this hypothesis and presented no evidence that worsened mental health 
after cessation was associated with future relapse.  
 
The thesis contributes evidence on the validity of three opposing hypotheses which could 
explain the association between smoking cessation and mental health. None of the findings in 
this thesis supported the self-medication hypothesis; other studies however have produced 
evidence for this (Section 1.9.2). Many longitudinal cohorts report that smoking during 
adolescence and early adulthood is associated with uptake of smoking later on in life, and 
researchers have argued this occurs because smoking offers mental health benefits. In support 
of this notion, there are some studies which have shown nicotine offers moderate benefits for 
depression symptoms and for cognitive performance, although the duration of these effects is 
unknown. However nicotine is not an isolated constitute of tobacco, there are other chemicals 
which act independently from and interactively with nicotine, and these interactions are not 
entirely understood (Borgerding and Klus, 2005; Rose, 2006; 2010; Thielen et al., 2008; 
United States Environmental Protection Agency, 1992). The few studies showing any benefit 
from nicotine are contradicted by other studies showing smoking tobacco has no effect on 
emotional outcomes in non-smokers. Furthermore, the suggestion that tobacco’s chemical 
properties are therapeutic does not stand strong compared with evidence derived from studies 
showing tobacco leads to unfavourable neuroadaptations in mood regions of the brain (section 
1.6). If smoking was therapeutic, surely daily use would alleviate mental disorder, or 
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symptoms of stress, however the evidence shows tobacco use and poor mental health 
commonly occur, and studies of people with mood disorders who take up smoking show no 
evidence of improved mental health later on in life (Boden et al., 2010; Fergusson et al., 2003; 
Jamal et al., 2012; McGee et al., 2000). 
 
Many studies have found an association between a third factor such as genes, environment or 
personality traits and the co-occurrence of smoking and mental health problems (section 
1.9.3). It is possible that a common factor could cause both improved mental health and 
smoking cessation. However, there is no evidence that positive life events or changing 
environment, for example, are associated with sustained cessation. The possibility of a single 
event leading to both cessation and improved mental health seems less plausible, particularly 
considering the evidence presented in Chapter Two, where improved mental health was seen 
nine years after cessation.  
 
The thesis mostly supports the misattribution hypothesis (whereby smokers’ perceptions of 
smoking having positive mental health effects is misattributed to the effects of smoking on 
relieving withdrawal) which suggests that smoking cessation leads to improved mental health. 
The hypothesis is bolstered by the vast majority of other longitudinal studies which have 
examined the association between smoking cessation and mental health (reported in Chapter 
Two, and section 1.10.1), and is further supported by a plausible biological pathway 
(discussed in section 1.6). The systematic review in this thesis found that all included studies 
consistently favoured the quit group who displayed improved mental health.  Importantly, one 
must note that in some of the studies the difference in change was not significantly different 
between groups, however once the estimates were pooled the association became significant. 
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Other longitudinal studies reporting the risk of mental health disorder after cessation 
predominately follow a similar pattern and report that cessation is associated with a reduced 
risk of disorder, or no association (previously discussed in section 1.10), therefore it is 
possible that if these studies were meta-analysed the reduced risk may reach significance, in 
favour of the quit group (these studies were not meta-analysed in Chapter 2 because they 
reported dichotomous outcomes rather than mean differences).  
 
There are only two studies which have calculated an increased risk of mental disorder after 
cessation (Glassman, et al., 2001; Tsoh et al., 2000) and it is these studies which have lead to 
mixed conclusions in two out of the four existing systematic reviews in the field (Hughes 
2007c; Ragg et al., 2013). In the first study reported by Glassman et al. (2000) there was a 
seven-fold increase in depression amongst quitters, however the study had significant 
differential loss to follow-up, in which outcome data were not available for 39% of smokers, 
compared with 5% of quitters. This was a likely source of bias (Touloumi et al., 2001) thus 
limiting the study’s findings, and moreover, this study had received previous criticism from 
experts in the field for producing misleading findings (Prochaska et al., 2008). The second of 
these studies conducted by Tsoh and colleagues (2000) reported that 14.7% of quitters had 
major depression after cessation treatment, and that this was significantly increased compared 
with continuing smokers (13.7%). However, after adjustment for depression history and other 
covariates, abstinence status was no longer a significant predictor of depression. Thus, the 
studies by Glassman et al. (2001) and Tsoh et al. (2000) provide weak evidence but have 
contributed to significant ambiguity in the field. In Hughes’ (2007c) review rates of 
depression were reported to be between 1% and 31% for quitters, and 0% to 14% for 
continuing smokers. If the Glassman et al. (2001) and Tsoh et al. (2000) studies were 
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removed, the rates for depression for quitters would have been between 1% and 15%, which 
was very similar to the smoking group; furthermore in Hughes’ review the other included 
studies were of case reports and descriptive data, and only one study statistically tested their 
findings. Ragg et al. (2013) also reported mixed evidence for depression, and this was also 
due to inclusion of the Glassman study, the other studies reported improved mental health or 
reduced risk for depressed quitters. Thus, these two studies (Glassman et al. (2001) and Tsoh 
et al. (2000)) have produced unusual results, compared with the plethora of positive data 
showing cessation is associated with improved mental health or decreased risk of mood 
disorder (Khaled et al. 2012; Ragg et al. 2013; Sanchez-Villegas et al. 2008; Taylor et al. 
2014). 
 
Bradford Hill (1965) proposed a set of guidelines to use for concluding causation from 
epidemiological evidence and these have been recently updated by Howick et al. (2009). I 
have summarised evidence investigating smoking cessation and mental health outcomes 
according to these guidelines. Summary of this evidence shows there is strong argument that 
cessation leads to improved mental health (Table 7.1). 
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Table 7.1 The association between smoking cessation and mental health according to Bradford Hill’s guidelines (as revised by 
Howick et al. (2009))
5
 
Type of 
evidence 
Guidelines Evidence Summary 
Direct Size of effect not 
attributable to confounding 
1) In Chapter 2, section 2.3.9.1 adjusted and unadjusted estimates were not significantly different;  
2) Chapter 4 shows the size of the effect was not greatly altered by adjustment for confounding or 
through PSM techniques;  
3) Reduced risk of mental health symptoms after cessation not attributable to confounding in 
strongest studies (Bolam et al., 2011; Khaled et al., 2012; Sanchez-Villegas et al., 2008; Shahab et al., 
2014). Two studies found risk of depression after cessation, however one was confounded by 
depression history (Tsoh et al., 2000), and the other was of weak evidence (Glassman et al., 2001).  
Guideline 
mostly satisfied 
Appropriate temporal 
proximity (cause precedes 
effect and effect occurs 
after a plausible interval) 
Improved mental health occurs after breaking the tobacco withdrawal cycle, data from FMRI studies, 
self-report and a systematic review (Chapter 2) indicates this occurs at around six weeks of sustained 
cessation (Hughes, 2007b; Mamede et al., 2007).  
Guideline 
satisfied 
Dose-responsiveness and 
reversibility 
1) Dose-response evidence that higher tobacco consumption is associated with worse mental health 
(Boden et al., 2010; Jamal et al., 2012).  
Guideline 
mostly satisfied 
                                                 
5
 Copied with permission granted from Jeremy Howick on August 5th, 2014 
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2) Cessation associated with improved mental health (Chapter 2);  
3) Unsure if reduced tobacco consumption is associated with improved mental health. 
Mechanistic Evidence for a mechanism 
of action (biological, 
chemical) 
Chronic smoking is associated with neuroadaptations in mood regions, some of these 
neuroadaptations have been found to reverse after cessation (previously discussed in section 1.6). 
However, unsure if tobacco use leads to damage in some pathways. Some evidence that nicotine may 
offer some benefits, however the evidence is weak and the duration of effect is unknown (section 
1.9.2.1). 
Guideline 
mostly satisfied 
Coherence (does the 
hypothesis cohere to what 
is currently known?) 
No adequate study has found cessation to be associated with worsened mental health. No evidence 
that a common cause leads to cessation and improved mental health. 
Guideline 
satisfied 
Parallel Replicability (results are 
similar across the same 
study designs, using the 
same outcome) 
Chapters Two and Four, Khaled et al. (2012); Ragg et al. (2013); Sanchez-Villegas et al. (2008). Guideline 
satisfied 
Similarity (evidence is 
consistent across similar 
study designs, using 
similar outcomes) 
Chapters Two and Four; Khaled et al. (2012); Ragg et al. (2013); and Sanchez-Villegas et al. (2008). Guideline 
satisfied 
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7.3. Implications 
 
7.3.1. Cessation is associated with clinically important improvements in mental 
health 
 
The belief that smoking is therapeutic and that cessation may cause psychological harm is 
widespread and upheld by both smokers and health professionals. Many health professionals 
are deterred from treating patients’ smoking during times of stress and in patients with mental 
health problems, and moreover smokers with and without mental health problems state that 
smoking to cope with stress and low mood is a reason to continue. It is possible that these 
beliefs have also contributed to health inequalities, such that the smoking population is over-
represented by people with mental health disorders (previously discussed in section 1.8).  
 
The thesis shows no evidence that tobacco use offers mental health benefits, but instead 
supports the hypothesis that smoking worsens mental health as evidenced by my findings that 
smoking cessation was associated with mental health benefits. The data are primarily from the 
general population, although included a few studies from psychiatric populations. It can be 
used in combination with other evidence (Banham and Gilbody 2010; Ragg, Gordon, Ahmed, 
and Allan 2013) when treating patients with and without mental health disorders.In primary 
care, general practitioners, nurses and smoking cessation specialists can apply these data 
when treating patients. Specifically, smokers may report they are too stressed, depressed or 
anxious to quit, however these data suggest that on average sustained cessation likely leads to 
improved mental health. In secondary care, recent NICE guidelines have recommended 
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implementation of smoke-free policies in mental health hospitals. This thesis, in combination 
with other major works, provides evidence that cessation is not associated with psychological 
harm in psychiatric populations. Therefore clinicians in these settings can be reassured that 
cessation is very unlikely to cause psychological harm. Public health campaigns and 
interventions in these health care settings should be updated to include data about the mental 
health benefits of cessation. 
 
7.3.2. Cessation interventions should target the misconception that smoking has 
mental health benefits. 
 
The misattribution hypothesis states that smokers attribute the ability of smoking to relieve 
withdrawal symptoms as an ability of smoking to relieve stress and other negative emotion. 
Consequently, many smokers suggest that they return to smoking because they could not cope 
without cigarettes. However as the findings in Chapter Six and from similar studies suggest 
(Gruder et al., 2013; Manning et al., 2005), worsened mental health does not predict relapse. 
It is possible that the belief that smoking can alleviate distress may mediate smokers reports 
(Yong et al., 2010). 
 
PRIME theory of addiction suggests that smoking behaviour is driven by motivation, defined 
as “decisions to do or not do things based on an analysis of their costs and benefits” (Baron, 
2000; West and Brown, 2013). The theory recognises that relapsing often occurs during 
exposure to cues that stimulate behavioural or psychological pathways which would have 
previously led to smoking (West and Brown, 2013). A person’s ability to refrain from 
smoking is mediated by their impulse control, their wants/needs at the time, and the person’s 
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evaluation (belief) about the benefits or costs of smoking in that situation at that time. Thus, 
during a time of stress or negative emotion, the need/want to alleviate emotional distress is 
high. If the smoker is someone who strongly believes that smoking can alleviate emotional 
distress, the benefit of smoking outweighs the costs of relapsing at that time, this will then 
heighten the person’s impulse to smoke, therefore increasing risk of relapse.  
 
There are many multi-component interventions designed to promote smoking cessation in the 
UK and NHS smoking cessation services usually provide an element of relapse prevention in 
their care plans (McEwen, 2014). Common behaviour change techniques based upon PRIME 
theory are used in interventions to enhance motivation during cessation attempts. Usually, 
patients are educated about the physical health benefits of cessation, helped to identify 
smoking cues and to discuss coping strategies to use during times of temptation. When 
applicable, patients are also provided with advice on methods to cope without cigarettes 
during times of stress or negative emotion. According to PRIME theory targeting these 
aspects of motivation will strengthen the belief system to support cessation, albeit directly or 
indirectly.  
 
Many patients are currently informed of alternative emotional coping strategies. However, by 
suggesting that these are ‘alternative’ or ‘substitute’ methods infers that smoking was an 
adaptive or effective coping strategy, especially if this information is conveyed by a health 
professional. Health professionals should be cautious of using such language. Alternatively, 
patients should be informed that there are consistent data showing that smoking relieves 
withdrawal and that smoking cannot remove stressful circumstances or unwanted emotion. 
Patients should also be informed that there is very limited evidence to suggest that smoking is 
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therapeutic; rather there is evidence to show that adaptive coping techniques (relaxation, 
breathing, exercise, social support) are effective at relieving stress and negative affect. The 
contrast of evidence between maladaptive (smoking) versus adaptive coping strategies will 
challenge the patient’s belief that smoking was an effective coping strategy.  
 
7.3.3. Public health campaigns 
 
Public health campaigns designed to educate smokers about the physical benefits of cessation 
are based upon findings observational data. These campaigns should now be updated with 
observational data from this thesis and other studies, showing that cessation is associated with 
mental health benefits.  
 
7.4. Future research 
 
7.4.1. Methodological recommendations 
 
Future studies investigating the association between stopping smoking and mental health 
should use statistical techniques which can strengthen causal inferences from observational 
research. As propensity score matching is a useful tool for comparing quitters with continuing 
smokers (previously discussed in section 4.2), future research should use this technique and 
also examine interactions between variables when calculating propensity scores. In addition, 
Mendelian randomisation can be used as an instrumental variable approach by using genes or 
other factors which have a common association with change in mental health and smoking 
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status. Use of such techniques can strengthen causal inference by minimising bias from 
confounding and removing possibility of reverse causation. 
 
7.4.2. A new model of smoking and mental health 
 
Previous studies have suggested that other factors such as shared vulnerabilities and self 
medication effects contribute towards the association between smoking, cessation and mental 
health. Although the findings in the thesis largely supported the misattribution model, these 
findings cannot completely discount the validity of other explanatory hypotheses. Other fields 
have developed models which encompass numerous contributing factors to the development 
of disease. It is possible that misconceptions about smoking’s mental health benefits are 
restraining the development of comprehensive models in this field. Future research should 
aim to develop a multi-component model which includes genetic, environmental, 
psychological, social and neurobiological factors to explain the association between smoking, 
cessation and mental health. 
 
7.4.3. Repeat methods from Chapter Five using a larger sample 
 
The results from Chapter Five, although inconclusive, found that approximately 2% more 
smokers reported mood disorders than quitters. It is possible that smoking is a risk factor in 
the development of psychiatric disorder, and that by removing this factor (by quitting) one 
reduces their risk of disorder. This notion is supported by other epidemiological studies 
(Khaled et al., 2012, Sanchez-Villegas et al., 2008) and neurobiological evidence (section 
1.6).  
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Tobacco is commonly referred to as a psychoactive substance, (Benowitz, 2010) however, 
tobacco is not under the same regulations as other psychoactive drugs. Most drugs with 
psychoactive effects are under the regulation of the Medicines and Healthcare Products 
Regulatory Agency (MHRA), which considers a drug to have a common side effect if 
between one in 10 and one in one-hundred people experience the same symptom. PSM can be 
used to infer causal estimates (Rosenbaum and Rubin, 1983a) and therefore results from PSM 
could be used to determine if psychiatric disorder is a side-effect of continuing tobacco use. In 
Chapter Five about two in every 100 (1.72%) continuing smokers reported evidence of a 
mood disorder and although this was not significant, this result meets MHRA’s definition of a 
common side-effect. Medicines with similar estimates of psychiatric risk have at a minimum a 
warning label of this information or are removed from the market. Tobacco packaging in 
western countries include warnings about the physical health risks associated with smoking, 
which are founded upon observational data, not randomised data. If a larger study, using PSM 
methodology displayed that risk of mood disorder was an ‘effect’ of continued tobacco use, 
its findings would be supported by other observational data and would have significant 
implications for policy makers concerning the packaging of tobacco. This is a strong reason 
for future research to repeat this study using a larger sample. 
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7.5. Overall conclusion 
 
Smoking damages every aspect of physical health. This thesis is part of a growing body of 
evidence suggesting that tobacco is not a useful therapeutic substance. I believe the findings 
of this thesis, in light of the other evidence reviewed should be used to inform smokers that on 
average, smoking cessation is associated with mental health benefits.  
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2. EXAMPLE SEARCH STRATEGY (CHAPTER TWO) 
 
Appendix 2 has been previously published: 
 
Taylor, G., McNeill, A. and Girling, A. et al. (2014). Change in mental health after 
smoking cessation: systematic review and meta-analysis. BMJ, 348 (g1151). 
 
Example search strategy from Medline, inception (1955) to April 13th, 
2012 (via OVID) 
1. SR.mp. 
2. reduc$ smoking.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests and measures] 
3. exp "tobacco use cessation"/ or exp smoking cessation/ 
4. modified tobacco consumption.mp. 
5. modification of cig$.mp. 
6. modification of smoking.mp. 
7. cigarette reduction.mp. 
8. reduced cig$.mp. 
9. reduction in cig$.mp. 
10. Harm Reduction/ 
11. harm reduction.mp. 
12. reduced tobacco consumption.mp. 
13. tobacco consumption.mp. 
14. cold turkey.mp. 
15. abrupt.mp. 
16. smoking cessation.mp. 
17. quit$ smoking.mp. 
18. stop$ smoking.mp. 
19. give$ smoking.mp. 
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20. cease smoking.mp. 
21. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 
18 or 19 or 20 
22. mental health.mp. or *Mental Health/ 
23. *Stress, Psychological/ or psychological health.mp. 
24. psycholog$.mp. 
25. psychological well?being.mp. 
26. *Anxiety/ or Anxiety Disorders/ or anxiety.mp. 
27. anxious.mp. 
28. *Depression/ or depression.mp. 
29. depressive.mp. 
30. exp Emotions/ or psychological process$.mp. 
31. mental hygiene.mp. 
32. quality of life.mp. 
33. mental well?being.mp. 
34. well?being.mp. 
35. *"Quality of Life"/ 
36. affect.mp. or *Affect/ 
37. emotion.mp. or *Emotions/ 
38. psychological resilience.mp. or *Resilience, Psychological/ 
39. emotional problem?.mp. 
40. Affective Symptoms/ or psychological disturbance?.mp. 
41. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 
37 or 38 or 39 or 40 
42. 21 and 41 
43. limit 42 to yr="1955 -Current" 
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3. FORMULAE USED IN META-ANALYSIS (CHAPTER TWO) 
Appendix 3 has been previously published: 
 
Taylor, G., McNeill, A. and Girling, A. et al. (2014). Change in mental health after 
smoking cessation: systematic review and meta-analysis. BMJ, 348 (g1151). 
 
The formulae and guidance provided within Chapter Seven of the Cochrane handbook for 
systematic reviews of interventions was followed (Higgins and Green, 2011) with additional 
advice from statisticians.  
 
Calculating change and its variance using a standard formula: The standard error of the mean 
change over time was not reported for some studies, though it is needed for inverse-variance 
weighting. Where necessary it was estimated by adjusting the expression for the standard 
error of the difference between two independent samples to take account of within-subject 
correlation (Follmann, Elliott, Suh, and Cutler 1992). Thus the SE of the mean change: 
 
2
2
2
1
2
11
n
s
n
s
r 
 
 
Where s1, s2 are the standard deviations at the two time points and n1, n2 are the 
corresponding sample sizes – notionally equal but which may differ because of data 
incompleteness or patient drop-out. A generic value of r = 0.312 was assumed from a 
secondary analysis of individual-level patient data from a randomised controlled trial of 
multi-component treatment for smoking cessation (Marteau et al., 2012). These data were 
used to conduct a Pearson correlation using SPSS17.  The variables input into the Pearson 
correlation were: Smokers’ and non-smokers’ anxiety scores (State-Trait Anxiety Inventory 
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(STAI) (Marteau and Bekker, 1992) at baseline, and at six month follow-up (N=491). The 
baseline and follow-up scores showed a significant positive correlation (  =0.312, P<0.001).  
This correlation co-efficient was then entered into the above formulae.  
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4. ADAPTED VERSION OF THE NOS (CHAPTER TWO) 
Appendix 4 has been previously published: 
 
Taylor, G., McNeill, A. and Girling, A. et al. (2014). Change in mental health after 
smoking cessation: systematic review and meta-analysis. BMJ, 348 (g1151). 
 
Justification for adaptations to the Newcastle-Ottawa scale 
 
The association between smoking cessation (exposure) and mental health (outcome) in this 
review affects the validity of NOS quality scores.  Therefore, the current review uses an 
adapted version of the NOS. The adapted version’s maximum rating is five stars. The 
following adaptations have been made (see Table A for adapted version).  
 
Adaptation one — ascertainment of exposure: The NOS aims to assess the validity of 
exposure ascertainment.  It cites use of secure records, structured interview and written self-
report as methods to establish the cohorts’ exposure status. The current review’s exposure is 
smoking status. Smoking status is principally established via self-report or biological 
verification; rather than by secure records or structured interviews. Thus, this section was 
adapted to include only these methods of ascertainment of exposure status. In smoking-
cessation research some participants claim to be non-smokers when they are still smoking, 
this can overestimate the number of people quit in a study (Gorber et al., 2009). The most 
accurate way to ascertain smoking status is via biological verification (West et al., 2005). 
Valid methods of biological verification were considered as: expired air carbon monoxide 
(CO) or level of continine concentration (saliva, urine or plasma). If a study reported 
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biologically-validated smoking status it was awarded one star and no stars if only self-report 
was used or if there was no description of how the exposure was ascertained. 
 
Adaptation two — demonstration that outcome of interest was not present at start of study: 
The NOS awards a star if the outcome of interest was not present at the start of the study.  
However, this is based upon the diagnosis of the presence or absence of a disease.  The 
current review is not assessing a dichotomous outcome. Our outcome was the change in 
mental health as measured by continuous scales. Thus, it is not possible for a study to 
demonstrate that change in mental health was present at the start of the study. Accordingly, 
this item was not included in the adapted version of the NOS. 
 
Adaptation three — comparability of cohorts on the basis of the design or analysis: The NOS 
awards a star if the study controls for the “most important factor” which is likely to influence 
the main outcome, and one star if the study controls for an additional factor which is likely to 
influence the main outcome.  However, not all studies included in the current analysis 
investigated change in mental health as their primary outcome, thus not all studies controlled 
for covariates which influence mental health. Accordingly, this item was not included in the 
adapted version of the NOS.  
 
Adaptation four — assessment of outcome: The NOS awards a star if the study’s outcome has 
been assessed via an independent blind assessment or record linkage, and awards no star if the 
outcome has been assessed via self-report or no description.  The outcome for the current 
review could only be assessed via a self-report questionnaire or a structured-interview. Firstly, 
for assessment of mental health to be clinically useful, psychometric assessments need to be 
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standardised (Hunsley et al., 2003).  Secondly, psychological questionnaires cannot be blindly 
assessed, as the participant completes the answers. Thus independent-blind assessment in the 
self-report category was not considered.  Structured interviews can be assessed by someone 
who is blinded to study hypotheses, thus this has been considered for outcomes assessed via 
interview.  Accordingly, one star was awarded for use of a standardised self-report 
questionnaire, or standardised interview schedule with blind assessor, and zero stars were 
awarded for use non-standardised self-report questionnaires, non-standardised interview 
schedules and standardised interview schedules with an un-blinded assessor. In the case that a 
study used a standardised self-report questionnaire and a standardised interview schedule, 
only one star was awarded; as use of both types of outcome assessment does not improve the 
study’s quality for the purpose of this review. 
 
Adaptation five— length of follow-up: The NOS awards a star if the study’s follow-up was 
long-enough for the outcome to occur.  However, I included studies that assessed mental 
health is assessed after the end of the withdrawal period (six weeks). Thus our inclusion 
criterion ensures that the follow-up is long enough for outcomes to occur.  Accordingly, this 
item was not included in the adapted version of the NOS. 
 
Adaptation six — determining an attrition threshold: The NOS awards a star if a study reports 
that all subjects were accounted for at follow-up.  The NOS also awards a star if “a small 
number” of subjects are lost to follow-up, or if the study provides a description of those who 
were lost.  The scale allows the researcher to select their own adequate rate (%) of attrition.  
There are no empirical studies which determine an agreed attrition threshold for observational 
studies of smoking populations. Other quality assessment tools for observational studies 
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recommend the use 80% to 100% follow-up to determine the lowest attrition-bias, and 60% to 
79% to determine moderate attrition-bias (Thomas et al., 2004). Lundth and Gotzsche (2008) 
conducted a review of trials in aim to provide a list of recommendations for assessing the 
methodological quality of studies. They reported that the use of arbitrarily defined cut-off 
points is not empirically justified. Fewtrell et al. (2008) conducted a review of nutritional 
interventions and concluded that there are no universally agreed criteria for acceptable follow-
up rates in nutrition cohort studies.  
 
Thus, there is no empirical evidence to adopt a specific cut-off percentage for determining 
attrition bias.  However, there is empirical evidence that drop-out from a study may affect the 
study’s results (Touloumi et al., 2001), in turn affecting the study’s validity.  Although there 
is no agreed cut off, a method of determining attrition bias is necessary. Thus GT, PA and 
AM discussed different cut-off points and factors which may influence attrition.  A consensus 
was made that if loss to follow-up was >30% overall or >20% difference between the arms 
then there is a possibility of bias.  Accordingly if there was a complete follow-up or if loss to 
follow-up was less than 30% overall and there was a difference of less than 20% between the 
arms the study was awarded one star.  If the study did not meet these criteria or if there was 
no statement on follow-up rates the study did not receive a star. 
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Newcastle-Ottawa quality assessment scale cohort studies (NOS) adapted version 
  Star 
awarded 
system 
Star (*) 
awarded 
Study’s selection criteria 
1) Representativeness of the 
exposed cohort (maximum 1 star) 
a) truly representative of the average _______________ (describe) in the community  *  
b) somewhat representative of the average ______________ in the community  *  
c) selected group of users e.g. nurses, volunteers                                                (no  star)  
d) no description of the derivation of the cohort                                                               (no  star)  
2) Selection of the non-exposed 
cohort (maximum 1 star) 
a) drawn from the same community as the exposed cohort  *  
b) drawn from a different source (no  star)  
c) no description of the derivation of the non-exposed cohort (no  star)  
3) Ascertainment of exposure 
(maximum 1 star) 
a) bio-validated smoking status   *  
b) smoking status validated only by self-report (no star)  
c) no description                                                                                                                                                                                               (no star)  
Study’s outcome criteria 
1) Assessment of outcome 
(maximum 1 star)1 
a) standardised self-report questionnaire *  
b) standardised interview schedule with blind assessor *  
c) non-standardised self-report questionnaire or non-standardised interview schedule (no  star)  
d) no description (no  star)  
2) Adequacy of follow-up of 
cohorts (maximum 1 star) 2 
a) complete follow-up - all subjects accounted for   *  
b) subjects lost to follow-up unlikely to introduce bias - small number lost - > __ % 
(select an adequate %) follow-up, or description provided of those lost)  
*  
c) follow-up rate < __% (select an adequate %) and no description of those lost (no  star)  
d) no statement (no  star)  
Final Score  
1 In the case that a study has used a standardised self-report questionnaire and a standardised interview schedule, only one star will be awarded. This is 
as use of both outcome assessments will not improve the study’s quality for the purpose of this review. 
2 Describe based on attrition from enrolment to final follow-up 
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5. ARTICLES EXCLUDED AFTER EXAMINATION OF FULL TEXT 
(CHAPTER TWO)  
Appendix 5 has been previously published: 
 
Taylor, G., McNeill, A. and Girling, A. et al. (2014). Change in mental health after 
smoking cessation: systematic review and meta-analysis. BMJ, 348 (g1151). 
 
References of articles excluded based on examination of full text and reasons for exclusion 
Reference (N=166) Reason for exclusion 
Abrams, D.B., Monti, P.M. and Pinto, R.P. et al. (1987). Psychosocial stress 
and coping in smokers who relapse or quit. Health Psychology, 6 (4): 289-
303. 
No baseline measures of 
mental health taken prior to 
attaining/not attaining 
abstinence. 
Abrantes, A.M., Palm, K.M. and Strong, D.R. et al. (2006). Cigarette 
smokers who have difficulties quitting: The role of negative mood. 
Medicine and Health, 89 (5): 169-71. 
Review of cessation 
interventions. 
Acri, J.B. and Grunberg N.E. (1992). A psychophysical task to quantify 
smoking cessation-induced irritability: The reactive irritability scale (RIS). 
Addictive Behaviour, 17 (6): 587-601. 
Mental health outcome was 
measured during the 
withdrawal period. 
Ahlberg, J., Savolainen A. and Rantala M. et al. (2004). Reported bruxism 
and bio-psychosocial symptoms: A longitudinal study. Community 
Dentistry and Oral Epidemiology, 32 (4): 307-11. 
No mental health outcome. 
Allen, A.M., Prince, C.B. and Dietz, P.M. (2009). Postpartum depressive 
symptoms and smoking relapse. American Journal of Preventative 
Medicine, 36 (1): 9-12. 
Relapse as the outcome. 
Almeida, O.P., Garrido, G.J. and Alfonso, H. et al. (2011). 24-month effect 
of smoking cessation on cognitive function and brain structure in later life. 
Neuroimage, 55 (4): 1480-9. 
Mental health outcome was 
measured during the 
withdrawal period. 
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Baker, A., Richmond, R. and Lewin, T.J. et al. (2010). Cigarette smoking 
and psychosis: Naturalistic follow-up 4 years after an intervention trial. 
Australian and New Zealand Journal of Psychiatry, 44 (4): 342-50. 
Does not compare smokers 
with quitters. Randomised 
controlled trial follow-up. 
Berg, C.J., Thomas, J.L. and Guo, H. et al. (2010). Predictors of smoking 
reduction among Blacks. Nicotine and Tobacco Research, 12 (4): 423-31. 
Smoking status was the 
outcome. No mental health 
outcome. 
Bercaw, E.L. (2008). A behavioural activation approach to smoking 
cessation for depressed smokers at veterans affairs medical centres. 
Dissertation Abstracts International: Section B: The Sciences and 
Engineering, 68 (8-B): 5557.  
Smoking status as outcome. 
Billert, H., Gaca, M. and Adamski, D. et al. (2006). Significance of smoking 
and cigarette abstinence regarding anxiety in gynecologic patients in a 
perioperative period. Przeglad Lekarski, 63 (10): 870-7. 
Mental health outcome was 
measured during the 
withdrawal period. 
Borrelli, B., Niaura, R. and Keuthen, N.J. et al. (1996). Development of 
major depressive disorder during smoking-cessation treatment. Journal of 
Clinical Psychiatry, 57 (11): 534-8. 
Does not report mental 
health data by smoking 
status. 
Boudrez, H. (2009). Psychological factors and long-term abstinence after 
smoking cessation treatment. Journal of Smoking Cessation, 4 (1), 10-17.  
Smoking status as outcome. 
Mental health as predictor. 
Breslau, N., Novak, S.P. and Kessler, R.C. (2004). Psychiatric disorders and 
stages of smoking. Biological Psychiatry, 55 (1): 69-76. 
No quit group. Age range 
below 18. 
Catley, D., Ahluwalia, J.S. and Resnicow, K. et al. (2003). Depressive 
symptoms and smoking cessation among inner-city African Americans 
using the nicotine patch. Nicotine and Tobacco Research, 5 (1): 61-8. 
Smoking status as outcome. 
Cohen, S.B. (1999). Tranquilizing effects of smoking cessation. American 
Journal of Psychiatry, 156 (4): 666-7. 
Review article. 
Cooley, M.E., Sarna, L. and Kotlerman, J. et al. (2009). Smoking cessation 
is challenging even for patients recovering from lung cancer surgery with 
curative intent. Lung Cancer, 66 (2): 218-25. 
Smoking status as outcome. 
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Covey, L.S., Glassman, A.H. and Stetner, F. (1997). Major depression 
following smoking cessation. American Journal of Psychiatry, 154 (2): 263-
5. 
No continuing smoker 
group. 
Covey, L.S., Bomback, A. and Yan, G.W. (2006). History of depression and 
smoking cessation: A rejoinder. Nicotine and Tobacco Research, 8 (2): 315-
9. 
Meta-analysis of smoking 
status as the outcome. 
Dalack, G.W., Becks, L. and Hill, E. et al. (1999). Nicotine withdrawal and 
psychiatric symptoms in cigarette smokers with schizophrenia. 
Neuropsychopharmacology, 21 (2): 195-202. 
Mental health outcome was 
measured during the 
withdrawal period. 
Dempsey, J.P. and Cohen, L.M. Commentary on Hajek et al. (2010). 
Investigating the stress reduction in smoking cessation. Addiction, 105 (8): 
1472-3. 
Commentary article. 
Etter, J.F. and Hughes, J.R. (2006). A comparison of the psychometric 
properties of three cigarette withdrawal scales. Addiction, 101 (3): 362-72. 
Mental health outcome was 
measured during the 
withdrawal period. 
ez-Ganan, L., Guallar-Castillon, P. and Banegas, J.R. et al. (2002). 
Subjective health of male ex-smokers: Relationship with time since smoking 
cessation, intensity and duration of tobacco consumption. Preventative 
Medicine, 35 (4): 320-5. 
No mental health outcome. 
Frederick, S.L., Hall, S.M. and Humfleet, G.L. et al. (1996). Sex differences 
in the relation of mood to weight gain after quitting smoking. Experimental 
and Clinical Psychopharmacology, 4 (2): 178-85. 
Does not report baseline or 
follow-up mental health 
scores of quitters and 
continuer smokers. 
Frederick, S., Reus V. and Ginsberg, D. et al. (1998). Cortisol and response 
to dexamethasone as predictors of withdrawal distress and abstinence 
success. Biological Psychiatry, 43 (7): 525-530. 
Mental health outcome was 
during the withdrawal 
period. 
Garces, Y.I., Yang, P. and Parkinson J. et al. (2004). The relationship 
between cigarette smoking and quality of life after lung cancer diagnosis. 
Does not measure mental 
health. 
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Chest, 126 (6): 1733-41. 
Gelenberg, A.J., de Leon, J. and Evins, A.E. et al. (2007). Smoking 
cessation in patients with psychiatric disorders. Journal of Clinical 
Psychiatry, 68 (9): 1404-10. 
Commentary article. 
Gilbert, D.G., McClernon, F.J. and Rabinovich, N.E. et al. (1998). Effects of 
smoking abstinence on mood and craving in men: Influences of negative-
affect-related personality traits, habitual nicotine intake and repeated 
measurements. Personality and Individual Differences, 25 (3): 399-423. 
Mental health outcome was 
measured during the 
withdrawal period. 
Gilbert, D.G., McClernon, F.J. and Rabinovich, N.E. et al. (1999). EEG, 
physiology, and task-related mood fail to resolve across 31 days of smoking 
abstinence: Relations to depressive traits, nicotine exposure, and 
dependence. Experimental and Clinical Psychopharmacology, 7 (4): 427-43. 
Mental health outcome was 
measured during the 
withdrawal period. 
Gilbert, D.G., McClernon, F.J. and Rabinovich, N.E. et al. (2002). Mood 
disturbance fails to resolve across 31 days of cigarette abstinence in women. 
Journal of Consulting and Clinical Psychology, 70 (1): 142-52. 
Mental health outcome was 
measured during the 
withdrawal period. 
Gilbert, H.M. and Warburton, D.M. (2003). Individual variation in 
psychological and psychomotor symptoms following smoking cessation: 
The implications for treatment. Psychology and Health, 18 (5): 613-24. 
Mental health outcome was 
measured during the 
withdrawal period. 
Ginsberg, D., Hall, S.M. and Reus VI. et al. (1995). Mood and depression 
diagnosis in smoking cessation. Experimental and Clinical 
Psychopharmacology, 3 (4): 389-95. 
Smoking status as outcome. 
Giskes, K., van Lenthe, F.J. and Turrell G. et al. (2006). Smokers living in 
deprived areas are less likely to quit: A longitudinal follow-up. Tobacco 
Control: An International Journal, 15 (6), 485-8.  
Cessation status as 
outcome. 
Glassman, A.H., Covey, L.S. and Dalack, G.W. et al. (1992). Cigarette 
smoking, major depression, and schizophrenia. Clinical 
Neuropharmacology, 15: 561A. 
Commentary article. 
Glassman, A.H. and Hercher, L.S. (1999). Which aspects of nicotine Commentary article. 
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addiction should concern mental health professionals? Harvard Mental 
Health Letter, 16 (2): 8. 
Goldberg, J.O. and Van E.J. (2008). Longitudinal rates of smoking in a 
schizophrenia sample. Tobacco Control, 17 (4): 271-5. 
No mental health outcome. 
Goto, R. and Takahashi, Y. and Nishimura, S. et al. (2009). A cohort study 
to examine whether time and risk preference is related to smoking cessation 
success. Addiction, 104 (6): 1018-24. 
Smoking cessation status as 
outcome. 
Grassi, M.C, Enea, D. and Ferketich, A.K. et al. (2011). Effectiveness of 
varenicline for smoking cessation: A 1-year follow-up study. Journal of 
Substance Abuse Treatment, 41 (1): 64-70. 
Randomised controlled 
trial. Analysis by treatment 
group. 
Gritz, E.R., Carr, C.R. and Marcus, A.C. (1991). The tobacco withdrawal 
syndrome in unaided quitters. British Journal of Addiction, 86 (1): 57-69. 
No continuing smoker 
group. 
Gross, J. and Stitzer, M.L. (1989). Nicotine replacement: ten-week effects 
on tobacco withdrawal symptoms. Psychopharmacology, 98 (3): 334-41. 
No continuing smoker 
group. 
Grunberg, N.E. (2003). The tobacco use crisis and mental health. 
Psychiatry, 66 (3): 200-1. 
Commentary article. 
Guiterrez-Bedmar, M., Segui-Gomez, M. and Gomez-Gracia E. et al. 
(2009). Smoking status, changes in smoking status and health-related quality 
of life: findings from the SUN ("Seguimiento Universidad de Navarra") 
cohort. International Journal of Environmental Research and Public Health, 
6 (1): 310-20. 
No psychological outcome 
data presented at baseline. 
Hajek, P. and Belcher, M. (1991). Dream of absent-minded transgression: 
An empirical study of a cognitive withdrawal symptom. Journal of 
Abnormal Psychology, 100 (4), 487-91.  
No mental health outcome. 
No continuing smoker 
group. 
Hall, S.M, Bachman, J. and Henderson, J.B. (1983). Smoking cessation in 
patients with cardiopulmonary disease: An initial study. Addictive 
Behaviour, 8 (1): 33-42. 
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interventions. 
Vidrine, D.J., Arduino, R.C. and Gritz, E.R. (2007). The effects of smoking 
abstinence on symptom burden and quality of life among persons living with 
HIV/AIDS. Aids Patient Care STD, 21 (9): 659-66. 
Change in mental health 
measured during the 
withdrawal period. 
Wang, Y.Z., Chen, H.H. and Yeh, M.L. et al. (2010). Auricular acupressure 
combined with multimedia instruction or alone for quitting smoking in 
young adults: A quasi-experimental study. International Journal of Nursing 
Studies, 47 (9): 1089-95. 
No continuing smoker 
group. No quitter group. 
West, R., Gilsenan, A. and Coste, F. et al. (2006). The ATTEMPT cohort: A 
multi-national longitudinal study of predictors, patterns and consequences of 
smoking cessation; introduction and evaluation of internet recruitment and 
data collection methods. Addiction, 101 (9): 1352-61. 
Smoking status as outcome. 
West, R. and Hajek, P. (1997). What happens to anxiety levels on giving up 
smoking? American Journal of Psychiatry, 154 (11): 1589-92. 
No continuing smoker 
group. 
West, R. and Hajek, P. (2004). Evaluation of the mood and physical 
symptoms scale (MPSS) to assess cigarette withdrawal. 
Psychopharmacology, 177 (1-2): 195-9. 
No continuing smoker 
group. Mental health was 
assessed during the 
withdrawal period. 
Wewers, M.E and Ahijevych, K.L. (1991). Work stress after smoking No continuing smoker 
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cessation. American Association of Occupational Health Nurses, 39 (12): 
547-51. 
group.  Analysis of a 
relapse group. 
Yoder, Y.B. (1991). Smoking cessation and stress. Journal of the American 
Board of Family Practice, 4 (3): 198. 
Commentary article. 
Zelman, D.C., Brandon, T.H. and Jorenby, D.E. et al. (1992). Measures of 
affect and nicotine dependence predict differential response to smoking 
cessation treatments. Journal of Consulting and Clinical Psychology, 60 (6): 
943-52. 
Randomised controlled 
trial. Analysis by treatment 
group. 
Ziegelstein, R.C. Smoking cessation and the risk for type 2 diabetes 
mellitus. Annuals of International Medicine; 152 (1): 10-7.  
Commentary article. 
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6. ARTICLES EXCLUDED FROM META-ANALYSIS (CHAPTER TWO) 
Appendix 6 has been previously published: 
 
Taylor, G., McNeill, A. and Girling, A. et al. (2014). Change in mental health after 
smoking cessation: systematic review and meta-analysis. BMJ, 348 (g1151). 
 
References of articles excluded from meta-analysis and reasons for exclusion 
Reference (N=27) Reason for exclusion 
Bolam B, West R, Gunnell D. Does smoking cessation cause depression 
and anxiety? Findings from the ATTEMPT cohort. Nicotine and 
Tobacco Research 2011; 13: 209-14. 
Binary outcome. 
Bolliger CT, Zellweger JP, Danielsson T, et al. Influence of long-term 
smoking reduction on health risk markers and quality of life. Nicotine 
and Tobacco Research 2002; 4: 433-9. 
Does not report any data on 
individuals who quit.  No 
response to additional data. 
Breslau N, Peterson EL, Schultz LR. et al. Major depression and stages 
of smoking: A longitudinal investigation. Archives of General 
Psychiatry 1998; 55:161-6.  
Binary outcome. 
Carey MP, Kalra DL, Carey KB. et al. Stress and unaided smoking 
cessation: a prospective investigation. Journal of Consulting and 
Clinical Psychology 1993; 61:831-8. 
Provides only a verbal 
description of change in mental 
health.  The author no longer 
has access to the requested data. 
Cohen S, Lichtenstein E. Perceived stress, quitting smoking, and 
smoking relapse. Health Psychology 1990; 9:466-78. 
Does not provide enough data to 
calculate mean change for each 
group. The author no longer has 
access to the requested data. 
George TP, Vessicchio JC, Termine A. et al. Effects of smoking 
abstinence on visuospatial working memory function in schizophrenia. 
Neuropsychopharmacology 2002; 26:75-85. 
Does not present enough data at 
the final follow-up.  The author 
sent additional data, however 
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the data were not presented by 
smoking status. 
Glassman AH, Covey LS, Stetner F. et al.Smoking cessation and the 
course of major depression: A follow-up study. Lancet 2001; 16:1929-
32. 
Percentage outcome. 
Hughes JR, Gust SW, Skoog K. et al. Symptoms of tobacco 
withdrawal: A replication and extension. Archives of General 
Psychiatry 1991; 48:52-9. 
Extracted data.  However, as the 
M scores were calculated by 
ruler.  All the SEs were 
assumed as less than 1.  The 
research team decided that the 
calculations were based on too 
many assumptions to be 
accurate. 
John U, Meyer C, Rumpf HJ. et al.Smoking, nicotine dependence and 
psychiatric comorbidity-a population-based study including smoking 
cessation after three years. Drug and Alcohol Dependence 2004 ; 
76(3):287-95. 
Binary outcome. 
Kaetsu A, Fukushima T, Moriyama M. et al.Change of the smoking 
behaviour and related lifestyle variables among physicians in Fukuoka, 
Japan: a longitudinal study. Journal of Epidemiology 2002 May; 
12:208-16. 
Binary outcome. 
Khaled SM, Bulloch AG, Williams . et al. Persistent heavy smoking as 
risk factor for major depression (MD) incidence: Evidence from a 
longitudinal Canadian cohort of the National Population Health Survey. 
Journal of Psychiatric Research 2012; 46:436-43. 
Binary outcome. 
Marqueta A, Jimenez-Muro A, Beamonte A. et al. Evolution of anxiety 
during the smoking cessation process at a Smoking Cessation Clinic. 
Adicciones 2010; 22:317-24. 
Does not report follow-up data 
by smoking status.  No response 
to request for additional data. 
McMahon SD, Jason LA. Stress and coping in smoking cessation: A Does not state how many people 
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longitudinal examination. Anxiety Stress and Coping 1998; 11:327-43. were in quit group and 
continuing smoking group at 
baseline or follow-up.  No 
response to request for 
additional data. 
McMahon SD, Jason LA, Salina D. Stress, Coping, and Appraisal in a 
Smoking Cessation Intervention. Anxiety Stress and Coping 1994; 
7:161-71. 
Data reported in McMahon 
(1998) 
Pertschuk MJ, Pomerleau OF, Adkins D. et al. Smoking cessation: The 
psychological costs. Addictive Behaviours 1979; 4:345-8.  
Frequency of event outcome. 
Prochaska JJ, Hall SM, Tsoh JY. et al. Treating tobacco dependence in 
clinically depressed smokers: Effect of smoking cessation on mental 
health functioning. American Journal of Public Health 2008; 98:446-8.  
Provides only a verbal 
description of change in mental 
health.  No response to request 
for additional data. 
Sales MP, Oliveira MI, Mattos IM. et al. The impact of smoking 
cessation on patient quality of life. Jornal Brasileiro de Pneumologia 
2009; 35:436-41. 
Not enough data to calculate 
SDs.  No response to request for 
additional data. 
Sanchez-Villegas A, Serrano-Martinez M, Alonso A. et al. Role of the 
tobacco use on the depression incidence in the SUN cohort study. 
Medicina Clinica 2008; 130:405-9. 
Binary outcome. 
Schwartz JL, Dubitzky M. One-year follow-up results of a smoking 
cessation program. Canadian Journal of Public Health 1968; 
Revue:161-5. 
Narrative description and a P-
value only.  Could not locate 
either authors’ contact details to 
request additional data. 
Segan CJ, Borland R, Wilhelm KA. et al. Helping smokers with 
depression to quit smoking: collaborative care with Quit-line. Medical 
Journal of Australia 2011; 195:7-11. 
Percentage outcome. 
Siahpush M, Spittal M, Singh GK. Association of smoking cessation Binary outcome. 
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with financial stress and material well-being: Results from a 
prospective study of a population-based national survey. American 
Journal of Public Health 2007; 97:2281-7.  
Tranel D, McNutt A, Bechara A. Smoking Cessation After Brain 
Damage Does Not Lead to Increased Depression: Implications for 
Understanding the Psychiatric Complications of Varenicline. Cognitive 
and Behavioural Neurology 2012; 25:16-24. 
Not enough data to calculate 
mean and SD at baseline.  No 
response to request for 
additional data. 
Tsoh JY, Humfleet GL, Munoz RF. et al. Development of major 
depression after treatment for smoking cessation. Am J Psychiatry 
2000; 157:368-74. 
Binary outcome. 
Ward KD, Relyea G, Weg et al. Changes in quality of life after 
smoking cessation among older adults. Nicotine and Tobacco Research 
2005; 7(4):700. 
Conference abstract. Emailed 
author for mean mental health 
scores and standard deviations. 
Author response: no longer has 
access to the data. 
Wiggers LC, Oort FJ, Peters RJ. et al. Smoking cessation may not 
improve quality of life in atherosclerotic patients. Nicotine and Tobacco 
Research 2006; 8:581-9. 
Does not provide baseline data 
for quit group or mean changes.  
No response to request for 
additional data. 
Weinberger AH, Hitsman B, Papandonatos GD. et al. Predictors of 
abstinence and changes in psychiatric symptoms in a pooled sample of 
smokers with schizophrenia receiving combination pharmacotherapy 
and behavioural therapy for smoking cessation. Journal of Clinical 
Psychopharmacology 2009; 29:601-3. 
Not enough data to calculate M 
and SD for continuing smoker 
group.  No response to request 
for additional data. 
Zillich AJ, Ryan M, Adams A. et al. Effectiveness of a pharmacist-
based smoking-cessation program and its impact on quality of life. 
Pharmacotherapy 2002; 22:759-65. 
Not enough data to calculate 
SDs for quitter and continuing 
smoker groups.  Requested 
additional data from author; 
however the author sent data of 
259 
 
combined groups. 
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7. EXAMINATION OF 15 PAPERS WHERE AUTHORS COULD NOT SUPPLY ADDITIONAL DATA (CHAPTER 
TWO) 
Appendix 7 has been previously published: 
 
Taylor, G., McNeill, A. and Girling, A. et al. (2014). Change in mental health after smoking cessation: systematic review and meta-
analysis. BMJ, 348 (g1151). 
 
Direction, strength and statistical significance of change in mental health between continuing smokers and quitters in 15 papers 
where the authors could not supply additional data 
First 
author and 
year of 
publication 
Reason for exclusion from meta-analysis In-text quote or verbal summary of results Summary of results 
Bolliger 
2002 
Does not provide any data on the quit group. No 
response to request for additional data. 
Does not report any data on individuals who quit. Unclear 
Carey 1993 Provides only a verbal description of change in mental 
health. The author no longer has access to the 
“Quitters perceived less stress during their quit efforts than did non-
quitters” 
Quitters improve 
compared with 
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requested data. continuing smokers. 
 
Direction of change: 
quitters improve. No 
indication of change for 
continuing smokers 
Cohen 
1990 
Does not provide enough data to calculate mean 
change for each group. The author no longer has 
access to the requested data. 
“Relapsers had higher stress levels than those remaining abstinent at 
all lags. Quitters had lower stress levels that those who continued to 
smoke at all lags” 
 
“Changes from smoking to abstinence were associated with 
decreased feelings of stress, whereas changes from abstinence to 
smoking were associated with increased feelings of stress. Stress 
levels did not change for subjects whose smoking status did not 
change. 
Quitters improve in 
comparison to continuing 
smokers. 
 
Direction of change: 
Quitters improve, 
continuing smokers show 
no change. 
George 
2002 
Does not present enough data for the final follow-up.  
The author sent additional data, however the data 
were not presented by smoking status. 
Does not report follow-up BDI scores. Unclear 
262 
 
Hughes 
1991 
Extracted data.  However, the mean scores were 
extracted from a diagram and all the SEs were 
assumed to be less than 1.  The research team decided 
that the calculations were based on too many 
assumptions to be accurate. Author no longer had 
access to the data. 
Does not directly discuss the change in anxiety from baseline to 6 
month follow-up for either group.  Graphs which present the time 
sequence of change are presented.  From the graphs it is clear that 
continuing smokers and quitters decreased in anxiety, however the 
decrease appears greater in quitters.  This was not statistically 
assessed. 
Unclear 
Marqueta 
2012 
Not enough data to calculate M and SDs. No response 
to request for additional data. 
Does not report 3-month STAI results for quitters and continuing 
smokers. 
Unclear 
McMahon 
1998  
Does not state how many people were in quit group 
and continuing smoking group at baseline or follow-
up.  No response to request for additional data. 
Presents   table of raw M and SD data but does not state how many 
people were in each group at any time point. 
 
Both groups improve. 
Unsure if the difference 
is significant. 
 
Direction of change: 
Both groups show 
improvement in mental 
health but it was greater 
in quitters 
Prochaska Provides only a verbal description of change in mental “Time effects for BDI-II scores indicated significant reductions No difference between 
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2008  health.  No response to request for additional data. from baseline levels and no difference by smoking status.” 
 
“both groups exhibited a significant 
decline in depressive symptoms and 
days with emotional problems over time” 
groups. 
 
Direction of change: 
Both groups show 
improvement in mental 
health. 
Sales 2009  Not enough data to calculate M SDs for the 
continuing smoker group.  No response to request for 
additional data. 
“quitters presented a statistically significant improvement in vitality 
(positive affect) and the mental component summary (P<0.05)” 
 
“the quitters presented higher post-intervention scores than did the 
non-quitters for the vitality and mental health domains, as well as 
for the mental component summary” 
Quitters improve 
compared with 
continuing smokers. 
 
Direction of change: 
quitters improve, no 
indication of direction 
for continuing smokers 
Schwartz 
1968  
Narrative description and a P-value only. Could not 
locate either author’s contact details to request 
additional data. 
“both before and during treatment, successful subjects scored less 
anxious on the mood scale than persons who did not change 
(P<0.5)” 
Quitters improve 
compared with 
continuing smokers. 
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Direction of change: 
quitters improve, no 
indication of direction 
for continuing smokers. 
Tranel 
2012  
Not enough data to calculate mean and SD at baseline.  
No response to request for additional data. 
1.) At follow-up “For the BDI-II the mean scores did not differ 
statistically: 10.1 between quitters and 12.3 for non-quitters.” 
2.) “At follow-up for the BAI, the mean was somewhat higher in the 
non-quitters (13.0) than quitters (8.5), but the difference was not 
statistically significant.” 
3.) “we checked each group for patients who had substantially 
elevated scores on the depression outcomes... we found no 
significant between group differences: 10 quitters and 16 non 
quitters” 
No difference between 
groups 
 
Direction of change: no 
indication of direction 
for either group. 
Ward 2005 Conference abstract. Presents verbal description of 
change in for quitters and smokers. Emailed author for 
additional data. Author response: no longer has access 
to the data. 
“A significant time by smoking status interaction was observed for 
energy/fatigue indicating that non-quitters worsened substantially 
over time while quitters experienced no change. “ 
 
“QOL was greater in quitters compared with non-quitters for 
Significant difference 
between groups. 
 
Direction of change: 
quitters show no change, 
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emotional well-being” continuing smokers 
worsen. 
Wiggers 
2006  
Does not provide baseline data for quit group or mean 
changes.  No response to request for additional data. 
“We found no effects of smoking status on patients’ mental QOL” No difference between 
groups. 
 
No indication of 
direction of change. 
Weinberger 
2009 
Not enough data to calculate M and Ds for continuing 
smoker group.  No response to request for additional 
data. 
Abstinence was associated with a 2.97-U increase in BDI scores as 
compared with no change in BDI scores for non-abstinence 
participants. 
Quitters increase in 
depression compared 
with continuing smokers. 
 
Direction of change: 
quitters worsen, no 
change for continuing 
smokers. 
Zillich 
2002  
Not enough data to calculate SDs for quitter and 
continuing smoker groups.  Requested additional data 
from author; however the author sent data of 
“In those who remained abstinent... (change in scores from) baseline 
to 3 months revealed statistically significant improvements for 
vitality and mental health” 
Quitters improve. No 
comparison with 
continuing smokers. 
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combined groups.  
Direction of change: 
quitters improve, no data 
for continuing smokers. 
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8. REFERENCES OF STUDIES INCLUDED IN THE META-ANALYSIS 
(CHAPTER TWO) 
 
Appendix 8 has been previously published: 
 
Taylor, G., McNeill, A. and Girling, A. et al. (2014). Change in mental health after 
smoking cessation: systematic review and meta-analysis. BMJ, 348 (g1151). 
 
References of final studies included in the meta-analysis 
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smokers who do not manage to stop smoking after a target quit day. Addiction 2010; 105(12):2209-16. 
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Busch AM, Wagener TL, Gregor KL. et al. Utilizing reliable and clinically significant change criteria to 
assess for the development of depression during smoking cessation treatment: The importance of tracking 
idiographic change. Addictive Behaviours 2011; 36(12):1228-32. 
 
Chassin L, Presson CC, Sherman SJ. et al. Long-term psychological sequelae of smoking cessation and 
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9. FUNNEL PLOTS FOR EVIDENCE OF PUBLICATION BIAS (CHAPTER 
TWO) 
 
Figure 9.1 Funnel plot of SMD (SE) and SMD, for studies measuring anxiety 
 
 
 
Figure 9.2 Funnel plot of SMD (SE) and SMD, for studies measuring depression 
 
272 
 
 
Figure 9.3 Funnel plot of SMD (SE) and SMD, for studies measuring psychological QOL 
 
 
 
Figure 9.4 Funnel plot of SMD (SE) and SMD, for studies measuring mixed anxiety and 
depression 
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10. SENSITIVITY AND SUBGROUP ANALYSES (CHAPTER TWO) 
Appendix 9 has been previously published: 
 
Taylor, G., McNeill, A. and Girling, A. et al. (2014). Change in mental health after 
smoking cessation: systematic review and meta-analysis. BMJ, 348 (g1151). 
 
Sensitivity analysis with removal of studies in which different numbers of participants were 
analysed at baseline and follow-up 
Outcome 
No of studies 
included 
No of studies 
excluded 
Standardised mean difference (95% CI) 
Effect estimate 
Original effect 
estimate 
Anxiety 4 0 0.37 (0.70 to 0.03) 0.37 (0.70 to 0.03) 
Depression 3 7 0.30 (0.67 to 0.07) 0.25 (0.37 to 0.12) 
Mixed 
anxiety and 
depression 
3 2 0.26 (0.44 to 0.07) 0.31 (0.47 to 0.14) 
Positive 
affect 
3 0 0.40 (0.09 to 0.71) 0.40 (0.09 to 0.71) 
Psychological 
quality of life 
5 3 0.18 (0.02 to 0.33) 0.22 (0.09 to 0.36) 
Stress 2 1 0.27 (0.42 to 0.12) 0.27 (0.40 to 0.13) 
 
Sensitivity analyses after ascertainment of smoking status 
Removed studies 
and outcome 
No of 
studies 
included 
No of 
studies 
excluded 
Standardised mean difference (95% CI) 
Effect estimate Original effect estimate 
Smoking status not biochemically validated 
Anxiety 4 0 0.37 (0.70 to 0.03) 0.37 (0.70 to 0.03) 
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Depression 7 3 0.32 (0.50 to 0.13) 0.25 (0.37 to 0.12) 
Mixed anxiety 
and depression 
3 2 0.35 (0.59 to 0.10) 0.31 (0.47 to 0.14) 
Psychological 
quality of life 
4 4 0.17 (0.02 to 0.35) 0.22 (0.09 to 0.36) 
Positive affect 1 2 0.68 (0.24 to 1.12) 0.40 (0.09 to 0.71) 
Stress 2 1 0.23 (0.39 to 0.07) 0.27 (0.40 to 0.13) 
Point-prevalence smoking status 
Anxiety 2 1 0.51 (1.04 to 0.03) 0.37 (0.70 to 0.03) 
Depression 6 4 0.34 (0.52 to 0.16) 0.25 (0.37 to 0.12) 
Mixed anxiety 
and depression 
3 2 0.29 (0.52 to 0.07) 0.31 (0.47 to 0.14 ) 
Psychological 
quality of life 
1 7 0.37 (0.07 to 0.67) 0.22 (0.09 to 0.36) 
Positive affect 2 1 0.39 (0.11 to 0.90) 0.40 (0.09 to 0.71) 
Stress 2 1 0.27 (0.42 to 0.12) 0.27 (0.40 to 0.13) 
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Subgroup analysis with comparison of studies in which 
participants were motivated or not motivated to quit 
Population (No of studies) 
Standardised mean 
difference (95% CI) 
Test for subgroup 
differences 
Anxiety 
Overall (4) 0.37 (0.70 to 0.03)  
Motivated to quit (3) 0.41 (0.81 to 0.00) 
²=2.77, P=0.10 
Not motivated to quit (1) 0.19 (0.68 to 0.30) 
Depression 
Overall (10) 0.25 (0.37 to 0.12)  
Motivated to quit (6) 0.31 (0.53 to 0.09) 
²=1.16, P=0.28 
Not motivated to quit (4) 0.17 (0.30 to 0.05) 
Mixed anxiety and depression 
Overall (5) 0.31 (0.47 to 0.14)  
Motivated to quit (3) 0.35 (0.59 to 0.10) 
²=0.19, P=0.66 
Not motivated to quit (2) 0.27 (0.50 to 0.04) 
Psychological quality of life 
Overall (8) 0.22 (0.09 to 0.36)  
Motivated to quit (4) 0.20 (0.03 to 0.38) 
²=0.17, P=0.68 
Not motivated to quit (4) 0.26 (0.04 to 0.49) 
Positive affect 
Overall (3) 0.40 (0.09 to 0.71)  
Motivated to quit (2) 0.39 (0.11 to 0.90) 
²=3.95, P=0.11 
Not motivated to quit (1) 0.47 (0.04 to 0.90) 
Stress 
Overall (3) 0.27 (0.40 to 0.13)  
Motivated to quit (2) 0.23 (0.39 to 0.07) ²=0.74, P=0.39 
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Not motivated to quit (1) 0.36 (0.61 to 0.11) 
 
Sensitivity analysis after removal of studies with psychological component 
within cessation intervention 
Outcome 
No of 
studies 
included 
No of 
studies 
excluded 
Standardised mean difference (95% CI) 
Effect estimate 
Original effect 
estimate 
Anxiety 4 0 0.37 (0.70 to 0.03) 0.37 (0.70 to 0.03) 
Depression 6 4 0.15 (0.26 to 0.03) 0.25 (0.37 to 0.12) 
Mixed anxiety 
and depression 
3 2 0.28 (0.46 to 0.10) 0.31 (0.47 to 0.14) 
Psychological 
quality of life 
5 3 0.15 (0.01 to 0.31) 0.22 (0.09 to 0.36) 
Positive affect 1 2 0.47 (0.04 to 0.90) 0.40 (0.09 to 0.71) 
Stress 3 0 0.27 (0.40 to 0.13) 0.27 (0.40 to 0.13) 
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Subgroup with comparison of effect estimates between different study designs 
Study design 
Effect estimate 
standardised mean 
difference (95% CI) 
Test for subgroup 
differences 
Anxiety 
Overall 0.37 (0.70 to 0.03) — 
Cohort (1 study) 0.06 (0.42 to 0.30) 
²=4.07, P=0.13 
Randomised controlled trial (1 study) 0.19 (0.68 to 0.30) 
Secondary analyses of cessation intervention (2 
studies) 
0.57 (0.93 to 0.21) 
Depression 
Overall 0.25 (0.37 to 0.12) — 
Cohort (3 studies) 0.12 (0.25 to 0.01) 
²=5.15, P=0.08 
Randomised controlled trial (1 study) 0.39 (0.88 to 0.10) 
Secondary analyses of cessation intervention (6 
studies) 
0.36 (0.53 to 0.18) 
Mixed anxiety and depression 
Overall 0.31 (0.47 to 0.14) — 
Cohort (3 studies) 0.28 (0.46 to 0.10) 
²=0.76, P=0.38 Secondary analyses of cessation intervention (2 
studies) 
0.51 (0.99 to 0.03) 
Psychological quality of life 
Overall 0.22 (0.09 to 0.36) — 
Cohort (5 studies) 0.28 (0.08 to 0.48) 
²=0.95, P=0.33 Secondary analyses of cessation intervention (3 
studies) 
0.15 (0.04 to 0.33) 
Positive affect 
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Overall 0.40 (0.09 to 0.71) — 
Cohort (2 studies) 0.28 (0.02 to 0.57) 
²=2.22, P=0.14 Secondary analyses of cessation intervention (1 
study) 
0.68 (0.24 to 1.12) 
Stress 
Overall 0.27 (0.40 to 0.13) — 
Cohort (1 study) 0.36 (0.61 to 0.11) 
²=0.74, P=0.39 Secondary analyses of cessation intervention (2 
studies) 
0.23 (0.39 to 0.07) 
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Subgroup analysis after comparison of effect estimates between studies with follow-up periods from baseline to 
follow-up between six weeks to six months and studies with follow-ups from baseline to >6 months 
Outcome 
Standardised mean difference (95% CI) Test for subgroup 
differences Original estimate 6 weeks to <6 months >6 months 
Anxiety 0.37 (0.70 to 0.03) 0.35 (0.83 to 0.12) (3 studies) 0.37 (0.72 to 0.02) (1 study) 
²=0.00 
P=0.95 
Depression* 0.25 (0.37 to 0.12) 0.18 (0.31 to 0.05) (8 studies) 0.23 (0.41 to 0.06) (5 studies) 
²=0.25 
P=0.62 
Mixed  anxiety and 
depression* 
0.31 (0.47 to 0.14) 0.37 (0.58 to 0.15) (4 studies) 0.27 (0.50 to 0.04) (2 studies) 
²=0.34 
P=0.56 
Positive affect 0.40 (0.09 to 0.71) 0.68 (0.24 to 1.12) (1 study) 0.28 (0.02 to 0.57) (2 studies) 
²=2.22 
P=0.14 
Psychological quality 
of life* 
0.22 (0.09 to 0.36) 0.30 (0.15 to 0.44) (7 studies) 0.23 (0.09 to 0.37) (8 studies) 
²=0.36 
P=0.92 
Stress 0.27 (0.40 to 0.13) 0.25 (0.58 to 0.08) (1 study) 0.27 (0.42 to 0.12) (2 studies) 
²=0.01 
P=0.92 
*Please note some studies measured outcome at multiple follow-ups, these were compared within the corresponding subgroup analysis 
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11. PROTOCOL FOR MCNEIL STUDIES (CHAPTER THREE) 
 
PROTOCOL: A PROSPECTIVE COHORT STUDY TO EXAMINE THE EFFECTS 
OF SMOKING CESSATION ON MENTAL HEALTH 
 
Authors: Taylor, G., Aveyard, P. and McNeil, A. 
 
The University Of Birmingham 
 
BACKGROUND 
 
Smokers believe that smoking reduces stress and provides psychological benefits. McEwen et 
al. (2008b) examined smokers’ motives to continue smoking.  Stress relief, boredom relief 
and enjoyment were the highest rated motives to continue smoking.  This suggests that 
smokers believe smoking cigarettes can alleviate negative emotions, and that by stopping 
smoking they may be losing a mechanism which facilitates positive emotions. 
 
However, smokers’ beliefs about smoking do not coincide with research which investigates 
the relationships between smoking status and psychological well-being. The 2004 Surgeon 
General’s report collated evidence from ecological, cross-sectional, cohort, case-control 
studies and intervention trials, reference lists from important publications, consultations with 
experts and a extensive literature searches. The report concluded that the reviewed evidence 
provides a clear indication that smokers report more negative mental health symptoms 
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compared with non-smokers.  The report showed strong evidence of poor psychological well-
being within the smoking population. However, the causal relationship is unclear. It is 
possible that smoking causes poor mental health, poor mental health causes smoking, or that 
both have a common cause.   
 
There is some evidence that smoking may cause poor mental health. Parrott (2003) reviewed 
longitudinal studies investigating the relationship between smoking initiation and 
subsequently occurring psychological well-being. The studies reviewed by Parrott (2003) 
indicated that nicotine dependency is associated with heightened psychological distress in 
tobacco smokers. 
 
The misattribution hypothesis seeks to explain why smokers can feel that smoking is stress 
relieving in the face of evidence that smoking may cause psychological distress (Parrott, 
1999). The hypothesis is based upon research which indicates that smokers experience the 
distressing psychological symptoms of nicotine withdrawal shortly after finishing smoking a 
cigarette. Psychological withdrawal symptoms include anxiety, irritability, stress, depression, 
restlessness and difficulty concentrating.  In nicotine dependent smokers these negative 
changes in mood are relieved by smoking a cigarette. However, the relief only takes the 
smoker back to a normal mood state (Parrott, 1998).  As a result, nicotine dependent smokers 
suffer many periods of poor mood every day, with nicotine dependency being a cause of 
negative mood (Parrott, 1994). The re-occurrence of negative mood causes the dependent 
smoker to experience a worse daily mood; in turn lowering overall psychological well-being. 
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Withdrawal effects, offset effects and psychological well-being 
 
The abstinent smoker will experience various negative psychological symptoms during the 
withdrawal period.  The length of the withdrawal period varies. Two cohort studies reported 
that depression and negative mood states last longer than four weeks post-cessation (Gilbert et 
al., 2002; Gilbert et al., 1998). However, in Gilbert et al.’s (1998, 2002) studies individuals 
were considered as abstinent even if they smoked up to 10 cigarettes during the abstinence 
period. Including smokers smoking occasionally may have prolonged withdrawal in these 
studies. Hughes (2007d) systematically reviewed cohort studies examining the occurrence of 
tobacco withdrawal symptoms after abstinence and found that anxiety, depression, and 
negative mood states (e.g. anger, impatience) peak within the first week of abstinence and last 
two to four weeks. Thus to assess the association between maintained smoking cessation and 
change in psychological well-being measurement of psychological well-being should take 
place from four weeks onwards post-cessation. 
 
There is uncertainty pertaining to whether some psychological symptoms display a 
unidirectional change after cessation (known as an offset effect) (Hughes, 2007a; Hughes, 
2007e). If an offset effect occurs, the level of symptom is abnormal.  For example if 
depression displays an offset effect, this would mean that the person will permanently display 
a lower level of psychological well-being. Hughes (2007b, 2007c) argues that there are two 
interpretations of the offset effect. Firstly, the person’s level of psychological well-being may 
have been low before they began to use tobacco. This is supported by the self-medication 
hypothesis, which suggests that the chemical properties of nicotine are used by the smoker to 
alleviate psychological distress (Khantzian, 1997). Another explanation is that the post-
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abstinence level of psychological well-being is a new level caused by long-term use of 
tobacco.   
 
Research suggests that cessation may be associated with an offset of depressive symptoms.  
For example Glassman et al. (2001) conducted a longitudinal analysis and found that smokers 
with a history of depression who abstain from smoking display an increased risk of 
developing a new episode of depression (OR=7.17, 95% CI 1.5-34.5) at six-months. Tsoh et 
al. (2000) compared the risk of developing depression between quitters and continuing 
smokers and found that both groups displayed a similar rate of incidence of depression (N=25 
of 170, 14.7% versus N=18 of 134, 13.4%.  However, the reported incidence of post cessation 
depression was higher amongst those with a history of depression (23.7%, N=23 of 97 versus 
9.7%, N=20 of 207).  These results suggest that not everyone reports depression upon 
cessation; but a subgroup of individuals are susceptible to this offset effect  
 
Smoking cessation and change in psychological well-being 
 
If the misattribution hypothesis is correct then smokers who maintain cessation should 
experience a decrease in negative psychological symptoms.  There is evidence to support this. 
Cohen et al. (1990) compared change in levels of perceived stress from baseline to six-
months, between individuals who remained continuously abstinent with individuals who 
continued smoking.  Those who remained continuously abstinent displayed a greater 
reduction in perceived stress than those who did not quit. Carey et al. (1993) reported that 
those who remained continuously abstinence displayed decreased stress in comparison to non-
quitters at a twelve-month follow-up. Parrot et al. (1995) examined stress levels at six months 
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after cessation accounting for daily stressors. Successful quitters displayed reduced stress 
levels even though there was no reduction in environmental stressors Hughes et al. (1992) 
prospectively investigated anxiety and depression levels after cessation. Anxiety and 
depression decreased but the authors did not compare quitters to continuing smokers.  Thus, 
long-term studies are consistent with the misattribution hypothesis.  
 
There are some data that do not fit well with the misattribution hypothesis. Chassin et al. 
(2002) examined change in perceived stress and negative affect from baseline to six years in 
people who stopped smoking and those who continued. Although perceived stress was 
reduced in quitters, there were no significant reductions in other symptoms of negative affect.  
This suggests that reduced stress may not improve psychological well-being. However, 
Chassin et al.’s (2002) study used measures of negative affect that are of uncertain validity.  
 
Other data are incompatible with the misattribution hypothesis I found two reviews which 
found evidence to suggested that smoking cessation is associated with worsening mental 
health (Hughes 2007c; Parrott 2003). Parrott (2003) noted the association between adverse 
effects of smoking cessation on psychological well-being (Gilbert et al. 1998c; Glassman et 
al. 1990). However, Gilbert et al. (1998b) assessed mental health outcomes at thirty days; as 
discussed above, this is within the withdrawal period. Accordingly, this study does not 
provide sufficient evidence to show that smoking cessation worsens psychological well-being.  
Hughes (2007b) identified seven studies which examined the incidence of major depressive 
disorder (MDD) among individuals who had maintained cessation for seven to sixty four 
weeks. Hughes’ (2007a) analysis found that the incidence of MDD over two to twelve months 
post-cessation varied in the studies between 1% and 31% amongst smokers who remained 
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abstinent.  Hughes (2007b) review did not compare the occurrence of MDD of successful 
quitters with unsuccessful quitters, thus this study provides no evidence of an association 
between abstinence and MDD. 
 
Smoking reduction and change in psychological well-being 
 
Smoking reduction is an intervention which aims to assist smokers who have no immediate 
plans to quit to reducing their daily cigarette consumption. According to the misattribution 
hypothesis, reduction may change psychological well-being in three ways.  Firstly, the 
smoker may not become less dependent; and as the smoker increases the length of time 
between cigarettes smoked, they will experience longer periods of withdrawal and in-turn 
experience an increase in negative psychological symptoms. Secondly, if an individual 
successfully reduces the number of cigarettes consumed daily they may become less 
dependent on tobacco and experience a decrease in withdrawal symptoms between cigarettes, 
in-turn experiencing less negative psychological symptoms.  Thirdly, there may be no change 
in mood symptoms because of compensation. Compensation means inhaling the reduced 
number of cigarettes more intensively, thus extracting as much nicotine as when smoking 
normally (National Cancer Institute, 2001). Hughes and Carpenter (2005) reviewed fifteen 
studies and found that when smokers reduce their daily consumption of cigarettes, 
compensatory inhalation occurs.  If compensation occurs, smokers may not experience 
changes in psychological well-being. It is therefore unclear how reduction may affect 
psychological well-being under the misattribution hypothesis.  
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There is little research examining the effect of smoking reduction on psychological well-
being. There are two systematic reviews in this area: Pisinger et al. (2007) and Banham and 
Gilbody (2010). Pisinger et al. (2007) conducted a systematic review of the association 
between smoking reduction and subsequent health. This review identified one study which 
examined the effect of smoking reduction on psychological well-being (Bolliger et al., 2002).  
Bollinger et al. (2002) reported an increase in emotional well-being from baseline to twenty-
four months in individuals who had successfully reduced their smoking by at least 50%. 
However, this increase in emotional wellbeing was not significant compared with the change 
in emotional well-being of non-reducers. However, the sample sizes used in the analysis are 
too small to exclude an effect at (N=25) and non-reducers (N=285). Furthermore, the non-
reducer group included people who had reduced their smoking by less than 50%. Thus the 
two groups may not have been very different in their reduction status, which perhaps explains 
the null effect.  
 
Understanding the association between smoking reduction and change in psychological well-
being is important as smoking reduction is currently being proposed as a means to quit for 
individuals with mental health problems. Thus it is especially important to understand the 
possible impact on mental health for these people.  Banham and Gilbody (2010) 
systematically reviewed trials of smoking cessation interventions in psychiatric populations.  
The review included eight RCTs which used validated mental health symptom scales as 
outcome measures.  The review showed that people randomized to assistance with cessation 
were more likely to stop than those getting usual care or placebos.  In people randomized to 
cessation assistance there was no evidence of a marked deterioration and perhaps some 
evidence of an improvement in mental health. However, the trials obviously did not compare 
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individuals who stopped smoking to those who continued nor did they compare people who 
reduced their smoking to people who continued at the same rate thus the review does not 
show if smoking reduction is associated with a change in mental health. 
 
Smoking cessation, smoking reduction and change in positive affect 
 
The focus on positive affect is an emerging branch of psychology which focuses on 
promoting positive affect (e.g. happiness, positive emotions), rather than a sole focus on the 
absence of psychological disorder or low mood (Seligman et al., 2005).  The Action on 
Mental Health report published by the European Commission (2004) suggested that mental 
health (or psychological well-being) has two dimensions: positive mental health (feeling well) 
and negative mental health (experiencing symptoms of psychological disorder). The report 
called for research into positive mental health.  
 
There is little research on the association between smoking cessation (or reduction) and 
positive affect.  One study reported that current smokers were 2.68 (95% CI=2.00-3.59) times 
more likely to report low levels of happiness with their lives compared to non-smokers 
(Koivumaa-Honkanen et al., 2003).  In contrast, smokers most commonly endorsed reason for 
smoking is enjoyment (McEwan et al., 2008).  This indicates that smokers’ feel they may be 
less happy without cigarettes. It may encourage smokers to quit if they were confronted with 
evidence that this belief is wrong. 
 
There are no studies which investigate the association between smoking reduction and change 
in positive affect. There are two studies which investigate the association between smoking 
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cessation and happiness.  A cross-sectional survey of 879 ex-smokers’ reported changes in 
happiness following cessation (Shahab and West, 2009); 69.3% (95% CI=66.2 to 72.3) 
percent of ex-smokers reported feeling happier compared to when they were smokers, 26.6% 
reported feeling the same (95% CI: 23.7 to 29.5) and 3.3% reported that they were less happy. 
In a second study, (Shahab and West, 2012) analysed the association between length of 
abstinence in ex-smokers and happiness. Smokers who had been abstinent for more than a 
year reported being happier than smokers and were as happy as never smokers.  These studies 
do not show that stopping smoking improves happiness Firstly, reports of change in post-
cessation happiness are retrospective, thus may be susceptible to recall bias. Recall bias 
occurs when the respondents’ answer is susceptible to inaccuracies in memory (Coughlin, 
1990).  Secondly, one cannot be sure if the smoker became happy and then quit, or if the 
smoker quit and then became happy. Finally, both studies are reporting analyses of the same 
data from the UK Smoking Tool Kit Study (West 2006). 
  
Post cessation change in psychological well-being and the association with relapse 
 
Smoker’s cite stress relief as a motive for smoking (McEwen et al., 2008); thus if a smoker’s 
psychological well-being worsens as a results of a post-cessation offset effect they may be 
more likely to relapse to smoking to relieve unwanted emotion.  
 
Research indicates that adverse mood prior to quitting is associated with relapse to smoking. 
Zvolensky et al. (2009) reported that depression and anxiety symptoms at baseline were 
associated with an increased likelihood to relapse two weeks after quit day (OR=1.3, P=.01) 
(Zvolensky et al., 2009). Perez et al. (2008) reported that depressive symptoms prior to 
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quitting was associated with an increased likelihood to relapse at six months among patients 
hospitalized for acute coronary syndrome (OR=2.54, 95% CI: 1.51 to 4.27). Allen et al. 
(2009) reported that women who had given up smoking in pregnancy and then experienced 
postpartum depressive symptoms were 1.86 (95% CI: 1.31 to 2.65) times more likely to 
relapse compared to those who did not experience postpartum depressive symptoms. Zhou et 
al. (2009) systematically reviewed cohort studies to identify predictors of relapse. They 
reported that individuals who reported being bothered by symptoms of anxiety and depression 
in the past three months were more likely to relapse back to smoking (OR=1.42, 95% CI: 1.02 
to 1.99). These studies show that there is an association between psychological distress and 
subsequent relapse. However, this does not indicate that post-cessation change in 
psychological well-being (or an offset effect) is associated with relapse.   
 
I conducted a literature review of Embase, PsychInfo and Medline using terms related to 
“relapse” AND “smoking” AND “mental health” to find cohort studies which reported the 
association between post-cessation change in psychological well-being and relapse to 
smoking. After reviewing titles and abstracts of the search results: two studies were located.  
 
Burgess et al. (2002) conducted a cluster analysis to identify patterns of change in depression 
symptoms two weeks after cessation.  They identified five patterns of change in depression 
symptoms: depression symptoms rapidly increased or decreased, slowly increased or 
decreased, or rapidly increased then decreased. Burgess et al. (2002) then analysed the 
association between patterns of change in depression symptoms and rates of abstinence using 
generalised estimating equations. They reported that individuals who displayed a rapid 
increase or slow increase in depression symptoms were less likely to be abstinent at twelve 
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months (respectively, OR=5.95, P <0.01; OR=0.66, P<0.02). However, the findings of this 
study are limited.  The change in depression symptoms was assessed during the withdrawal 
period; thus, these results may be explained if those with worse withdrawal were more likely 
to relapse rather than the occurrence of long-term mood changes after cessation represent 
withdrawal severity, rather than an established change in post-cessation psychological well-
being.  
 
Yong et al. (2010) conducted a prospective cohort study of over 2000 adult smokers.  They 
reported that participants’ who reported that their psychological well-being had worsened 
were more likely to relapse (OR=1.33, 95% CI, 1.00-1.76). However, these results are 
limited, as a participants’ change in psychological well-being is a retrospective opinion; thus 
is susceptible to recall bias and does not indicate an empirically measured change in 
psychological well-being. The most accurate method to determine post-cessation change in 
psychological well-being would be to calculate the difference between mental health scores 
pre-cessation and before the time at which the individual relapsed. 
 
In sum, the studies reviewed show that change in mood is associated with an increased 
likelihood to relapse. However, these studies do not provide robust evidence that changes in 
mood after cessation prompt people to relapse.  It is important to investigate this for two 
reasons. Firstly, it is important to understand an offset effect is associated with increased 
relapse.  Secondly, it could be that some smokers do use smoking to self-medicate and 
prevent negative psychological symptoms or improve psychological well-being.  If they 
relapse because cessation uncovers this, then knowing that this is the case is the first stage of 
being able to prevent this in future.   
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CONCLUSION 
 
Firstly, research investigating the effect of smoking cessation on change in psychological 
well-being is limited.  Some studies are not applicable to long-term changes in psychological 
well-being as they assess well-being during the withdrawal period (Gilbert et al., 1998a). 
Secondly, the most robust longitudinal data (Cohen and Lichtenstein, 1990; Parrott, 1995) 
(Carey et al., 1993) only show a reduction in negative psychological symptoms follows 
smoking cessation; which does not necessarily imply that positive affect increases. 
Furthermore, to improve rigor studies require use of a biochemically validated measure of 
cessation, and instruments known to provide valid assessments of psychological well-being. 
 
Secondly, there is very little research examining the effect of smoking reduction on changes 
in psychological well-being. There is only one study with a longitudinal design (Bolliger et 
al., 2002); but the study may have lacked power to detect a plausible influence of reduction on 
psychological distress.  
 
Thirdly, there are two cross-sectional studies showing that ex-smokers report feeling happier 
since quitting smoking (Shahab and West, 2009; Shahab and West, 2012). However, there are 
no longitudinal cohort studies investigating the change in positive affect post cessation or 
reduction.  
 
Research indicates that psychological distress prior to cessation are associated with an 
increased likelihood of relapse (Allen et al., 2009; Perez et al., 2008; Zvolensky et al., 2009; 
Zhou et al. 2009). However, there have been no studies to date which show if worsening 
  
 
292 
 
psychological well-being occurring after cessation but outside of the normal withdrawal 
period is associated with relapse.  There are three studies which provide insight into the 
association between post-cessation change in psychological well-being and smoking 
cessation. However in one study the timing of outcome assessment does not warrant a robust 
conclusion (Park, 2009), another study is likely to be assessing withdrawal severity (Burgess 
et al., 2002) and the final study is susceptible to recall bias (Yong et al., 2009).  
 
Primary study objectives 
 
An analysis of the McNeil trials will permit us to analyse the associations in a prospective 
longitudinal study with a sufficiently large sample, using biochemically validated cessation 
and valid measures of psychological distress and positive affect.  Analysis of these data will 
allow us to examine the association between smoking cessation, smoking reduction and 
changes in psychological distress and positive affect.  Also, these data will permit us to 
examine whether worsening mood occurring perhaps as an offset effect after cessation is 
associated with relapse.  
 
Primary questions  
 
Is successful abstinence from cigarette consumption associated with changes in psychological 
distress and positive affect?  
 
Is successful reduction in daily cigarette consumption associated with an changes in 
psychological distress and positive affect?  
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Is successful abstinence or successful reduction in smoking associated with a higher or lower 
risk of an adverse mental health event? 
 
Are post-cessation and post-reduction changes in psychological well-being associated with an 
increase risk of relapse? 
 
Secondary study objectives  
 
If time and resources permit, these data will also be used to provide a descriptive account of 
changes in people’s smoking behaviour.  Smoking reduction is a novel public health strategy.  
It is currently being considered by the English National Health Service (NICE, 2011) 
(National Centre of Smoking Cessation and Training, 2011). However, there is uncertainty 
about the whether or not encouraging reduction promotes cessation or deters cessation; and, in 
particular, whether people can maintain a reduced consumption level.   
 
I will be able to assess how many people have successfully maintained reduction, successfully 
reduced-to-quit, relapsed after attempting to reduce. 
 
METHOD 
 
Required variables 
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Data from seven randomised controlled trials of nicotine replacement therapy for use in 
smoking reduction interventions will be provided by McNeill pharmaceutical company. I will 
require access to the following baseline data for each participant 
–Date of birth or age 
–Sex 
–Participant randomization ID 
–Intention/interest to quit 
–Contemplation ladder 
–Stages of change 
 
I will require the following individual participant data, recorded at every available time-point 
(including baseline): 
–Which follow-up point the data were recorded (e.g. baseline, week one, etc) and date of the 
participant’s visit 
–Any adverse event information recorded at follow-up visits 
–CO ppm measurement after 15 smoke free minutes and time for CO measurement 
–Self-reported cigarettes consumed per day (CPD) 
–Single question responses from the RAND-36 
–Global score for the RAND-36 
–Single question responses from the Withdrawal Symptoms Questionnaire  
–Fagerström Test of Nicotine Dependence Score 
–Smoking history 
–Smoking status 
 
  
 
295 
 
Analysis 
 
Firstly, participants will be categorised according to their smoking behaviours. All 
participants who were enrolled and followed up during the McNeill trials will have stopped, 
reduced and continued smoking at different time points. Accordingly, each participant will 
need to be categorised based upon their individual smoking patterns. Participants will be 
categorised according to the groups described below.  
 
Assessing baseline 
 
Baseline will be assessed for each person. Each participant’s baseline characteristics will be 
recorded at the closest time-point, to the first change in smoking status which was used to 
categorise them (i.e. pre-cessation or pre-reduction)  
 
Participants 
 
Reducers: Some participants may permanently reduce the number of cigarettes consumed per 
day (CPD). The definition of reducers will be based upon a key review on the feasibility of 
smoking reduction conducted by Hughes and Carpenter (Hughes and Carpenter, 2005). 
Hughes (2005) defined smoking reduction as an achievement of ≥ 50% reduction in CCPD. 
However, ≥ 50% reduction in CPD from baseline will also include people who have 
completely stopped smoking.  As smoking zero cigarettes per day is total abstinence, the 
current study will consider any amount of daily, first-hand cigarette inhalation from ‘one puff’ 
daily up to a reduction in CPD ≥ 50% from daily baseline consumption. 
  
 
296 
 
Successful reduction will be defined as reporting <50% of baseline consumption for a 
minimum of two consecutive months will be considered a successful reducer. Self-reported 
smoking reduction must also be validated by an expired CO concentration lower than baseline 
on every occasion.  
 
Successful abstainers: Successful abstainers will be considered individuals who maintain two 
continuous abstinence starting at any time before the end of treatment. This is a robust 
measurement of smoking abstinence (West et al., 2005). Self-reported abstinence at each 
follow-up must be biochemically validated by an expired CO level of <10 ppm. Biologically-
validated cessation must be reported at each time their mental health scores are considered for 
analysis (except pre-cessation scores). 
 
Reduction relapsers: Relapse is defined as smoking more than 50% of baseline consumption 
or having a CO>baseline. 
 
Cessation relapsers: This is defined as smoking more than 5 cigarettes since last observed or 
having a CO >=10ppm. 
 
Continuing smokers (matched comparison group for study questions 1 and 2): Not all 
participants quit.  Continuing smokers will be considered as individuals who have reported to 
have continued smoking from the initial assessment, and at every subsequent time point and 
who do not meet the criteria for reduction.  
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The continuing smokers group will be used in the main analysis to compare the change in 
mental health between those who are successful reducers or abstainers. However, the review 
of the literature suggests that continuing smokers are likely to suffer from higher negative 
affect at baseline compared to  abstainers or reducers. Likewise, the groups may differ in 
other ways that may influence the change in psychological symptoms or well-being.  I will 
therefore account for these baseline differences in the study. Accordingly, it is important to 
remove the influence of potential confounding variables in the analysis.  One method of doing 
so is to use propensity matching.   
 
Propensity score matching (PSM) 
 
Propensity score matching will be used to match groups on baseline sociodemographic and 
psychological covariates rather than adjusting for covariates. There are several advantages to 
using propensity score matching in comparison to adjusting for covariates.   
 
Random assignment of participants to groups is gold standard methodology to obtain 
interferences about causality.  Random assignment ensures that the groups are similar in terms 
of background characteristics; this enables a sound comparison of the groups’ outcomes.  
However, when analyzing observational data, one cannot randomize participants to groups.  
For example, in the current study will compare quitters with continuing smokers, however 
one cannot randomize people to maintain abstinence, nor to continuing smoking.  Thus, one 
cannot assert that the groups are similarly matched on background characteristics.  
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One method of accounting for this problem is to fit a linear regression which includes 
background characteristics as covariates, however, the groups in the analysis may still differ. 
Propensity score matching differs from regression models as it balances the distribution of 
background characteristics between the groups. Regression models have been criticized for 
producing misleading results when including too many covariates (Concato et al., 1993); this 
can be overcome by matching groups, rather than adjusting for numerous covariates.  
Additionally, interpretation of a regression model is limited when the number of cases for 
each covariate characteristic is low.  This has been found to bias the parameter estimates, in 
turn affecting validity of the regression coefficients (Cepeda et al., 2003; Peduzzi et al., 1996). 
 
Propensity score matching procedure for groups 
 
To ensure the continuing smoker group will be an adequate comparison group I will use 
propensity score matching. A propensity score is a conditional probability that represents how 
likely a participant is to be a case (reducer or abstainer) compared to a control (continuing 
smoker), based on their baseline characteristics. Matching Propensity score matching will 
balance the distribution of socio-demographic and psychological covariates between the 
continuing smokers group and other groups (Thoemmes and Kim, 2011). Propensity score 
matching will involve three stages. 
 
Stage 1: Estimation of propensity score  
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Participants’ propensity scores will be estimated using logistic regression (conducted on 
SPSS) in which smoking status category will be used as the outcome variable and the 
covariates as predictors.  
 
Covariates available in the McNeil dataset will be chosen based upon their association with 
one’s motivation to quit (Haukkala, 2000), their association with likelihood of attempting to 
quit (Zhou et al., 2009), changing smoking status (Berlin and Covey, 2006) or relapsing 
(Zhou et al., 2009). The following covariates will be used to determine each participant’s 
propensity score: age, sex, treatment group, baseline CPD, baseline RAND-36 MCS, baseline 
Fagerström Test of Nicotine Dependence score, number of years smoking, number of 
previous quit attempts and baseline intention/interest to quit score. These covariates will then 
be entered into a regression model using a backward stepwise technique.  This will determine 
which covariates have the highest association with the participants’ smoking status.  Only 
covariates which reach statistical significance (P<0.05) will be entered into the final 
propensity score model. 
 
Stage 2: Matching participants’ propensity scores 
 
Participants will be matched using a 1:1 nearest neighbour technique, which will be based 
upon an optimal matching algorithm. This will match participants who have approximately 
the same propensity scores; scores will be matched in a manner which will minimise the 
average absolute distance between the propensity scores of all units in the whole matched 
sample (Thoemmes and Kim, 2011).  
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Stage 3: Checking model adequacy and underlying assumptions 
A propensity score model will be checked to ensure that a balance of means and variances has 
been achieved for covariates (known as the balance property) and to determine the overlap 
between the propensity score distribution (the common support region) (Thoemmes and Kim, 
2011). To check the balance property between the groups, I will examine the standardised 
differences of each groups’ covariates before and after matching.  
 
To ensure the propensity score distribution has sufficient overlap I will examine the range of 
the propensity score distributions in both groups. If the overlap between the two propensity 
score distributions is broad, this allows for causal effects estimates over the full range of 
propensity scores in the sample. Whereas small common support regions restrict the 
estimation of a causal effect. Units (a matched pair) which fall outside of the common support 
region will be removed from the analysis; this is advised to improve the balance between the 
matched groups (Ho et al., 2007) 
 
Outcome measures 
 
The current study will use the following data as primary outcome measures during statistical 
analyses. 
 
Mental health: The RAND-36 (SF-36) (Hays et al., 1993) is a short form self-report 
questionnaire designed to detect changes in health status. The scale includes two composite 
scores which are of interest in the current study; the mental health composite score (MHC) 
and the Energy and Vitality Index (EVI). The MCS will be used to measure changes in 
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negative mood (Gill et al., 2007; Hays and Morales, 2001). Low scores on the MHC indicate 
that the participant is likely to be experiencing psychological symptoms which may impede 
life functioning (Hays et al., 1998). The EVI will be used to measure changes in positive 
psychological-wellbeing (Ware et al., 1993). High scores on the EVI indicate higher levels of 
positive psychological well-being.   
 
Withdrawal symptoms questionnaire (WSQ): The current study will only analyse anxiety and 
depression single scale items from the WSQ (American Psychiatric Association, 1994). These 
will be used to represent change in anxiety and depression. These items are ranked using a 
five-point likert scale to assess the degree of nicotine withdrawal (0=not at all, 1=somewhat, 
2=moderately so, 3=very much so, 4=extremely so).  This is ordinal data however is it also a 
continuous scale, thus will be considered a continuous variable in the analysis. 
 
Adverse mental health events: All McNeil studies recorded adverse events at all follow-up 
time-points.  The following events will be considered a sign of an adverse mental health 
event: new diagnosis of anxiety or depression mental health disorder, admission to a mental 
health unit for anxiety or depression, referral to psychology or counselling for anxiety or 
depression and referral to psychiatry for anxiety or depression. 
 
The following variables will be used for analyses:  
 
Groups: rapid reducers, gradual reducers, long-term reducers,  
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successful abstainers, rapid reduction relapsers, gradual reduction relapsers, long-term 
reduction relapsers, cessation relapsers, relapse improvers and decliners (see section 3.7.4), 
continuing smokers (matched comparison group) 
 
Mental health measures: MCS, EVI, anxiety WSQ, depression WSQ, adverse events. 
Statistical procedures for study objectives 
 
Firstly, mental health composite and subscale scores will be calculated for each participant. 
All participants’ responses on the RAND-36 will be scored to determine mental health 
composite scores (MCS) and the energy and vitality scores (EVI) and global scores. The 
procedure outlined by Hayes et al. (1993) and Ware et al. (1993) for scoring composite scores 
will be followed. This scoring method will be applied to the data acquired at each time point 
that the participant completed the RAND-36. This will provide a negative mental health score 
(MCS) and positive mental health score (EVI) and a quality of life score (RAND-36 total 
score) for each individual participant at every follow-up visit they attended.  If there are any 
missing responses on the RAND-36 the individual’s data for that time point will be excluded 
from analysis. 
 
Is successful abstinence from cigarette consumption associated with an improvement or 
worsening of psychological well-being? 
 
SPSS for Windows will be used to create a linear regression model to determine if smoking 
status is associated with a change in mental health. Successful abstainers and continuing 
smokers will be coded as categorical predictor variables (1 and 0). A separate model using 
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abstainers and continuing smokers as the predictive variable will be fit for each mental health 
outcome: MSC, EVI, anxiety WSQ, depression WSQ. A separate model will be run for each 
month.  
 
Is successful reduction in daily cigarette consumption associated with an improvement or 
worsening of psychological well-being?  
 
To determine the effect of smoking reduction on psychological well-being SPSS for windows 
will be used to conduct a simple linear regression. This analysis will determine if smoking 
status associated with a change in mental health. Successful reducers and intervention 
continuing smokers will be coded as categorical predictor variables (1 and 0). A separate 
model for each reduction group successful reducers and continuing smokers as the predictive 
variable will be fit for each mental health outcome: MSC, EVI, RAND-36 anxiety WSQ, 
depression WSQ.  A regression will be run on a month by month basis, in which there are a 
sufficient number of participants.   
 
Statistical procedure: is successful abstinence or successful reduction in smoking associated 
with an increased risk of an adverse mental health event? 
 
A Cox regression (Cox proportional hazards model) will be conducted using SPSS 17 to 
determine there is an increased risk of experiencing an adverse mental health event following 
cessation or reduction in comparison to continuing smokers. The use of a Cox regression 
model will allow us to determine the adjusted hazard ratio (HR). This method is not common 
in smoking cessation research.  However, the adjusted HR will allow us to account for the 
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occurrence of censored data.  Censored data in the current study will occur as one is only able 
to assert that the patient remained free of an adverse mental health event during the 
timeframes outlined by the dataset. 
 
I will match groups using propensity score matching.  Groups will be matched on covariates 
which can influence likelihood of experiencing anxiety and depression.  The following factors 
have been found associated with an increased likelihood of experiencing anxiety or 
depression; sex (Piccinelli and Wilkinson, 2000), age (Christensen et al., 1999) and previous 
report of negative psychological well-being (MHC) (Horwath et al., 1992).  
 
Statistical procedure for question four: Is post-cessation and post reduction improvement or 
worsening or psychological well-being associated with an increase risk of relapse? 
 
Step one: stratification of relapser groups 
 
Firstly, participants in relapse groups will be stratified classified into those where 
psychological well being improved and those where it decreased after cessation (Figure 1). To 
determine the direction of change the individual’s MHC and EVI scores at baseline (T1) will 
be used (see section 2.4 for assessment of individual baseline), and the individual’s MHC and 
EVI scores at the closest follow-up prior to the relapse event (T2) in which the individual 
reports a minimum of six weeks (Biologically-validated) abstinence. The individuals MHC 
score at T1 will be subtracted from the individual’s MHC score at T2; this will give us the 
difference between the MHC scores. The difference will be used to determine the direction of 
change in psychological well being. 
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This will be repeated to calculate the change EVI scores.  The difference in T2 and T1 scores 
will result in a positive (+) or a negative number (-); it is the +/-.  Will represent a positive (+) 
or negative (-) change in psychological well being. It is the +/- value of the number which will 
be used to stratify the relapsers. 
 
 
 
There will be two groups for each smoking status category categorized depending on the 
direction of change in psychological well-being (Table 1).  These will be developed according 
to interpretation of the MHC and EVI scores. Low scores (≤38) on the MHC are likely to 
indicate the presence of psychological symptoms which may impede life functioning, high 
scores (≥53) on the MHC are not likely to perceive psychological symptoms which may 
impede life functioning (Hays et al., 1998).  Therefore, a positive difference will indicate an 
improvement in mental health, and a negative difference will indicate a worsening of mental 
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health. Low scores on the EVI indicate a lower level of happiness; high scores on the EVI 
indicate a higher level of happiness.  Therefore, therefore a positive difference will indicate an 
increase in happiness, and a negative difference will indicate a decrease in happiness.   
 
Table 1: groups to be developed from stratification technique 
Long-term reduction relapsers Improvers1 
Decliners2 
Abstainers Improvers1 
Decliners2 
1= determined by a positive (+) change in psychological well-being, 2=determined by a negative (-) 
change in psychological well-being 
 
Thus, if an individual displays negative changes in MHC and EVI scores this will indicate 
that their psychological well-being worsened prior to relapse (Decliner). And, if an individual 
displays positive changes in MHC and EVI scores this will indicate that their psychological 
well-being improved prior to relapse (Improver). Each type of smoking category relapse 
group will be stratified based on this technique (Table 1). Please see Table 2 for an example 
of the stratification technique. 
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Table 2: stratification of relapsers based on direction of change in MHC and EVI scores 
Relapse 
group 
MHC score 
at baseline1 
MHC at 
closest time-
point prior to 
relapse2 
Direction of 
difference in 
MSC scores 
EVI score 
at 
baseline1 
EVI score at 
closest time-
point prior to 
relapse2 
Direction of 
difference in 
EVI scores 
Stratification 
based on 
change in 
psychological 
well-being 
Reduction 
relapser 
30 38 +8 50 55 +5 Improver 
(rapid 
reduction) 
Reduction 
relapser 
52 40 -12 48 44 -4 Decliner 
(long-term 
reduction) 
Cessation 
relapser 
40 35 -5 45 39 -6 Decliner 
(gradual 
reduction) 
Cessation 
relapser 
38 42 +4 43 48 +5 Improver 
(cessation) 
Baseline MHC and EVI scores will be obtained at the closest time point prior to the change in smoking behaviour in which dictates 
the participants smoking category (e.g. rapid reducer or abstainer). 
Pre-relapse MHC and EVI scores will be obtained at the closest time-point to relapse. The individual must report at least six weeks 
Biologically-validated abstinence at this time point. 
 
Survival curve analysis of time to relapse 
 
To determine the pattern of relapse related to pre-relapse change in mental health a survival 
curve will be plot.  The survival curve will show the time to relapse between decliners and 
improvers (Figure 2.). This will provide a visualisation of the number of decliners and number 
of improvers who maintained abstinent or reduced on a monthly basis. 
 
Calculating the hazard ratio (HR) to determine the likelihood of relapse  
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A Cox regression (Cox proportional hazards model) will be conducted using SPSS 17 to 
determine if there are any significant differences between the time to relapse of improvers and 
decliners. The use of a Cox regression model will allow us to determine the adjusted HR.  The 
adjusted HR will allow us to control for variables which may also affect relapse rate.  I will 
control for age, baseline FTND score and previous number of failed quit attempts (as recorded 
via smoking history section); these factors have all been found associated with an increased 
likelihood to relapse (Zhou et al., 2009).  
 
Secondary study objectives: Descriptive statistics of smoking reduction behaviour 
 
I will be able to report descriptive data showing how many people have successfully 
maintained reduction, successfully reduced then quit, and relapsed after reducing (Table 3). 
 
Table 3: Descriptive statistics of smoking reduction behavior 
Number of people who successfully maintained reduction N(%) 
Number of successful successfully reduced then quit N(%) 
Number of people who relapsed after reducing N(%) 
 
CONCLUSIONS 
 
These data will show that smoking cessation and smoking reduction are associated with either 
an improvement or worsening of psychological well-being.  These data will also elucidate if 
there is an offset effect from smoking cessation, and if this offset effect is associated with an 
increased likelihood to relapse back to smoking.  Thirdly, I will be able to show if smoking 
reduction is maintainable and how many people quit after reducing their smoking.   
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12. METHODS FOR COMBINING MCNEIL TRIAL DATA (CHAPTER 
THREE) 
 
McNeil pharmaceutical company uploaded each trial’s data to a secured server held by 
Johnson and Johnson. Each trial’s data were uploaded to a separate folder by McNeil, and 
downloaded separately by GT.  Each trial’s folder contained 10 or more text (.txt) files.  Each 
text file contained numerous variables in a tab-delimitated format (Table 11.1 below).  
 
Most trials text files were labelled the same and within each file was similar variable content. 
However, the number of variables within each text file differed between the trials.  For 
example, the “adverse event” text file contained seventeen variables which measured adverse 
events for Trial 1, but for Trial 2 the “adverse events” file contained twenty variables which 
also measured adverse events.  These differences between trials existed as some trials 
included additional variables to measure the same construct. 
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Table 11.1 Trials' original data contents 
Original text 
file label 
Text file content Description of variables Trials which supplied text file Number of variables within 
text file 
AE Adverse events Dates pertaining to start, end of event, comments of event, severity of event, coding 
information for event.  
Trial 1 Switzerland 17 
Trial 2 Denmark 20 
Trial 3 Australia 21 
Trial 4 US 18 
Trial 5 Germany 24 
Trial 6 Switzerland 21 
CRAVEQ Relief of craving 
questionnaire 
Self-reported effects of smoking on withdrawal symptoms Trial 1 Switzerland 13 
Trial 2 Denmark 12 
Trial 3 Australia Located in different file 
Trial 4 US 12 
Trial 5 Germany 12 
Trial 6 Switzerland Not available 
DEM Demography Age, sex  Trial 1 Switzerland 4 
Trial 2 Denmark 4 
Trial 3 Australia 4 
Trial 4 US 4 
Trial 5 Germany 4 
Trial 6 Switzerland 4 
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DOS Dispensed nicotine 
replacement therapy 
Amount of dispensed NRT medication Trial 1 Switzerland 26 
Trial 2 Denmark 10 
Trial 3 Australia 23 
Trial 4 US 23 
Trial 5 Germany 23 
Trial 6 Switzerland 9 
FTN Fagerström Test for  Nicotine 
Dependence 
Self-reported answers to items on the FTND questionnaire and global score Trial 1 Switzerland 18 
Trial 2 Denmark 18 
Trial 3 Australia 18 
Trial 4 US 18 
Trial 5 Germany 18 
Trial 6 Switzerland 18 
INTQUIT Intention to quit Self-reported answers pertaining to intention to quit or reduce smoking Trial 1 Switzerland 12 
Trial 2 Denmark 11 
Trial 3 Australia 18 
Trial 4 US 18 
Trial 5 Germany 18 
Trial 6 Switzerland 10 
LAB Laboratory results Blood test results 2 Trial 2 Denmark 22 
Trial 3 Australia 22 
NU Nicotine use Results for expired carbon monoxide  Trial 1 Switzerland 10 
Trial 2 Denmark 10 
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Trial 3 Australia 10 
Trial 4 US 10 
Trial 5 Germany 10 
Trial 6 Switzerland 11 
QOL DATA SF-36 subscales SF-36 subscale scores Trial 1 Switzerland 9 
Trial 2 Denmark 9 
Trial 3 Australia 9 
Trial 4 US 9 
Trial 5 Germany 9 
Trial 6 Switzerland Not recorded 
SMINCHK Smoking status check CPD, self-reported current smoking behaviour Trial 1 Switzerland 18 
Trial 2 Denmark 18 
Trial 3 Australia 22 
Trial 4 US 19 
Trial 5 Germany 18 
Trial 6 Switzerland 15 
SMKHIST Smoking history Past smoking behaviour Trial 1 Switzerland 41 
Trial 2 Denmark 37 
Trial 3 Australia 39 
Trial 4 US 44 
Trial 5 Germany 39 
Trial 6 Switzerland 16 
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TRT Allocation of treatment 
groups 
Randomisation sequence Trial 1 Switzerland 5 
Trial 2 Denmark 5 
Trial 3 Australia 7 
Trial 4 US 5 
Trial 5 Germany 7 
Trial 6 Switzerland 7 
VISIT Visit dates Each participants visit dates Trial 1 Switzerland 7 
Trial 2 Denmark 10 
Trial 3 Australia 10 
Trial 4 US 11 
Trial 5 Germany 11 
Trial 6 Switzerland 10 
WSQ Withdrawal symptoms 
questionnaire 
Cognitive and psychological nicotine withdrawal symptoms Trial 1 Switzerland 21 
Trial 2 Denmark 21 
Trial 3 Australia 28 
Trial 4 US 21 
Trial 5 Germany 21 
Trial 6 Switzerland Not recorded 
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Transforming downloaded data into useable files 
 
Original file format: Within each text file the variables were stored in a ‘long’ format.  This 
means that the file was horizontally sorted by variable, vertically sorted by participant 
identifier and then vertically sorted by follow-up point (Figure 11.1, below). For the 
secondary analyses the data needed to be in a ‘wide’ format. ‘Wide’ means that the file is 
horizontally sorted by variable, then by follow-up point, and vertically sorted by participant 
identifier (Figure 11.2). 
 
 
Figure 11.1 Trial in 'long format' 
 
Converting data to ‘wide’ format 
 
To convert each text file from a ‘long’ format I first had to develop a continuous time variable 
for when the follow-up data were recorded.  Each text file contained a follow-up point 
variable as a string which was converted to a continuous variable of weeks in the year.  For 
example:  ‘baseline’, ‘week 3’, ‘month 6’ became, ‘0’, ‘3’, ‘26’ weeks.  Then the ‘reshape’ 
command was used to convert each text file into a ‘wide’ format in STATA12.  Random 
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checks of the files against the original text files were performed to ensure that there were no 
errors.  
 
 
Figure 11.2 Trial in 'wide format' 
 
Differences between trials’ measurement of variables 
 
I examined each trial’s text files to determine consistency of variable content across trial’s 
text files.  All text files which did not have relevant data for this study were excluded.  Next 
all text files were against each trials’ questionnaire/outcome-set to ensure that the variables 
within the text files were consistently named, stored, and measured across the trials. Variables 
used to determine exposure and outcome variables (smoking status and mental health 
outcomes) were consistently labelled, stored and measured across the trials. Adverse events, 
demographic information, prescribed NRT, Fagerström Test of Nicotine Dependence 
(FTND), expired CO, smoke history, smoking status, VISIT, relief from craving and 
withdrawal symptoms were the also the same across trials, except for in Trial 6.  
 
Trial 6 was missing SF-36 data, which was used as an outcome variable in Chapter Four, an 
important covariate in Chapter Five, and the exposure variable in Chapter Six.  In addition, 
Trial 6 was missing the ‘Relief from craving questionnaire’ which was an important covariate 
  
 
316 
 
required for the propensity scoring matching techniques used in Chapters 4 and 5. For these 
reasons, Trial 6 was excluded from the McNeil trial analyses. 
 
Variables within ‘Relief of craving’, ‘Intention to quit’ and ‘treatment allocation’ varied 
between trials. For ‘Relief of craving’, all trials measured the same three questions; however 
the remaining four questions were measured differently across all trials. Variables measured 
for ‘Intention to quit’ were also different.  Each trial used different questions and a different 
number of questions to measure ‘Intention to quit’, and also participant’s answers were not 
consistently coded as categorical or continuous across the trials. Ideally each variable would 
have measured its content in the same manner, however, as this was not the case, this was 
accounted for by within trial analyses described in Chapters 4 to 6.  
 
‘Treatment allocation’ was slightly different for each trial. This is as some trials had two 
active treatment groups (e.g. 2mg gum and 4mg gum), whereas some trials had one active 
treatment group. Secondly, the treatments were different between the trials.  To account for 
these differences participants were coded as allocated to receive either active or placebo NRT. 
This is justified for three reasons 1.) This study concerns receipt of treatment, rather than the 
type of treatment 2.) The treatments were quite similar and 3.) There is no difference in 
effectiveness between different forms of NRT (Stead et al., 2012). Finally, potential 
differences between trials’ treatments were accounted for by adjustment for Trial ID when 
necessary, as described within Chapters 4 to 6.  
 
There was a slight variation between the trials’ variables recorded within the SF-36 text files.  
The US trial included an additional section on the SF-36 which included questions about 
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“smoking-related quality of life”, these assessed smoking related symptoms such as coughing 
and phlegm.  However, these additional questions were not used to calculate the subscale of 
interest to this thesis (emotional well-being subscale). Therefore this difference between the 
trials’ versions of the SF-36 did not influence the analyses reported in this thesis.  
 
Importantly, all variables used to determine each secondary analyses ‘exposure’ and 
‘outcome’ variables were measured in the same manner across trials.  All differences between 
covariates were accounted for by a series of sensitivity analyses and statistical adjustment as 
described within each chapter.  
 
Combining text files within trials 
 
The next step was to combine all text files within each trial, by participant ID.  This produced 
one dataset per trial, within which one can browse each participant’s variables at each time-
point, by participant ID. For example, in Figure 11.3 text files 1 and 2 from trial 1 have been 
merged for each participant.  To combine trials text files the ‘merge 1:1’ command was used 
in STATA12.  Random checks were performed against the original trial files to ensure no 
errors were made.   
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Figure 11.3 Combining variable text files for the same trial 
 
Appending the trials 
 
The ‘append’ command (STATA13) in was used to append each trial’s merged data to form 
one dataset (Figure 11.4). Variables which were measured differently, or which measured 
similar constructs were not appended. Only variables which measured to the exact same 
question/variable, and which were measured in exactly the same manner were combined 
across trials (Table 3.1, Chapter 3). However, as excluding variables which were measured 
differently may have omitted important information about the associations in question, a 
series of within-trial sensitivity analyses were conducted to explore this (described in 
Chapters Four to Six).  
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Figure 11.4 Appending different trials into one dataset 
  
  
 
320 
 
13. MANUSCRIPT SUBMITTED FOR PUBLICATION IN THE BRITISH 
JOURNAL OF PSYCHIATRY (CHAPTER FOUR) 
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14. CHARACTERISTICS OF BASELINE COVARIATES (CHAPTER FOUR) 
 
Characteristics of baseline variables entered into logistic regression models to determine smoking status at follow-up 
Variable group Across trials Within trials 
 
 
Trial 96NNIN016 98NNCG014 96NNIN027 98NNCG017 980CHC90210013 
Nicotine dependency 
FTND (continuous variable; 
range 0 to 10; 0=low 
dependency) 
FTND FTND FTND FTND FTND 
Treatment status 
Treatment status (binary 
variable; 0=placebo 1=active) 
Treatment status Treatment status Treatment status Treatment status Treatment status 
Demographic Age (continuous variable) Age Age Age Age Age 
 
Sex (categorical variable, 
1=Male 2=female) 
Sex Sex Sex Sex Sex 
Intention to quit  
How much does a part of 
you want to go on 
smoking? (continuous 
variable; range 0 to 3; 
0=not at all, 3=a lot) 
Motivation to quit 
smoking? (continuous; 
range 0 to 10; 
10=maximum) 
Likelihood of not smoking in 
one year (continuous; range 0 to 
10; 10=maximum) 
Likelihood of not 
smoking in one year 
Likelihood of not 
smoking in one year 
   
Likelihood of quitting smoking 
 
Likelihood of quitting 
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during the next 6 months 
(continuous; range 0 to 10; 
10=maximum) 
smoking during the next 
6 months 
Intention to reduce 
 
What is your personal goal 
in terms of cigarettes per 
day? (continuous variable) 
Motivation to reduce 
smoking from current 
level? (continuous; range 
0 to 10; 10=maximum) 
Likelihood within one year from 
now will be smoking at least 
50% less than current level 
(continuous; range 0 to 10; 
10=maximum) 
Likelihood within one 
year from now will be 
smoking at least 50% 
less than current level 
Likelihood within one 
year from now will be 
smoking at least 50% 
less than current level 
   
Likelihood of making a serious 
attempt to reduce smoking 
during the next month 
(continuous; range 0 to 10; 
10=maximum) 
Likelihood of making a 
serious attempt to 
reduce smoking during 
the next month 
Likelihood of making a 
serious attempt to reduce 
smoking during the next 
month 
   
Likelihood of reducing smoking 
by 50% (continuous; range 0 to 
10; 10=maximum) 
Likelihood of reducing 
smoking by 50% 
Likelihood of reducing 
smoking by 50% 
Smoking history 
Age started regular smoking 
(continuous variable) 
Age started regular 
smoking 
Age started regular 
smoking 
Age started regular smoking 
Age started regular 
smoking 
Age started regular 
smoking 
Time since last tried to quit 
(continuous variable 
Time since last tried to 
quit) 
Time since last tried to 
quit 
Time since last tried to quit 
Time since last tried to 
quit 
Time since last tried to 
quit 
How long time was the last 
time you tried to stop? 
How long time was the last 
time you tried to stop? 
How long time was the 
last time you tried to stop? 
How long time was the last time 
you tried to stop? 
How long time was the 
last time you tried to 
How long time was the 
last time you tried to 
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(categorical variable; range 1 
to 3; 1= 0 to 6 months, 3= >12 
months)* 
stop? stop? 
Longest period without 
smoking (categorical variable; 
range 1 to 4; 1= <1 week, 4= 
>3 months)* 
Longest period without 
smoking 
Longest period without 
smoking 
Longest period without smoking 
Longest period without 
smoking 
Longest period without 
smoking 
Times Tried to Quit 
Smoking? (categorical 
variable; range 0 to 4; 
0=never, 4=more than 10 
times)* 
Times Tried to Quit 
Smoking 
Times tried to quit 
smoking 
Times tried to quit smoking 
Times tried to quit 
smoking 
Times tried to quit 
smoking 
SF-36 
SF-36 mental health score 
(continuous variable; range 0 
to 100; 0=worse mental 
health) 
SF-36 mental health score SF-36 mental health score SF-36 mental health score 
SF-36 mental health 
score 
SF-36 mental health 
score 
Cigarettes per day 
(CPD) 
CPD (continuous variable) CPD CPD CPD CPD CPD 
Relief from smoking 
questionnaire 
Experience from last cigarette 
(continuous variable; range 1 
to 5; 1=very unpleasant, 
5=very pleasant) 
Experience from last 
cigarette 
Experience from last 
cigarette 
Experience from last cigarette 
Experience from last 
cigarette 
Experience from last 
cigarette 
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Calming effect of smoking 
(continuous variable; range 0 
to 10; 10=maximum) 
Calming effect of smoking 
Calming effects of 
smoking 
Calming effect of smoking 
Calming effect of 
smoking 
Calming effect of 
smoking 
 
Unpleasant symptoms 
from your last cigarette 
(continuous variable; 
range 0 to 4; 0=not at all, 
4=very strong) 
    
Pepping up feeling from 
smoking (continuous variable; 
range 0 to 10; 10=maximum) 
Pepping up feeling from 
smoking 
Pepping up feeling from 
smoking 
Pepping up feeling from 
smoking 
Pepping up feeling from 
smoking 
Pepping up feeling from 
smoking 
  
Strength of urges to 
smoke (continuous; range 
0 to 10; 10=maximum) 
Strength of urges to smoke 
Strength of urges to 
smoke 
Strength of urges to 
smoke 
  
Satisfaction from smoking 
(continuous; range 0 to 
10; 10=maximum) 
Satisfaction from smoking 
Satisfaction from 
smoking 
Satisfaction from 
smoking 
  
Frequency of urges to 
smoke (continuous; range 
0 to 10; 10=maximum) 
Frequency of urges to smoke 
Frequency of urges to 
smoke 
Frequency of urges to 
smoke 
Highlight in grey indicates variable was measures consistently across trials 
* indicates categorical variable treated as continuous 
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15. PSM SENSITIVITY MODELS (CHAPTER FOUR) 
 
PSM sensitivity models: Odds ratios and 95% CI for baseline predictors of smoking status at follow-up 
Within/across trials Trial ID Important predictors OR (quit=1) 95% CI 
Within trials 
1 
FTND (high score = more dependent) 0.52 0.36 to 0.74 
Active treatment (active=1) 0.41 0.09 to 1.86 
Age started smoking 1.38 1.18 to 1.62 
Calming effect from smoking (high score=maximum effect) 2.15 1.15 to 4.00 
Number of unpleasant symptoms from smoking 2.17 1.12 to 4.2 
2 
FTND 0.87 0.59 to 1.27 
Active treatment 11.65 1.38 to 98.17 
Time to last cessation attempt 3.74 0.85 to 16.38 
 
3 
FTND (high score = more dependent) 0.98 0.74 to 1.30 
Active treatment (active=1) 3.06 0.77 to 12.14 
Longest period without smoking 1.87 1.07 to 3.26 
4 
FTND (high score = more dependent) 0.80 0.55 to 1.16 
Active treatment (active=1) 2.91 0.50 to 16.79 
5 FTND (high score = more dependent) 0.85 0.62 to 1.16 
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Active treatment (active=1) 6.07 1.75 to 21.05 
Pleasant experience from last cigarette (high score=maximum enjoyment) 0.43 0.24 to 0.77 
SF-36 mental health (high score=better mental health) 1.05 1.01 to 1.09 
Age started smoking 0.77 0.59 to 1.00 
Age 1.07 1.00 to 1.15 
Across Trials  
FTND (high score = more dependent) 0.81 0.71 to 0.92 
Active treatment (active=1) 2.85 1.61 to 5.04 
Longest period without smoking 1.45 1.14 to 1.83 
Calming effect from smoking (high score=maximum effect) 1.11 1.02 to 1.19 
Pleasant experience from last cigarette (high score=maximum enjoyment) 0.73 0.56 to 0.95 
*Highlighted in blue indicates main analysis 
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16. MAIN PSM MODEL: BIAS DIFFERENCE AND REDUCTION IN BIAS (CHAPTER FOUR) 
 
Main PSM model: Within trial balance of matching variables before and after PSM: means, % bias difference and % reduction in 
bias* 
   Baseline value % bias T-test 
 Variable Unmatched /matched Quitters Smokers % bias difference % reduction bias T P 
Trial 
1 
FTND 
Unmatched 4.07 6.10 88.00 
95.90 
3.89 0.00 
Matched 4.08 4.00 3.60 0.08 0.94 
Treatment received 
Unmatched 0.60 0.51 16.90 
100.00 
0.64 0.525 
Matched 0.50 0.50 0.00 0.00 1.000 
Age started smoking 
Unmatched 23.2 17.15 87.30 
98.60 
6.14 0.000 
Matched 19.41 19.5 1.20 0.04 0.971 
Rate the calming effect from smoking 
Unmatched 1.67 0.93 66.80 
66.20 
2.51 0.013 
Matched 1.67 1.42 22.60 0.50 0.625 
Rate unpleasant symptoms from smoking 
Unmatched 0.87 0.34 45.60 
53.00 
2.39 0.018 
Matched 0.75 0.50 21.40 0.53 0.601 
How long time was the last time tried to stop? 
Unmatched 1.8 0 1.78 3.40 
803.50 
0.13 0.898 
Matched 1.92 2.08 30.40 0.79 0.436 
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Trial 
2 
FTND 
Unmatched 6.10 6.35 16.4 
100 
0.46 0.649 
Matched 6.10 6.10 0.00 0.00 1.000 
Treatment received 
Unmatched 0.90 0.47 101.90 
100 
2.63 0.010 
Matched 0.90 0.90 0.00 0.00 1.000 
Experience from last cigarette 
Unmatched 4.10 3.47 73.40 
100 
2.00 0.048 
Matched 4.10 4.10 0.00 0.00 1.000 
Trial 
3 
FTND 
Unmatched 6.15 6.35 8.00 
56.40 
0.32 0.752 
Matched 6.58 6.50 3.50 0.09 0.932 
Treatment received 
Unmatched 0.77 0.52 52.40 
100.00 
1.70 0.091 
Matched 0.75 0.75 0 0.00 1.000 
Longest period without smoking 
Unmatched 3.31 2.50 75.40 
100.00 
2.26 0.026 
Matched 3.25 3.25 0.00 0.00 1.000 
Trial 
4 
FTND 
Unmatched 5.86 6.54 26.40 
-21.9 
0.85 0.395 
Matched 6.50 7.33 32.20 0.60 0.565 
Treatment received 
Unmatched 0.71 0.51 40.50 
17.00 
1.01 0.315 
Matched 0.67 0.83 33.60 0.62 0.549 
Trial 
5 
FTND 
Unmatched 5.09 5.47 19.4 
72.5 
0.84 0.402 
Matched 5.26 5.16 5.3 0.16 0.871 
Treatment received 
Unmatched 0.68 .43 50.7 
100 
2.07 0.041 
Matched 0.68 .68 0 0.00 1.000 
Experience from last cigarette Unmatched 2.91 3.55 66 91.8 2.80 0.006 
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Matched 3.05 3.11 5.4 0.16 0.877 
SF-36 Mental health 
Unmatched 77.27 67.00 62.8 
98 
2.43 0.017 
Matched 76.21 76.00 1.3 0.05 0.962 
Age started smoking 
Unmatched 16.59 18.29 51.5 
93.8 
1.83 0.071 
Matched 17.05 17.16 3.2 0.16 0.873 
Age 
Unmatched 44.96 42.29 30.3 
80.3 
1.22 0.224 
Matched 45.37 44.84 6 0.17 0.863 
*The standardised percent bias is the percent difference of the sample means in the quitters and continuing smokers (whole or matched sample), as a percentage of the square root of the average of the sample 
variances in each group 
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17. PSM SENSITIVITY MODELS: COMPARISON OF EFFECT ESTIMATES (CHAPTER FOUR) 
PSM sensitivity models: Comparison of effect estimates between main model and sensitivity models 
Matching occurred within/ across 
trials 
Within/without 
common support 
restrictions 
Group (N) 
Baseline SF-36 
mental health 
M(SE) 
Follow-up SF-36 
mental health 
M(SE) 
B (95% CI) 
Within trials (adjusted for baseline 
mental health, age and sex) 
Within 
Smokers(N=67) 77.43(1.82) 76.72(1.97) 
3.37 (2.15 to 8.90) 
Quitters(N=67) 74.81(1.66) 79.70(1.79) 
Without  
Smokers(N=67) 77.43(1.82) 76.72(1.97) 
3.97 (1.00 to 8.93) 
Quitters(N=67) 74.81(1.66) 79.70(1.79) 
Across Trials (adjusted for baseline 
mental health, Trial ID, age and sex) 
Without  
Smokers(N=67) 74.09(1.94) 75.82(1.91) 
3.74 (1.19 to 8.66) 
Quitters(N=67) 74.81(1.66) 79.70(1.79) 
Within  
Smokers(N=66) 74.06(1.97) 75.76(1.94) 
3.55 (1.29 to 8.40) 
Quitters(N=66) 74.85(1.68) 79.88(1.80) 
*Highlighted in blue indicates main analysis 
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18. QUALITY ASSESSMENT OF STUDY (CHAPTER FOUR) 
 
Quality assessment of study presented in Chapter Four 
Newcastle-Ottawa quality assessment scale cohort studies (NOS) adapted version 
  Star 
awarded 
system 
Star (*) 
awarded 
GT reasons 
Study’s selection criteria  
1) 
Representativeness 
of the exposed 
cohort (maximum 1 
star) 
a) truly representative of the average ___ (describe) 
in the community  
*   
b) somewhat representative of the average ___ in 
the community  
* * Somewhat 
representative of 
the average 
smoker. Not 
motivated to quit, 
they were 
motivated to 
reduce. 
c) selected group of users e.g.. nurses, volunteers (no  star)   
d) no description of the derivation of the cohort (no  star)   
2) Selection of the 
non-exposed cohort 
(maximum 1 star) 
a) drawn from the same community as the exposed 
cohort  
* * Both groups were 
derived from the 
same sample. 
b) drawn from a different source (no  star)   
c) no description of the derivation of the non-
exposed cohort 
(no  star)   
3) Ascertainment of 
exposure 
(maximum 1 star) 
a) Biologically-validated smoking status   * *  
b) smoking status validated only by self-report (no star)   
c) no description (no star)   
Study’s outcome criteria  
1) Assessment of a) standardised self-report questionnaire * *  
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outcome (maximum 
1 star)1 
b) standardised interview schedule with blind 
assessor 
*   
c) non-standardised self-report questionnaire or 
non-standardised interview schedule 
(no  star)   
d) no description (no  star)   
2) Adequacy of 
follow-up of 
cohorts (maximum 
1 star) 2 
a) complete follow-up - all subjects accounted for 
 
*   
b) subjects lost to follow-up unlikely to introduce 
bias - small number lost > ___ % (select an 
adequate %) follow-up, or description provided of 
 
*   
c) follow-up rate < ___% (select an adequate %) 
and no description of those lost 
(no  star)  Overall 47% loss 
to follow-up.   
d) no statement (no  star)   
Final Score 4* 
1 In the case that a study has used a standardised self-report questionnaire and a standardised interview schedule, only one star will be 
awarded. This is as use of both outcome assessments will not improve the study’s quality for the purpose of this review. 
2 Describe based on attrition from enrolment to final follow-up 
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19. PSM SENSITIVITY ANALYSES (CHAPTER FIVE) 
 
Risk difference estimates after PSM sensitivity analyses 
Within/across trials Within/without 
common support 
Group (N) % reported psychiatric 
disorders (N) 
Risk difference 
(95% CI) 
McNemar’s 
Chi2 
Within trials Within common 
support 
Smokers (N=60) 1.67% (N=1) 0.02 (0.07 to 
0.03) 
1.00 
Quitters (N=60) 0% (N=0) 
Without common 
support 
Smokers (N=67) 2.99% (N=2) 
0.03 (0.09 to 
0.03) 
2.00 
Quitters (N=67) 0% (N=0) 
Across Trials Without common 
support 
Smokers (N=68) 0% (N=0) 
N/a N/a 
Quitters (N=68) 0% (N=0) 
Within common 
support 
Smokers (N=68) 0% (N=0) 
N/a N/a 
Quitters (N=68) 0% (N=0) 
*Highlighted in blue indicates main analysis 
*P>0.05, **P>0.01, ***P>0.001 
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20. QUALITY ASSESSMENT OF STUDY (CHAPTER FIVE) 
 
Quality assessment of study in Chapter Five 
Newcastle-Ottawa quality assessment scale cohort studies (NOS) adapted version 
  Star 
awarded 
system 
Star (*) 
awarded 
GT reasons 
Study’s selection criteria  
1) Representativeness 
of the exposed cohort 
(maximum 1 star) 
a) truly representative of the average ____ 
(describe) in the community  
*   
b) somewhat representative of the average _____ 
in the community  
* * Not motivated to quit, 
they were motivated to 
reduce. 
c) selected group of users e.g.. nurses, volunteers  (no  star)   
d) no description of the derivation of the cohort                                                               (no star)  
2) Selection of the non-
exposed cohort 
(maximum 1 star) 
a) drawn from the same community as the 
exposed cohort  
* * Both groups were 
derived from the same 
sample. 
b) drawn from a different source (no  star)   
c) no description of the derivation of the non-
exposed cohort 
(no  star)   
3) Ascertainment of 
exposure (maximum 1 
star) 
a) Biologically-validated smoking status   * * Bio-validated 
b) smoking status validated only by self-report (no star)   
c) no description (no star)   
Study’s outcome criteria  
1) Assessment of 
outcome (maximum 1 
star)1 
a) standardised self-report questionnaire *   
b) standardised interview schedule with blind 
assessor 
* * Key terms were coded 
according to 
MedDRA. Original 
data recorded by 
blinded researches as 
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they were unaware of 
this study’s aim. 
c) non-standardised self-report questionnaire or 
non-standardised interview schedule 
(no  star)   
d) no description (no  star)   
2) Adequacy of follow-
up of cohorts 
(maximum 1 star) 2 
a) complete follow-up - all subjects accounted 
 
*   
b) subjects lost to follow-up unlikely to 
introduce bias - small number lost  > ____ % 
(select an adequate %) follow-up, or description 
 
*   
c) follow-up rate < ___% (select an adequate %) 
and no description of those lost 
(no  star)  Overall 47% loss to 
follow-up.   
d) no statement (no  star)   
Final Score 4* 
1 In the case that a study has used a standardised self-report questionnaire and a standardised interview schedule, only one star will be 
awarded. This is as use of both outcome assessments will not improve the study’s quality for the purpose of this review. 2 Describe 
based on attrition from enrolment to final follow-up 
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21. QUALITY ASSESSMENT OF STUDY (CHAPTER SIX) 
 
Quality assessment of study 
Newcastle-Ottawa quality assessment scale cohort studies (NOS) adapted version 
  Star 
awarded 
system 
Star (*) 
awarded 
GT reasons 
Study’s selection criteria  
1) 
Representativeness 
of the exposed 
cohort (maximum 
1 star) 
a) truly representative of the average ______ 
(describe) in the community  
*   
b) somewhat representative of the average _______ 
in the community  
* * Not motivated to 
quit, they were 
motivated to 
reduce. 
c) selected group of users e.g.. nurses, volunteers (no  star)   
d) no description of the derivation of the cohort (no  star)   
2) Selection of the 
non-exposed 
cohort (maximum 
1 star) 
a) drawn from the same community as the exposed 
cohort  
* * Both groups were 
derived from the 
same sample. 
b) drawn from a different source (no  star)   
c) no description of the derivation of the non-
exposed cohort 
(no  star)   
1) Assessment of 
exposure 
(maximum 1 star)1 
a) standardised self-report questionnaire * * Sf-36 
b) standardised interview schedule with blind 
assessor 
*   
c) non-standardised self-report questionnaire or non-
standardised interview schedule 
(no  star)   
d) no description (no  star)   
Study’s outcome criteria  
Assessment of 
outcome 
(maximum 1 star) 
a) Biologically-validated smoking status   * * Biologically-
validated relapse 
status from 4 to 12 
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months 
b) smoking status validated only by self-report (no star)   
c) no description (no star)   
2) Adequacy of 
follow-up of 
cohorts (maximum 
1 star) 2 
a) complete follow-up - all subjects accou  *   
b) subjects lost to follow-up unlikely to introduce 
bias - small number lost <___ % (select an adequate 
%) follow-up, or description provided of those lost) 
 
*   
c) follow-up rate < __% (select an adequate %) and 
no description of those lost 
(no  star)  Overall 47% loss 
to follow-up.   
d) no statement (no  star)   
Final Score 4* 
1 In the case that a study has used a standardised self-report questionnaire and a standardised interview schedule, only one star will be 
awarded. This is as use of both outcome assessments will not improve the study’s quality for the purpose of this review. 
2 Describe based on attrition from enrolment to final follow-up 
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22. SENSITIVITY ANALYSIS (CHAPTER SIX) 
 
Sensitivity analysis for continuous quitters: regression model 
 Variable OR (1=relapsed) P-value 
Unadjusted  Pre to post cessation change in mental health  0.99 (0.94 to 1.05) 0.73 
Adjusted Pre to post cessation change in mental health  0.99 (0.93 to 1.07) 0.85 
Baseline SF-36 mental health 0.83 (0.92 to 1.10) 0.83 
Treatment status (1=active) 1.01 (0.08 to 12.12) 0.99 
Nicotine dependency FTND 1.11 (0.70 to 1.75) 0.65 
Sex (Female) 0.88 (0.12 to 6.45) 0.91 
Age 0.96 (0.86 to 1.08) 0.51 
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